<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <title>Parkinson's Guide</title>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3">
    <meta name="color-scheme" content="light dark">

    <link rel="stylesheet" href="css/nav.css">
    <link rel="stylesheet" href="css/diagrams.css">
<style>
:root {
    --body-background-color: #E2D8D6;
    --body-color: #111111cc;
    --body-border-color: #DDDDDDcc;

    --section-figure-border-color: #333333;
    --section-figure-bg-color: #FFFFFF33;
    
    --psuedo-target-bg-color: #FFFFFFCC;

    --treatment-legend-h3-bg-color: #FFFFFFCC;

    --tooltip-color: #444;
    --tooltip-bg-color: #EEE;
    --tooltip-border-color: #5555;
    --tooltip-shadow-color: #3333;
    --abbr-text-decoraction-color: hsl(0deg 3% 25% / 50%);
    --abbr-hover-bg-color: hsl(10deg 17% 96% / 73%);
    
    color-scheme: light dark;
}

@media (prefers-color-scheme: dark) {
    :root {
        --body-background-color: #331F1B;
        --body-color: #ffffffc2;
        --body-border-color: #330500cc;
    
        --section-figure-border-color: #333333;
        --section-figure-bg-color: #FFFFFF33;
        
        --psuedo-target-bg-color:  #5555;

        --treatment-legend-h3-bg-color: #401C16EE;

        --tooltip-color: #EEE;
        --tooltip-bg-color: #555;
        --abbr-text-decoraction-color: hsl(12deg 5% 80% / 50%);
        --abbr-hover-bg-color: hsl(10 31% 11% / 1);
    }
}

html {
    margin: 0;
    padding: 0;
    height: 100%;
    width: 100%;
    overflow-x: hidden;
    color-scheme: light dark;
}

body {
    background-color: var(--body-background-color);
    color: var(--body-color);
    border-color: var(--body-border-color);
    font-family: georgia, "Open Sans", Helvetica;
    position: relative;
    font-size: clamp(calc(12px + 0.8vi), 3vi, 32px);
    margin: 0;
    padding-left: 4vi;
    border-style: solid;
    border-width: 1px;
    min-height: 100%;
    overflow-x: hidden;
    position: relative;
    background-size: cover;
}

body > #metadata {
    font-size: smaller;
    margin: 0;
}

body > #metadata p {
    margin-top 0;
}

address.author {
    display: inline;
}

address.author strong {
    font-style: normal;
}

abbr[title], dfn[title] {
    position: relative;
    text-decoration: underline;
    text-decoration-style: dotted;
    border-radius: 0.5vi;
    padding:  0.3vi;
    margin: -0.3vi;
    text-decoration-color: var(--abbr-text-decoraction-color);
    cursor: text;
    transition: background-color 0.6s ease-out;
}

abbr[title]:hover, dfn[title]:hover {
    cursor: default;
    background-color: var(--abbr-hover-bg-color);
    transition: opacity 0.001s;
}

abbr[title]::after, dfn[title]::after {
    position: absolute;
    left: 0;
    bottom: 100%;
    right: unset;
    top: unset;
    padding: .5em .46em .5em .5em;
    background-color: var(--tooltip-bg-color);
    color: var(--tooltip-color);
    font-size: smaller;
    border-radius: .4em;
    transition: all 0.3s;
    content: attr(title);
    opacity: 0;
    z-index: 1;
    pointer-events: none;
    display: block;
    box-sizing: border-box;
    width: fit-content;
    block-size: fit-content;
    filter: drop-shadow(.1vi .1vi var(--tooltip-shadow-color));
    border: 1px solid  var(--tooltip-border-color);
}

abbr[title]:hover::after, dfn[title]:hover::after, 
    dfn[data-tip-r], dfn[data-tip-t],
    abbr[data-tip-r], abbr[data-tip-t]  {
    opacity: 0.9999999;
    transition: all 0.3s ease-out;
}

a:link, a:visited {
    color: inherit;
    text-decoration: underline;
    font-weight: bold;
    font-size: 90%;
}

cite.reflink {
    font-size: 60%;
}

cite.reflink::before {
    content: "(";
    padding-right: 0.15vi;
}

cite.reflink::after {
    content: ")";
    padding-left: 0.15vi;
}

a:visited {
    color: lighten;
    font-style: italic;
}

dl {
    font-family: cormorant, "Latin Modern Roman";
}
dt {
    font-style: italic;
}

section > figure {
    border-width: 0.1vh;
    border-style: solid;
    border-color: var(--section-figure-border-color);
    background-color: var(--section-figure-bg-color);
    padding: 2vi 3vi;
}

figure img.block-image {
    max-width: 100%;
    display: block;
    margin: auto;
}

figure.flex-row {
	display: flex;
	flex-direction: row;
}

figure.flex-row img {
	border-width: 1px;
	border-style: solid;
	padding: 0.5px;
}

ol.reference-list > li {
    margin-top: 1ex;
}

ol.reference-list > li[id]::before {
    font-size: 60%;
    font-style: italic;
    margin: .1em;
    content: "[" attr(id) "]"
}

body > section, body > header {
    padding-left: 1.2vw;
    padding-right: 1.2vw;
}

section, header {
    background-color: light-dark(lighten, darken);
    margin: 0;
    padding: 0.1vi 1.3vi;
    border: 2px solid transparent;
}

*:target {
    background-color: var(--psuedo-target-bg-color);
    animation: highlightFade 4s ease forwards; /* Play the animation */
}

section section {
    background-color: inherit;
}

@scope(.product-list) {
    figure, p {
        margin-bottom: 0;
    }
}
/* Animation for highlighting and fading out on in-page links */
@keyframes highlightFade {
    0% {
        border-color: #e635;
    }
    50% {
        border-color: light-dark(lighten, darken);
    } 
    100% {
        background-color: initial;
    }  
} 

.good-answers, .bad-answers, .baseline-answers {
    list-style: none;
}
.good-answers li::before {
    content: "‚úÖ";
}
.bad-answers li::before {
    content: "‚ùå";
}

.baseline-answers li::before {
    content: "‚úîÔ∏è";
}

.product-list {
    list-style: none;
    display: flex;
    flex-direction: row;
    flex-wrap: wrap;
    align-items: flex-end;
}

.product-list li {
    max-width: 30vw;
    height: auto;
    flex-grow: 1;
    flex-shrink: 3; /* default 1 */
}

.product-list img {
    width: auto;
    max-width: 28vw;
    min-width: 0;
    object-fit: cover;
    vertical-align: bottom;
}

#treatment-legend {
    margin-top: 1.2em;
    border: 1px solid #9999;
    position: relative;
}

#treatment-legend > h3:first-child {
    background-color: var(--treatment-legend-h3-bg-color);
    border-color: #777;
    border-width: 1px;
    border-style: solid;
    position: absolute;
    top: -1.4ex;
    display: inline-block;
    font-size: smaller;
    z-index: 10;
    margin-top: 0;
    margin-bottom: -1em;
    padding: 0.05em 0.3em;
}

#legend-legend {
    list-style: none;
    font-size: smaller;
}

</style>

<style id="tipsheet">
abbr[title][itemprop^=r]::after, dfn[title][itemprop^=r]::after {
    left: unset;
    right: -.22em;
    transition: all .3s ease-in;
}
abbr[title][itemprop$=t]::after, dfn[title][itemprop$=t]::after {
    bottom: unset;
    transition: all .3s ease-in;
    top: 3ex;
}
</style>
    <script type="module">
const documentElement = document.documentElement;

const clickHandler = event => {
    const target = event.target;
    if (!target) return;
    const nav = document.getElementById("nav");
    const isNotNav = !nav.contains(target);
    const isNavHeader = target.matches("#nav-heading");
    
    if (isNavHeader) {
        nav.classList.toggle("open");
        return;
    } else if (isNotNav) {
        nav.classList.remove("open");
    }
};
documentElement.addEventListener("click", clickHandler);
documentElement.addEventListener("touchstart", clickHandler); 

addEventListener("hashchange", (ev) => {
    const navRight = nav.getBoundingClientRect().right;
    const rightPageMargin = innerWidth - navRight;
    if (rightPageMargin < 50) {
        nav.classList.remove("open");
    }
});
</script>

<script type="module">
document.addEventListener("mouseover", tooltipPositionFixer);
document.addEventListener("transitionend", tooltipPositionResetter);
window.addEventListener("resize", windowChanged);
window.addEventListener("scroll", windowChanged);
window.addEventListener("orientationchange", windowChanged);

let isWindowChanged = false;
function windowChanged(ev) {
    isWindowChanged = true;
}

const TOOLTIP_ACTUATOR_SELECTOR = "dfn[title], abbr[title]";

const tipActuatorMouseLeave = (ev) => {
    ev.target.removeAttribute("itemprop");
};

function tooltipPositionFixer(ev) {
    const target = ev.target;
    
    if(target.hasAttribute("itemprop") && !isWindowChanged) return;
    if (isWindowChanged) {
        target.removeAttribute("itemprop");
        isWindowChanged = false;
    }
    if (target.matches(TOOLTIP_ACTUATOR_SELECTOR)) {
        const targetBox = target.getBoundingClientRect();
        const afterStyle = window.getComputedStyle(target, '::after');
    
        const wasClippedRight = isClippedRight(targetBox, afterStyle);
        const wasClippedTop = isClippedTop(targetBox, afterStyle);
        
        target.removeAttribute("itemprop");
        if (wasClippedRight) {
        // Cannot use "data-" prop here ,as it causes transitionend to not fire
        // on the ABBR and DFN elements. So, use itemprop.
            target.setAttribute("itemprop", 'r');
        }
        if (wasClippedTop) {
            target.setAttribute("itemprop", target.getAttribute("itemprop")+"t");
        }
    }
    ev.preventDefault();
}

function isClippedRight(targetBox, afterStyle) {
    const targetRight = targetBox.right;
    const tooltipRight = targetRight + parseInt(afterStyle.width, 10);
    const bodyRight = window.innerWidth;
    return tooltipRight + 3.5 >  bodyRight;
}

function isClippedTop(targetBox, afterStyle) {
    const targetTop = targetBox.top;
    const pseudoEltTop = parseInt(afterStyle.top, 10);
    return targetTop + pseudoEltTop <  0;
}

/** FIXME:
    In theory, this actuator hover-off post-transition 
    should prevent the tooltip from flickering back into place.
*/
const tooltipOffCriteria = (ev) => {
    const target = ev.target;
    const matchesCriteria = false === target.matches(":hover") 
                && "text" === getComputedStyle(target).cursor
                && .6 === ev.elapsedTime;

    return matchesCriteria;
};
function tooltipPositionResetter(ev) {
    const target = ev.target;
    if (tooltipOffCriteria(ev)) resetDefaultPosition(target);
}
function resetDefaultPosition(target) {
    target.removeAttribute("itemprop");
}

    </script>
</head>
<body>
    <header id="metadata">
        <h1>Parkinson's Disease Guide</h1>
        <p>
            <strong>Working Draft</strong>, 
            <time datetime="2024-08-22">2024-08-22</time>
        <p>
        <address class="author">
            <strong>Editor:</strong> Garrett Smith
        </address>
    </header>
    <nav id="nav">
        <div><h3 tabindex="0" id="nav-heading">Menu</h3></div>
        <ul>
            <li><a href="#purpose">The Purpose of This Guide</a></li>
            <li><a href="#how-to-use-this-guide">How to Use This Guide</a></li>
            <li><a href="#introduction-to-pd">Introduction to Parkinson's Disease</a>
                <ul>
                    <li><a href="#causes-of-pd">Causes and Risk Factors</a></li>
                    <li>
                        <a href="#testing-and-diagnosis">Testing and Diagnosis</a>
                        <ul>
                            <li>
                                <a href="#genetic-testing">Genetic Testing</a>
                            </li>
                        </ul>
                    </li> 
                </ul>           
            </li>
            <li><a href="#introduction-to-health">A Brief Introduction to Health</a></li>
            <li><a href="#care-team">How to Build a Care Team</a>
                <ul>
                    <li><a href="#care-team-introduction">Introduction</a></li>
                    <li><a href="#hypothetical-care-team">Hypothetical Care Team</a></li>
                    <li><a href="#tips-for-selecting-providers">Tips for Selecting Providers</a></li>
                </ul>
            </li>
            <li>
                <a href="#treatment-approaches">Treatment Approaches</a>
                <ul>
                    <li><a href="#treatment-approaches-overview">Overview</a></li>
                    <li><a href="#symptomatic-approach">Symptomatic</a></li>
                    <li><a href="#disease-progression-approach">Disease-progression</a></li>
                    <li><a href="#etiological-approach">Etiological</a></li>
                    <li><a href="#holistic-approach">Holistic</a></li>
                </ul>
            </li>
            <li><a href="#etiological-problems">Etiological Problems</a></li>
            <li><a href="#treatment-plan">Treatment Starter Plan</a></li>
            <li> <a href="#treatments">Detailed Treatments</a>
                <ul>
                    <li>
                        <a href="#medications">Medications</a>
                        <ul>
                            <li><a href="#dopamine-agonists">Dopamine Agonists</a></li>
                            <li><a href="#comt-inhibitors">COMT Inhibitors</a></li>
                            <li><a href="#mao-b-inhibitors">MAO-B Inhibitors</a></li>
                            <li><a href="#synuclean-d-and-minzasolmin">SynuClean-D and Minzasolmin</a> üß™</li>
                        </ul>
                    </li>
                    <li>
                        <a href="#hormonal-interventions">Hormonal Interventions</a>
                        <ul>
                            <li><a href="#hrt">Hormone Therapy &mdash; Estrogen and Testosterone</a></li>
                            <li><a href="#dhea">DHEA</a></li>
                            <li><a href="#pregnenolone">Pregnenolone</a></li>
                        </ul>
                    </li>
                    <li><a href="#dbs">Deep Brain Stimulation (DBS)</a></li>
                    <li><a href="#gene-therapy">Gene Therapy</a></li>
                    <li><a href="#stem-cell">Stem Cells (MSC, iPSC)</a></li>
                    <li><a href="#exercise"
                        >Exercise</a></li>
                    <li><a href="#pbm">Photobiomodulation</a></li>
                </ul>
            </li>
            <li><a href="#how-to-build-a-supplement-plan">How to Build a Supplement Plan</a></li>
            <li><a href="#food-and-supplements">Food and Supplements</a>
            	<li><a href="#food">Dietary Strategies for Parkinson's Disease</a>
                <ul>
                    <li><a href="#glynac">GlyNAC (Glycine n-acetylcysteine)</a></li>
                    <li><a href="#creatine">Creatine Monohydrate</a></li>
                    <li><a href="#cinnamon">Cinnamon</a></li>
                    <li>Cacao</li>
                    <li>Carvacrol - TODO</li>
                    <li><a href="#lions-mane">Lion's Mane</a></li>
                    <li><a href="#cordyceps">Cordyceps</a></li>
                    
                    <li class="neuroprotective anti-aggregant"><a href="#turmeric">Turmeric</a></li>
                    <li class="neuroprotective antifibrillogenic"><a href="#saffron">Saffron</a></li>
                    <li><a href="#coconut-oil">Coconut Oil</a></li>
                    <li><a href="#ginger">Ginger</a></li>
                    <li><a href="#egcg">Matcha</a></li>
                    <li><a href="#ginsenoside">Ginseng</a></li>
                    <li><a href="#acetyl-l-carnitine">Acetyl-L-Carnitine (ALCAR)</a></li>
                    <li><a href="#r-ala">Alpha-Lipoic Acid (ALA)</a></li>
                    <li>
                        <a href="#gaba-5-htp-melatonin">GABA, 5-HTP, and Melatonin</a>
                        <ul>
                            <li><a href="#gaba">GABA</a></li>
                            <li><a href="#5-htp">5-HTP</a></li>
                            <li><a href="#melatonin">Melatonin</a></li>
                        </ul>
                    </li>
                    <li>
                        <a href="#quinones">Mitochondrial Quinones (PQQ, CoQ10, K2)</a>
                        <ul>
                            <li><a href="#pqq">PQQ Pyrroloquinoline Quinone</a></li>
                            <li><a href="#k2">Menaquinone (Vitamin K2)</a></li>
                            <li><a href="#ubiquinol">Ubiquinol (Reduced Coenzyme Q-10)</a></li>
                        </ul>
                    </li>
                    <li><a href="#gg">Geranylgeraniol (GG)</a></li>
                    <li><a href="#nattokinase">Nattokinase</a></li>
                    <li><a href="#dha">Docosahexaenoic Acid (DHA)</a></li>
                    <li><a href="#cholinergics">Cholinergics and Membrane Support</a>
                        <ul>
                            <li><a href="#uridine">Uridine Monophosphate</a></li>
                            <li><a href="#citicoline">CDP-Choline</a></li>
                            <li><a href="#alpha-gpc">Alpha-GPC</a></li>
                            <li><a href="#phosphatidylserine">Phosphatidylserine</a></li>
                        </ul>
                    </li>
                    <li><a href="#magnesium-threonate">Magnesium Threonate</a></li>
                    <li><a href="#vitamin-d">Vitamin D</a></li>
                    <li><a href="#vitamin-b1">Vitamin B-1 (Thiamine)</a></li>
                    <li><a href="#vitamin-b6">Vitamin B-6 (Pyridoxine)</a></li>
                    <li><a href="#vitamin-b12">Vitamin B-12 (Cobalamin)</a></li>
                    <li><a href="#tocotrienols">Tocotrienols and Tocopherols</a></li>
                    <li>
                        <a href="#nicotinamides">NAD+, NMN, Niacin, and NR</a>
                        <ul>
                            <li><a href="#nmn">NMN (Nicotinamide Mononucleotide)</a></li>
                            <li><a href="#nr">NR (Nicotinamide Riboside)</a></li>
                            <li><a href="#niacin">Niacin</a></li>
                            <li><a href="#nad-injection">Injectable NAD+</a></li>
                        </ul>
                    </li>
                    <li>
                        <a href="#senolytics">Senolytics</a>
                        <ul>
                            <li><a href="#urolithin-a">Urolithin-A</a></li>
                            <li><a href="#resveratrol">Resveratrol</a></li>
                            <li><a href="#fisetin">Fisetin</a></li>
                            <li><a href="#quercetin">Quercetin</a></li>
                            <li><a href="#sulforaphane">Sulforaphane</a></li>
                            <li><a href="#piperlongumin">Piperlongumin</a></li>
                            <li><a href="#apigenin">Apigenin</a></li>
                            <li><a href="#theaflavin">Theaflavin</a></li>
                        </ul>
                    </li>
                    <!-- li>
                        <a href="#blueberry"></a>
                    </li -->
                </ul>
            </li>
            <li><a href="#summary">Summary</a></li>
        </ul>
    </nav>
    <header id="purpose">
        <h2>The Purpose of This Guide</h2>

		<p>
			This guide is crafted to empower individuals with Parkinson's Disease (PD) to optimize their health using the latest scientific evidence. It covers disease etiology, medication, exercise performance, diet and supplementation, care providers, photobiomodulation, and more, offering practical strategies for effective management and enhanced well-being.
		</p>
		<p>
			Started in 2021, this guide was inspired by a relative with PD who chose to eschew evidence-based strategies rather than investigate their veracity and incorporate them into her program. Her condition deteriorated due to complications of autonomic nervous system (ANS) failure, with severe gastrointestinal and heart problems. This guide reflects core principles of volition, self-ownership, evidence-based practice, informed decision-making, first principles, and critical thinking, aimed at helping others make proactive, informed choices to improve their health outcomes.
		</p>
    </header>
    <section id="how-to-use-this-guide">
        <h2>How to Use This Guide</h2>
        <p>
            To make the most of this Parkinson's Disease Guide, <a href="#introduction-to-pd">educate yourself about Parkinson's Disease</a>, learn about <a href="#food-and-supplements">supplements</a>, and get started with the <a href="#treatment-plan">Treatment Starter Plan</a>.
        </p>
    </section>
    <section id="introduction-to-pd">
        <h2>Introduction to Parkinson's Disease</h2>

        <p>
            Parkinson‚Äôs Disease (PD) is a progressive neurological condition caused by the aggregation of the pre-synaptic peptide Œ±-synuclein. This causes loss of dopaminergic neurons, leading to progressive neurodegeneration (PN) characterized by motor and non-motor symptoms.
        </p>

        <!--
        <p>
            Alpha-synuclein aggregates in the midbrain and damages neurons, including the autonomic nuclei, also located also throughout the body, which are responsible for autonomic functions (blood pressure, heart rate, GI system, etc).
        </p>
        <p>
            Progressive neurodegeneration ensues and is exacerbated by unilateral neurological modulation of the dopaminergic pathway (the L-Dopa / DDC inhibitors, aka "standard of care") and is more pronounced in later stages.
        </p>

        <p>
            Parkinson's Disease affects various brain regions, including the substantia nigra, basal ganglia, cerebral cortex, thalamus, hippocampus, cerebellum, and other regions involved in motor control, cognition, movement and the nervous systems.
        </p>
        -->
        <!-- p>
            The nervous system comprises the Central Nervous System (CNS), Peripheral Nervous System (PNS), and autonomic nervous system (ANS). The CNS, consisting of the brain and spinal cord, processes information and coordinates responses. The PNS connects the CNS to the body, relaying sensory input and motor output. The ANS regulates involuntary functions like heart rate and digestion.
        </p -->
        <p>
            PD primarily affects the Central Nervous System (CNS), particularly dopamine-producing neurons, leading to motor symptoms like tremors and rigidity. However, dysfunction of the autonomic nervous system (ANS) becomes more noticeably pronounced in the later stages, contributing to non-motor symptoms such as <abbr title="Gastrointestinal">GI</abbr> issues, low blood pressure, and urinary dysfunction.
        </p>
        <p>
            PD-related autonomic dysfunction can exacerbate renal issues, leading to a complex interplay of factors that contribute to orthostatic hypotension in PD.
        </p>
        <section id="causes-of-pd">
            <h3>Causes and Risk Factors</h3>
            <p>
                Parkinson's Disease is a neurological condition resulting from the pathology of alpha-synuclein (Œ±-synuclein), (Œ±-synucleinopathy). 
                <span class="call-out">Understanding the role and effects of Œ±-synuclein in PD is important to mitigating the disease's progression.</span>
            </p>
            <p>
                Overexpression of &alpha;-synuclein leads to its aggregation and formation into oligomers (peptides) and fibrils (see image). Oligomers of &alpha;-synuclein can form Lewy bodies, abnormal aggregations that develop inside nerve cells.
            </p>
            
            <figure>
                <img src="img/alpha-synuclein.jpeg" alt="Œ±-synuclein monomer, fibril, and oligomer." class="block-image">
                <figcaption>
                    <p>
                        Depiction of Œ±-synuclein monomer, fibril, and oligomer. Œ±-Synuclein fibrils are long, insoluble fibers composed of many monomers and oligomers.
                    </p>
                </figcaption>
            </figure>
            <p>
                Alpha-synuclein is abundant primarily in the brain, especially in the neocortex, hippocampus, and substantia nigra (SN). Smaller amounts are found in the heart, muscles, and other tissues. It is transported into and out of the
                brain by the blood-brain barrier. <cite class="reflink"><a href="#yu-ting-sui">Y. Sui</a></cite>
            </p>
            <p>
                Six mutations of &alpha;-synuclein are currently associated with familial parkinsonism. Mutant &alpha;-synuclein forms aggregates more readily than wild-type (normal) &alpha;-synuclein. <cite class="reflink"><a href="#v-c-ruf">V. Ruf</a>, <a href="#jie-li">J. Li</a></cite>
            </p>
            <p>
                Wild-type &alpha;-synuclein can be removed by lysosomes. Mutant forms of Œ±-synuclein resist degradation and inhibit the degradation of other substrates.
            </p>
            <p>
               &alpha;-synuclein oligomers, as well as other &alpha;-synuclein variants, disrupt mitochondrial function. The oligomers prevent autophagy¬†by blocking lysosomal degradation, disrupting membrane homeostasis (they poke holes in the cell), inhibiting endoplasmic reticulum (ER) function and synapses (connections between neurons), and causing inflammation that further damages cellular function. 
            </p>
        
            <!-- TODO: Where does this go??
            <h4>SNCA Gene Encodes Alpha-synuclein</h4>
            <p>
                The SNCA gene encodes &alpha;-synuclein. In the brain, &alpha;-synuclein is found mainly at the tips of nerve cells (neurons) in specialized structures called presynaptic terminals.
            </p>
            <p>Mutations in the SNCA gene lead to mutant &alpha;-synuclein.</p>
            <h4>
                Autosomal Dominant Parkinson's Disease, PARK1
            </h4>
            <p>
                PARK1 is an inherited, dominant genetic trait (autosomal dominant) in PD that causes heterozygous triplication of the SNCA gene.
            </p>
            <h4>LRRK2</h4>
            <p>
                Leucine-Rich Repeat Kinase 2 (LRRK2) is an enzyme encoded by a gene of the same name (the LRRK2 gene).
            </p>
            <p>
                LRRK2 mutations are implicated in PD pathogenesis and may influence &alpha;-synuclein metabolism and neuronal function.
            </p>
            <h5>LRRK2-G2019S</h5>
            <p>
                LRRK2-G2019S is a mutant form of LRRK2 found in PD. LRRK2-G20195 causes &alpha;-synuclein accumulation in dopaminergic neurons. &alpha;-synuclein accumulation leads to all of the problems previously mentioned,
                including &alpha;-synuclein oligomers and fibrils.
            </p>
            <p>
                LRRK2 mutants in genetic PD cause shortening and simplification of the dendritic tree in vivo and in cultured neurons.
            </p>
            <p>
                LRRK2 inhibitors can improve Parkinson's disease by reducing &alpha;-synuclein.
            </p>
            <h4>PINK1</h4>
            <p>
                PTEN-induced kinase 1 (PINK1) is a kinase produced by the PINK1 gene. Mutations in the PINK1 gene are a rare cause of one form of autosomal recessive early-onset Parkinson's disease that may be more associated with
                mitophagy, a process by which damaged or dysfunctional mitochondria are removed, reducing oxidative stress and inflammation.
            </p>
            <h4>Current Therapies in Clinical Trials of Parkinson‚Äôs Disease: A 2021 Update</h4>
            <p>
                The complex pathology is partially depicted in the figure below
            </p>
            <figure>
                <img src="img/figure-1-pd.png" alt="Parkinson's Disease Pathology Diagram" class="block-image" />
                <figcaption>
                    <p>
                        The pathological hallmarks of PD and the interplay of aging, environmental hazards, and genetics.
                    </p>
                    <p>
                        (A) The pathological hallmarks of Parkinson‚Äôs disease include dopaminergic neuronal death, &alpha;-synuclein aggregates, mitochondrial dysfunction, reactive oxygen species, apoptosis, and neuroinÔ¨Çammation.
                    </p>
                    <p>
                        (B) PD is a multifactorial disorder involving aging, genetics, and environmental factors, associated with dopaminergic neuronal death. Gene mutations associated with PD include DJ-1, PTEN-induced putative kinase-1 (PINK1), parkin, leucine-rich repeat kinase-2 (LRRK2), Synuclein alpha (SNAC), and ubiquitin carboxyl-terminal hydrolase-L1 (UCHL1). 
                    </p>
                    <p>
                        Neurotoxins (e.g., rotenone, paraquat) and gene mutations of DJ-1,  PINK1, parkin, LRRK2, and SNAC, induce mitochondria complex I inhibition, ATP depletion, reactive oxygen species (ROS) accumulation, mitochondria depolarization, and mitochondrial dysfunction in dopaminergic neurons to promote neuronal death in the substantia nigra of PD patients.
                    </p><cite class="reflink"><a href="[F. Pan-Montojo]">F. Pan-Montojo</a></cite>
                    <p>
                        Overexpression of the SNCA gene can lead to the accumulation of  &alpha;-synuclein in the brain, which, if &alpha;-synuclein is of a mutant form can cause problems and contribute to the formation of Lewy bodies. 
                    </p>
                    <p>
                        The UCHL1 gene and the overexpression of the SNCA gene are related in that UCHL1 is involved in the degradation of &alpha;-synuclein, a protein that is overexpressed in PD. 
                    <p>
                        The UCHL1 gene and the SNCA gene are both involved in PD pathogenesis.
                        UCHL1 gene mutations impair ubiquitin-proteasome systems and further induce autophagy lysosomal pathway dysfunction, contributing to Lewy body formation in dopaminergic neurons.
                    </p>
                </figcaption>
            </figure>
            <p>
                The diagram offers some visual depiction of PD, with small mistakes.
            </p>
            <p>The authors miscall the &alpha;-synuclein gene, SNCA, "SNAC". Most of what they categorize as genetic is epigenetic. That is, attributable to a combination of genetic <em>and</em> environmental factors.</p>
            <p>
                Lewy bodies are comprised of &alpha;-synuclein fibrils, the manifestation of which can be partly affected by environmental factors. Lewy bodies appear in the ‚ÄúGenetic factors" group below &alpha;-synuclein.
            </p>
            <p>
                &alpha;-synuclein increase is not solely attributable to genetics but to a variety of epigenetic factors that can be affected.
            </p>
            -->
            <p>
                In PD, aging, environmental hazards, and genetics interact pathologically. The pathological hallmarks of PD include dopaminergic neuronal death, &alpha;-synuclein aggregates, mitochondrial dysfunction, reactive oxygen species (ROS), apoptosis, and neuroinÔ¨Çammation. These problems, along with aging, genetics, and environmental factors, contribute to the disease progression. <cite class="reflink"><a href="#k-burton">K. Burton</a></cite>
            </p>
            
            
            <h4>Genetic Factors</h4>
            <p>
               Gene mutations of <abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr>, <abbr title="PTEN-induced Kinase 1">PINK1</abbr>, parkin, <abbr title="Leucine-Rich Repeat Kinase 2 gene">LRRK2</abbr>, and <abbr title="Synuclein Alpha Gene">SNCA</abbr> genes contribute to several cellular issues. Together, these factors promote neuronal death in the substantia nigra of PD patients. <cite class="reflink"><a href="#m-vlag">M. Vlag</a></cite>
            </p>
            
            <p>
                Epigenetic factors can influence the expression of genes like the <abbr title='Leucine-Rich Repeat Kinase 2 gene'>LRRK2</abbr> (<abbr title='Leucine-Rich Repeat Kinase 2 gene with a glycine to serine substitution at position 2019'>LRRK2-G2019S</abbr>) gene and <abbr title='Synuclein Alpha Gene'>SNCA</abbr>, affecting the production and pathogenicity of mutant Œ±-synuclein. <cite class="reflink"><a href="#christine-klein">christine-klein</a>, <a href="#alpha-synuclein-net">alpha-synuclein-net</a></cite>
            </p>
            <p>
                Vitamin B12, for example, is an external factor that prevents LRRK2-G2019S-potentiated &alpha;-synuclein accumulation in dopaminergic neurons. <cite class="reflink"><a href="#a-schaffner">a-schaffner</a></cite>
            </p>
                        
            <h4>Cell Dysregulation by SATB1 Inhibition</h4>
            <p>
                Special AT-rich sequence-binding protein 1 (SATB1), a cell regulator, represses the expression of p21 in dopaminergic neurons. P21 is a pro-senescence factor that maintains the viability of senescent cells under persistent DNA damage response.  <cite class="reflink"><a href="#markus-riessland">markus-riessland</a></cite>
            </p>

            <p>
                <abbr title="Special AT-rich sequence-binding protein 1">SATB1</abbr> is inhibited in PD resulting in more p21, decreased <abbr 
                title="cyclin-dependent kinases">CDKs</abbr>, and accumulation of senescent cells. Senescent dopaminergic neurons contribute to the downward spiral of PN.
                <cite class="reflink"><a href="#markus-riessland">markus-riessland</a></cite>
            </p>
                     
             
            <h5 class="diagram-header">SATB1 Pathway Diagram</h5>
            
            <div id="satb-diagram" class="diagram">
                <div class="step">SATB1 Inhibition
                    <div class="arrow"></div>
                </div>
                <div class="step"><b class="updown-arrow">&darr;</b> p21
                    <div class="arrow"></div>
                </div>
                <div class="step"><b class="updown-arrow">&darr;</b> CDKs
                    <div class="arrow"></div>
                </div>
                <div class="step"><b class="updown-arrow">&uarr;</b> Senescent Cells
                    <div class="arrow"></div>
                </div>
                
                <div class="step">SATB1 Inhibition</div>
            </div>
            <p>
                Senescent cells cease to function and divide, damaging healthy neighboring cells by secreting inflammatory factors and contributing to further tissue dysfunction and senescence.
            </p>

            <h5>Interruption of Progressive Neurodegeneration (PN)</h5>
            <p>
                <abbr title="progressive neurodegeneration">PN</abbr> can be interrupted with senolytics, mitochondrial support, antioxidants, and other neuroprotective approaches described herein.
            </p>
            
            <h4>Mitochondrial Dysfunction</h4>
            <p>
                Mitochondrial dysfunction more significantly contributes to senescence than SATB1 inhibition. In fact, it is one of the primary causal factors of disease progression. Solutions to mitochondrial dysfunction are addressed with respective proportion herein. 
            </p>


            <h4>The Role of Pesticides</h4> 
            <p>
                Pesticide and herbicide exposure causes mitochondrial dysfunction and, in certain individuals, &alpha;-synuclein overexpression. Herbicide rotenone and pesticide paraquat so reliably induce PD that they are used to induce PD in rodent model experiments. <cite class="reflink"><a href="#jae-hyeon-park">jae-hyeon-park</a>, <a href="#f-pan-montojo">F. Pan-Montojo</a></cite> 
            </p>

            <h4>References</h4>
            <ol class="reference-list">
                <li id="yu-ting-sui"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/25278492/"
                    title="Alpha synuclein is transported into and out of the brain by the blood-brain barrier"
                    target="_blank"
                    >Alpha synuclein is transported into and out of the brain by the blood-brain barrier</a>, Yu-Ting Sui, et al.
                    <p>
                        This rodent model study showed Œ±-synuclein is transported across the BBB bidirectionally, in both the brain-to-blood and blood-to-brain directions.
                    </p>
                </li>     
                <li id="v-c-ruf">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30605594/"
                    title="Different Effects of Œ±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements"
                    target="_blank"
                    >Different Effects of Œ±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements</a>, Viktoria C Ruf, et al.
                    <p>
                    This study showed the differential mechanisms of metals, such as iron, in Œ±-synuclein pathology at the molecular level.
                    </p>
                </li>
                <li id="jie-li">
                    <a href="https://pubs.acs.org/doi/10.1021/bi010616g"
                    title="Effect of Familial Parkinson's Disease Point Mutations A30P and A53T on the Structural Properties, Aggregation, and Fibrillation of Human Œ±-Synuclein"
                    target="_blank"
                    >Effect of Familial Parkinson's Disease Point Mutations A30P and A53T on the Structural Properties, Aggregation, and Fibrillation of Human Œ±-Synuclein</a>, Jie Li, et al.
                    <p>
                        This rodent study showed that the <dfn title="Alpha-53-Thr mutation: point mutation in the human alpha-synuclein (Œ±-synuclein) gene, associated with early-onset familial PD">A53T</dfn> and <dfn title="point mutation in the alpha-synuclein (SNCA) gene associated with autosomal dominant Parkinson‚Äôs disease">A30P</dfn> genetic mutations in Œ±-synuclein have an increased propensity to aggregate compared with the wild-type protein, and this shows how mutant Œ±-synuclein contributes to PD.
                    </p>
                    <p>
                        They note Œ±-synuclein in PD arose from gene-linkage experiments in familial early-onset Parkinson‚Äôs disease, which revealed the A53T mutation.
                    </p>
                </li>
                <li id="k-burton"> 
                    <a href="https://www.medscape.com/viewarticle/994849"
                    title="Why Genetic Testing May Be Our Best Shot at Progress in PD"
                    target="_blank"
                    >Why Genetic Testing May Be Our Best Shot at Progress in PD</a>, Kelli Whitlock Burton
                    <p>
                        Previous studies have shown that some genetic variants increase the risk for PD after exposure to environmental factors such as pesticides. Research has also shown that patient genotype can indicate survival time and treatment approaches.
                    </p>
                </li>
                <li id="m-vlag">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496448/"
                    title="The contribution of Parkin, PINK1 and DJ‚Äê1 genes to selective neuronal degeneration in Parkinson's disease"
                    target="_blank"
                    >The contribution of Parkin, PINK1, and DJ‚Äê1 genes to selective neuronal degeneration in Parkinson's disease</a>, Marc van der Vlag, et al.

                </li>
                <li id="christine-klein"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253033/"
                    title="Genetics of Parkinson‚Äôs Disease"
                    target="_blank"
                    >Genetics of Parkinson‚Äôs Disease</a>, Christine Klein and Ana Westenberger.
                    <p>
                        This 2014 paper provides compelling arguments that the identification of PD gene mutations, especially in patients with early-onset PD, can provide information on prognosis and will affect treatment choices in cases of PD that were initially suspected to be psychogenic. <em>Why is this 10-year-old paper not the standard of care!?</em>
                    </p>
                </li>

                <li id="alpha-synuclein-net">
                    <a href="https://alpha-synuclein.net/mutations/"
                    title="ALPHA-SYNUCLEIN: MUTATIONS"
                    target="_blank"
                    >ALPHA-SYNUCLEIN: MUTATIONS</a>
                    <p>
                        Individuals who developed a triplication of the <abbr title="Synuclein Alpha Gene">SNCA gene</abbr>, as opposed to a duplication, displayed more severe symptoms including early-onset parkinsonism with dementia. This indicates a dose-dependent correlation between the progression of PD and <abbr title="Synuclein Alpha">SNCA</abbr> gene dosage. <cite class="reflink"><a href="#alpha-synuclein-net">alpha-synuclein-net</a></cite>
                    </p>
                </li>
                <li id="a-schaffner"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
                    title="Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection"
                    target="_blank"
                    >Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection</a>, Schaffner, et al
                    <p>
                        This in vitro study found that adenosylcobalamin (a form of B-12) protects dopaminergic neurons from LRRK2-G2019S-induced neurotoxicity in C. elegans.
                    </p>
                </li>
                <li id="markus-riessland"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
                    title="Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons"
                    target="_blank"
                    >Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons</a>, Riessland, et al.
                    <p>
                        Moreover, we found that SATB1 directly represses the expression of the pro-senescence factor p21 in dopaminergic neurons. Our data implicate senescence of dopamine neurons as a contributing factor in the pathology of Parkinson's disease.
                    </p>
                </li>
                <li id="jae-hyeon-park"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/31931835/"
                    title="Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway"
                    target="_blank"
                    >Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway</a>, Jae-Hyeon Park, et al.
                    <p>
                        This rodent model showed that pesticides can initiate the progression of PD pathology and that this progression is based on the transneuronal and <dfn>"retrograde axonal transport"</dfn> (that &alpha;-synuclein goes back into the cell) of alpha-synuclein. If confirmed in patients, this study would have crucial implications for strategies used to prevent and treat PD.
                    </p>
                </li>                           
                <li id="f-pan-montojo">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/23205266/"
                    title="Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice"
                    target="_blank"
                    >Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice</a>, F. Pan-Montojo, et al.
                    <p>
                        This rodent model showed that pharmacologically increasing SIRT3, as recommended in this article, can counteract Œ±-synuclein-induced mitochondrial dysfunction by reducing Œ±-synuclein oligomers and normalizing mitochondrial bioenergetics. 
                    </p>
                </li>

            </ol>
        </section>
        <section id="testing-and-diagnosis">
            <h3>Testing and Diagnosis</h3>
            
            <p>
            Upon clinical diagnosis of PD (via <abbr title="Unified Parkinson's Disease Rating Scale">UPDRS</abbr> score), serious damage has already been done to nerve cells of the substantia nigra. This underscores the importance of early testing and genetic testing. <cite class="reflink"><a href="#f-nouri-emamzadeh">F. Nouri Emamzadeh</a></cite>
            </p>

            <p>
                Alpha-synuclein oligomers are higher in PD patients than in healthy subjects. This can be tested with AlphaSyn-SAA salivary test or Syn-One skin biopsy.
            </p>
            <h3>Early Testing and Diagnosis with AlphaSyn-SAA</h3>
            <p>
                The AlphaSyn-SAA salivary test measures the levels of salivary alpha-amylase (SAA). The results are used to assess autonomic nervous system activity, particularly sympathetic nervous system activation. This test can, with some margin of error, identify people at risk of developing Parkinson‚Äôs disease <em>up to ten years</em> before symptoms appear. 
            </p>
            <h3>Syn-One</h3>
            <p>
                The Syn-One skin biopsy detects the presence of phosphorylated alpha-synuclein in the skin. This is a much more accurate test than the AlphaSyn-SAA and is usually used as confirmation, rather than a preventive diagnostic. 
            </p>
            <section id="genetic-testing">
                <h4>Genetic Testing</h4>
                <p>
                    Most cases of Parkinson's Disease are not classified as genetic. Genetic testing for PD is not routinely performed because only about 15% of cases are determined to be genetic. It's a classic <dfn>absence of evidence</dfn> fallacy.
                </p>
                <p>
                    Genetic testing for PD can help better inform and guide its treatment.
                    Genes associated with PD may have varying effects on disease progression. (See also: <a href="https://www.michaeljfox.org/what-know-about-genetic-testing"
                    target="_blank"
                    >What to Know about Genetic Testing</a>) <cite class="reflink"><a href="#l-cook">L. Cook</a></cite>
                </p>
        
                <p>
                    All genetic types should be considered for the proposed treatments, with the focus and approach varying depending on the genetic mutation and its associated molecular pathway. Discussion of the genetic type and its associated treatments is recommended among the healthcare team.
                </p>
                <h5>Test Your Children</h5>
                <p>
                    Children of PD patients should be tested <em>before</em> they exhibit symptoms similar to those of PD. Symptoms may take up to 10 years to present. 
                </p>
                
                <h5>Testing Locations</h5>
        
                <p>
                Genetic testing for these mutations can be done at specialized medical centers and genetic testing companies. Some notable places include:
                </p>
                <ul>
                    <li>
                        <a href="https://www.mayo.edu/research/labs/parkinsons-disease/overview" target="_blank">Mayo Clinic</a>
                    </li>
                    <li>
                        <a href="https://www.hopkinsmedicine.org/health/conditions-and-diseases/parkinsons-disease/the-genetic-link-to-parkinsons-disease" target="_blank">Johns Hopkins Medicine</a>
                    </li>
                    <li>
                        <a href="https://www.23andme.com/topics/health-predispositions/parkinsons-disease/" target="_blank">23andMe</a>
                    </li>
                    <li>
                        <a href="https://www.invitae.com/us/providers/test-catalog/gene-21080" target="_blank">Invitae</a>
                    </li>
                    <li>
                        <a href="https://providers.genedx.com/tests/detail/parkinson-disease-panel-1005" target="_blank">GeneDx</a>
                    </li>
                </ul>
                <h4>Genetic Forms of PD and Corresponding Treatments</h4>
                <dl id="genetic-forms-treatments">
                    <dt><abbr title="Synuclein Alpha Gene">SNCA gene</abbr></dt>
                    <dd>Anti-aggregant, antifibrillogenic, antioxidant, neuroprotective.</dd>

                    <dt><abbr title="Leucine Rich Repeat Kinase 2">LRRK2</abbr></dt>
                    <dd>LRRK2 inhibitors, anti-inflammatory, neuroprotective, <a href="#dbs" title="Deep Brain Stimulation">dbs</a>, b-12.</dd>

                    <dt><abbr title="PTEN-induced Kinase 1">PINK1</abbr> &amp; Parkin</dt>
                    <dd>Mitochondrial, mitophagy, antioxidant.</dd>

                    <dt><abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr></dt>
                    <dd>Antioxidant, mitochondrial, <a href="#vitamin-b1">thiamine</a>.</dd>

                    <dt><abbr title="Ubiquitin C-Terminal Hydrolase L1">UCHL1</abbr></dt>
                    <dd>Ubiquitin-proteasome, anti-aggregant.</dd>
                </dl>

                <h4>Genetic Treatment Approaches</h4>

                <p>
                    A custom-tailored care plan based on the genetic type of PD will predict the best outcomes.
                </p>
                <p>
                    Effective treatment must approach PD from multiple angles. The review <cite>"Current Therapies in Clinical Trials of Parkinson‚Äôs Disease: A 2021 Update"</cite>, provides a fair overview of PD.
                </p>
        
				<h4>References</h4>
                <ol class="reference-list">
                    <li id="f-nouri-emamzadeh">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122110/"
                        title="Alpha-synuclein structure, functions, and interactions"
                        target="_blank"
                        >Alpha-synuclein structure, functions, and interactions</a>, Fatemeh Nouri Emamzadeh.
                        <p>
                            Upon clinical diagnosis of PD, serious damage has already been done to nerve cells of the substantia nigra pars compacta. This underscores the importance of early testing and genetic testing. 
                        </p>
                    </li>

                    <li id="l-cook"> 
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101316/"
                            title="Genetic Testing for Parkinson Disease"
                            target="_blank"
                        >Genetic Testing for Parkinson Disease</a>, Lola Cook, et al.
                        <p>
                            In some cases, identification of PD variants may aid in the diagnosis, management, and prediction of disease course.
                        </p>
                    </li>
                </ol>
            </section>
        </section>
    </section>
    <section id="introduction-to-health">
        <h2>A Brief Introduction to Health</h2>
        <p>
            Knowledge is crucial for achieving predictable success.
        </p>
    
        <p>
            <dfn>Optimal health</dfn> describes a state of physical and neurological functioning, not merely the absence of disease. However, healthcare professionals often describe it using broad and oversimplified terms. 
        </p>
        <p>
            The first step in optimizing health involves understanding the general condition and acquiring basic knowledge of cellular health, neurology, and the human organism (we've barely scratched the surface). 
        </p>
            <blockquote>
            <p>
                <q>If you are not your own doctor, you are a fool.</q>
            </p>
            <p><cite>‚Äî Hippocrates</cite> </p>
        </blockquote>
        
        <h3>Health Assessments:</h3>
        <ol>
            <li>Balanced hormone levels</li>
            <li>Efficient metabolism (<abbr title="Basic Metabolic Panel">BMP</abbr>)</li>
            <li>Healthy blood pressure and cholesterol levels</li>
            <li>Healthy Blood markers (<abbr title="Complete Blood Count">CBC</abbr>)</li>
            <li>Strong immune system (<dfn title="CBC with White Blood Cell Differential">CBC with WBC differential</dfn>)</li>
        </ol>

    
        <h4>But We Could Go Deeper:</h4>
        <ol>
            <li>Resting heart rate below 60 beats per minute (fitness trackers)</li>
            <li>Well-functioning organs and systems, including cardiovascular, respiratory, and digestive systems (<abbr title="Comprehensive Metabolic Panel">CMP</abbr>)</li>
            <li>Normal blood pressure (around 120/80 mmHg)</li>
            <li><del>Crude lipid profile with low LDL and high HDL cholesterol</del></li>
            <li>More useful lipid profile with <em>high</em> <abbr title="Large, Buoyant Low-Density Lipoprotein">lbLDL</abbr> and <abbr title="Large, Buoyant Low-Density Lipoprotein">lbHDL</abbr>, low <abbr title="Small, Dense Low-Density Lipoprotein">sdLDL</abbr> and <abbr title="Small, Dense High-Density Lipoprotein">sdHDL</abbr>, and a high ratio of <abbr title="Large, Buoyant High-Density Lipoprotein">lbHDL</abbr> to <abbr title="Large, Buoyant Low-Density Lipoprotein">lbLDL</abbr> (Cardio IQ¬Æ Advanced Lipid Panel)</li>
            <li>Healthy body composition; low visceral fat (<abbr title="dual-energy X-ray absorptiometry">DEXA</abbr>)</li>
            <li>Optimal levels of inflammation and oxidative stress (Test panels: Cytokine Markers, Inflammatory Markers, Oxidative Stress Markers Panel (for <abbr title="Malondialdehyde, to indirectly measure oxidative damage (of ROS and RNS)">MDA</abbr>))</li>
        </ol>

        <h4>Deeper Yet:</h4>
        <ol>
            <li>Genetic testing for personal health (<a href="https://www.innerbody.com/dna-testing/dna-health-testing">Finding the Best DNA Health Test</a>).</li>
            <li>Advanced hormone tests (<a href="https://dutchtest.com/info-dutch-complete/">Dutch Complete</a>).</li>
            <li>Healthy immune system, focusing on dendritic cells (DCs), with detailed analysis of lymphocyte subsets, activation, and tracking using the <abbr title="Co-Stimulatory Activity Test for Immune Modulation">COSTIM</abbr> bioassay to measure co-stimulatory activity. Antibody Response Exam (ARE) via <abbr title="Enzyme-Linked Immunosorbent Assay">ELISA</abbr> to measure autoantibodies in the blood.</li>

            <li>Stable blood glucose levels maintained by insulin sensitivity (<abbr title="Oral Glucose Tolerance Test">OGTT</abbr>, <abbr title="Continuous Glucose Monitor">CGM</abbr>).</li>
            <li>Adequate cellular repair mechanisms ensuring tissue integrity and longevity (<a title="TruAge COMPLETE at-home epigenetic test" href="https://shop.trudiagnostic.com/products/truage-complete-epigenetic-collection">TruAge</a>).</li>
            <li>Optimal mitochondrial function providing energy for cellular activities (<a href="https://aonm.org/mitochondrial-testing/">mitochondrial testing</a>).</li>
            <li>Healthy methylation (Genova Diagnostics Methylation Panel).</li>
            <li>Omega-3 Blood Test (<a target="_blank" href="https://requestatest.com/omega-3-blood-test">OmegaCheck¬Æ</a>)
            </li>
        </ol>
        
        <h4>Focusing on the Brain:</h4>
        <ol>
            <li>Low neuroinflammation through balanced cytokine production and microglial modulation (Cytokine Panel, Multiplex ELISA)
            <li>Synaptic plasticity for quick learning and memory formation (<abbr title="Brain-derived Neurotrophic Factor">BDNF</abbr> test, <abbr title="Mini-Mental State Examination">MMSE</abbr>, <abbr title="Montreal Cognitive Assessment">MoCA</abbr>, <abbr title="Digit Symbol Substitution Test">DSST</abbr>, Stroop Test, etc).
            <li>Minimal neuroinflammation and neuronal damage.
            <li>Efficient energy metabolism through optimal mitochondrial function and glucose utilization.
            <li>Precise and sensitive regulation of neurotransmitter synthesis via enzyme pathways and receptor feedback mechanisms (<abbr title="Liquid Chromatography-Tandem Mass Spectrometry">LC-MS/MS</abbr> and <abbr title="High-Performance Liquid Chromatography">HPLC</abbr> for dopamine, serotonin, and norepinephrine) 
        </ol>
    
        <h4>Monitoring and Testing Those Brain Health Parameters Involves:</h4>
        <ol>
            <li>Neuroimaging techniques like <abbr title="Functional Magnetic Resonance Imaging">fMRI</abbr>, <abbr title="Single Photon Emission Computed Tomography">SPECT</abbr>, and DaTscan (a specialized form of <abbr title="Single Photon Emission Computed Tomography">SPECT</abbr> optimized to detect changes in dopamine transporter density), to visualize brain structures.
            <li>Measurement of neurotransmitter levels in bodily fluids with chromatography.
            <li>PET imaging with specific radiotracers to assess microglial activation and neuroinflammation.
            <li>Analysis of cytokine levels in blood or cerebrospinal fluid through <abbr title="Enzyme-Linked ImmunoSorbent Assay">ELISA</abbr> or <abbr title="Polymerase Chain Reaction">PCR methods</abbr>.
            <li>Evaluation of mitochondrial function through assays measuring ATP production, membrane potential, and oxidative stress levels (ATP Bioluminescence Assay, <a target="_blank" href="https://www.caymanchem.com/product/701010">MitoCheck</a>, ROS Detection Assay Kit, JC-1 Assay, Glutathione Test (<a target="_blank" href="https://www.labcorp.com/tests/007700/glutathione-total">CPT: 82978</a>), CellTiter-Glo Luminescent Cell Viability Assay (<a target="_blank" href="https://www.promega.com/products/cell-health-assays/cell-viability-and-cytotoxicity-assays/celltiter_glo-luminescent-cell-viability-assay/">CellTiter-Glo¬Æ</a>))
        </ol>
        
        <p>
            Monitoring and testing brain health involves specialized assessments that require a deeper understanding of neurobiology and physiology. Understanding the interplay between that and some of the recommendations in this guide (<abbr title="Levodopa / Dopa-decarboxylase inhibitors">LD/DDC inhibitors</abbr>, melatonin, <abbr title="Photobiomodulation">PBM</abbr>, mitochondrial quinones), requires an extraordinary mind. Developing a care plan around that is monumentally difficult, not just for the complexity of the problem, but for the dearth of professionals up to the task.
        </p>
        <p>
            Those who take their condition seriously and employ the best strategies to mitigate the progression of the disease will enjoy a greater quality of life and longevity. The tired "ask your doctor" mantra does not lead to greater self-empowerment through understanding and does not apply here. Learn, you must.
        </p>
    </section>
    <section id="care-team">
        <h2>
            How to Build a Care Team
        </h2>
        <section id="care-team-introduction">
            <h3>Introduction</h3>

            <p>
                Optimizing health is complex, and a diagnosis with PD increases both the complexity and the need to overcome it. Conventional medicine generally fails to adequately address peripheral and autonomic nervous system (ANS) dysfunction, which typically manifests as GI issues, loss of bladder and bowel control, sleep problems, and ultimately, heart failure and death. 
            </p>
            <p>
				Seeking 'alternative' approaches without critical analysis is equally flawed. The only true alternative to effective treatment is ineffective treatment, and that raises the problem of determining efficacy.
            </p>
            <p>
				Many medical professionals 'conventional' or 'alternative', fall short, and trusting them them without questioning and verifying their recommendations leads may lead you to taking other medications, none of which improve health but instead hasten disease progression, down the aforementioned path of <abbr title="Progessive Neurodegeneration">PN</abbr>, <abbr title="autonomic nervous system">ANS</abbr> failure, and the inevitability of what follows. (For PD, these may include beta-3 agonists, anticholinergics, or fludrocortisones.) To add insult to injury, they might advise "mind, body, spirit" treatments that lack a clear mechanism of action or compelling evidence. 
            </p>
                        
            <p>
            	It is the patient's responsibility to audit his medical team. Start by consulting independent specialists, exploring reputable integrative medicine practices, and seeking out patient communities where you can find recommendations for doctors who prioritize a comprehensive approach. 
            </p>

            <p>
				The onus of responsibility to learn, assess claims, and take actions for your health is on you. This involves understanding the science behind treatments and engaging in self-advocacy to actively participate in the decision-making process. Skepticism isn't just healthy; it's fundamentally essential for survival and well-being.
            </p>
        </section>

        <!-- section id="how-to-interview-neurologist">
            <h3>Questions to Ask a Potential Neurologist</h3>
                How can I test my mitochondrial function?
                
        </section -->
        <section id="hypothetical-care-team">
            <h3>
                Hypothetical Care Team
            </h3>
            <p>
                This is a structured, customizable framework designed for self-directed health optimization in Parkinson's Disease.
            </p>

            <ol>
                <li>Neurologist for planning, diagnosis, and oversight.
                <li>Functional and Integrative Medicine Specialist for planning, diagnosis, and oversight.
                <li>Movement Specialist.
                <li>Physical Therapist.
                <li>Research involvement for cutting-edge options.
                <li>Biomarker Testing Laboratory for personalized testing to monitor disease progression, treatment response, and optimization.
            </ol>
            
            <h3>How to Interview Neurologists</h3>
            <p>
                Doctors are constrained by institutional protocols, which may limit their consideration of alternative treatment options.
             </p>
             <p>
                Assessing provider competence requires a more thorough approach than just checking credentials, affiliations, and years of experience.
            </p>
            <p>
                Approach the interview from a position of informed knowledge without revealing too much. When given the opportunity to speak freely, how do they err?
            </p>
            
            <p>
                The effectiveness of that strategy depends on one's knowledge and comprehension ‚Äî specifically the depth and breadth of understanding and the ability to evaluate and scrutinize the accuracy of the interlocutor's information.
            </p>
            
            <p>
                Better results are achieved by preparing detailed questions that delve into the neurologist's expertise in the specific area of concern.
            </p>
            
            <section>
                <h3>Q &amp; A</h3>
                <p>
                    Below are example questions from the perspective of an <em>active participant</em>. These questions should be critically examined and may be used as the basis for better questions.
                </p>
    
                <h4>"In your initial assessment of a patient suspected to have Parkinson's Disease, what tests and evaluations do you conduct?"</h4>
    
                <h4>
                ‚úÖ Good answers must include:
                </h4>
                <ul class="good-answers">
                    <li> Diagnostic imaging with DaTscan (Dopamine Transporter Scan) and <abbr title="Functional Magnetic Resonance Imaging">fMRI</abbr> to map dopamine distribution in the brain and assess broader brain function, respectively.
                    <li> Syn-One skin biopsy
                </ul>
                <p>
                    &mdash; and that is beyond the very basic fundamentals of:&mdash;
                </p>
    
                <ul class="baseline-answers">
                    <li> Detailed medical history and symptom review.
                    <li> Thorough examination of motor symptoms.
                    <li> Evaluation of non-motor symptoms such as sleep disturbances, autonomic dysfunction, and mood disorders.
                </ul>
    
                <h4>
                ‚ùå Bad Answers:
                </h4>
                <ul class="bad-answers">
                    <li> Not mentioning genetic testing without providing context or justification.
                    <li> 
                        Preferring simpler imaging over more detailed <abbr title="Functional Magnetic Resonance Imaging">fMRI</abbr> and DaTscan imaging.
                        <p>
                            <abbr title="Dopamine Transporter Scan">DaTscan</abbr> is a specialized form of <abbr title="Single Photon Emission Computed Tomography">SPECT</abbr> optimized to detect changes in dopamine transporter density and is useful in the broader assessment of the condition.
                        </p>
                        <p>
                             <abbr title="Functional Magnetic Resonance Imaging">fMRI</abbr> scans map out broader brain networks affected by PD, beyond just dopamine pathways. This information might help inform broader strategies, including supplementation.
                        </p>
                    </li>
                    <li>
                        Generalization without specifying the detailed steps of the neurological examination and symptom review.
                    </li>
                    
                </ul>
    
                <h4>"Why do you include or exclude genetic testing in your initial assessment for Parkinson's Disease?"</h4>
    
                <h4>‚úÖ Good answers:</h4>
                <p>
                    Acknowledgment of the importance of genetic factors in (1) creating custom-tailored solutions and (2) testing one's offspring for inherited traits. 
                </p>
    
                <h4>"How do you address non-motor symptoms in the management of Parkinson's Disease?"</h4>
                <p>
                    Treatments that the patient understands well and fall outside conventional medicine, along with their mechanisms of action, should be asked about.
                </p>
    
                <h4>‚ùå Bad answers:</h4>
                <ul class="bad-answers">
    
                    <li>
                        Dismissive generalizations about 'alternative' treatments ‚Äî reveal bias or knowledge gaps regarding effective treatments and their mechanisms of action.
                    </li>
                    <li>
                         If the doctor can't explain the mechanisms of action (e.g., of turmeric, photobiomodulation) in simple terms, he likely doesn't understand them well himself.
                    </li>
                </ul>
    
                <h4>"Can you provide an example of how you adapted a treatment plan based on new research findings in Parkinson's Disease?"</h4>
    
                <p>
                    ‚úÖ A good response should include a recent example of implementing new research-based treatment, with evidence, rationale, and measured results.
                </p>
            </section>
            <h4>Summary</h4>
                <p>
            These questions and expected answers help ensure doctors follow a comprehensive, current approach to PD but also demonstrate critical thinking and a nuanced understanding of the disease. Doctors are people, and are not immune to the irrational trappings of common mental errors.
                </p>
        </section>
        <section id="tips-for-selecting-providers">
                <h3>Tips for Selecting Providers</h3>
                <p>
                    Referrals can be initiated by a PCP, a neurologist, or a functional medicine specialist. The starting point is inconsequential; the objective is to assemble a comprehensive care team.
                </p>
                <p>
                    Some doctors are subject to protocols or guidelines established by their institution's medical board or regulatory bodies, and this can influence their treatment decisions. Seek a neurologist with the autonomy and openness to explore novel, evidence-based treatments beyond the standard of care.
                </p>
                <p>
                    Patient-centered care addressing root causes and individualized needs predicts the best results. Starting with a Functional and Integrative Medicine Specialist can be great. However, to avoid unqualified practitioners, it's essential to be well-informed.
                </p>
                <p>
                    During your initial consultation with a neurologist, discuss optimizing health to minimize <abbr title="Dopamine Replacement Therapy">DRT</abbr>.  Ask about specific treatments such as <a href="#hrt" title="hormone replacement therapy">HRT</a>, <a title="Photobiomodulation" href="#pbm">PBM</a>, and <a href="#5-htp">5-HTP</a>, and how they might interact with <abbr title="Dopamine Replacement Therapy">DRT</abbr>. If the doctor cannot explain their benefits or potential interactions, consider finding another doctor.
                </p>
        
                <blockquote>
                    <p>
                        &ldquo;It is better to know some of the questions than all of the answers.&rdquo;
                    </p>
                    <cite>&mdash; James Thurber</cite>
                </blockquote>
        
                <p>
                    Creating a health optimization plan is difficult, especially for PD, which requires specialized expertise. Those who approach this with seriousness and understanding can expect to achieve a better quality of life and longevity.
                </p>
            </section>

    </section>
    <section id="treatment-approaches">
        <h2>Treatment Approaches</h2>
        <section id="treatment-approaches-overview">
            <h3>Overview</h3>
            <!-- p>
                This section lists treatments for which strategies can be developed by one's care team.
            </p -->
        
            <!-- p>
                The approach recommended herein is not the tired "listen to your doctor," but to get informed and build a team of healthcare professionals with multiple specialties with whom to collaborate on an individualized treatment plan. 
            </p -->
        
            <p>
                Treatment strategies can be grouped into <dfn>symptomatic</dfn>, <dfn>disease progression</dfn>, <dfn>etiological</dfn>, and <dfn>holistic</dfn> categories, with some overlap.
            </p>
            <dl>
                <dt>Symptomatic Approach
                <dd>addresses symptoms rather than slowing or stopping their progression
                
                <dt>Disease-Progression Approach
                <dd>manages progression of the disease once it has already developed
                
                <dt>Etiological Approach
                <dd>targets the underlying causes of disease with thorough investigation and research
                <dt>Holistic Approach
                <dd>patient-centered care that targets underlying causes and addresses them more comprehensively
                </dl>
        </section>
        <section id="symptomatic-approach">
            <h3>Symptomatic Approach</h3>
            <h5>Gold Standard: Dopamine Agonism</h5>
            <p class="call-out">
                The gold standard for managing PD is symptomatic management via dopamine agonism (<abbr title="Levodopa / Dopa-decarboxylase inhibitors">LD/DDC inhibitors</abbr>, MAO-B inhibitors, and <dfn title="catechol-O-methyltransferase">COMT</dfn> inhibitors). Unfortunately, that leads to other neurological imbalances, causes other nutrient deficiencies, and leads to PN.
            </p>
            <p>
                Maintaining dopamine levels in the brain helps alleviate motor problems and can reduce fibrillization. However, unilateral dopamine replacement therapy creates some problems discussed further herein.
            </p>
            <p>
                Some doctors may attempt to enhance dopamine function by suppressing the cholinergic system using anticholinergics, but this approach leads to adverse effects.
            </p>        
        </section>
        
        <section id="disease-progression-approach">
            <h4>Disease-Progression Approach</h4>
            <p>
                Doctors tend to discount the idea of slowing the progression of the disease. Some off-handedly discount supplements and nutrition as "complementary" care without examination. Many of these same doctors once prescribed anticholinergics. (If the doctor falls into that category, finding a new doctor may be advisable.)
            </p>
        </section>
        <section id="etiological-approach">
         <h3>Etiological Approach</h3>
         
        <p>
            Etiological treatments target the underlying causes of disease. These providers address the root causes with scientific rigor however, some may rely on conventional medicine and focus on the disease itself, rather than individual factors and health optimization.
        </p> 
        </section>
        
        <section id="holistic-approach">
            <h3>Holistic Approach</h3>
            <p>
                The holistic approach is patient-centered care that aims to address the underlying causes of disease and promote overall health. However, some holistic providers use implausible or disproven strategies (e.g. homeopathy, reiki, "mind, body, spirit", etc). 
            </p>
        </section>
    <!-- TODO: Move where??
            <h4>The Role of Nutrition</h4>
            <p>
                Nutritional deficiencies can exacerbate symptoms in individuals with PD and may sometimes be mistaken for progressive neurodegeneration. This misinterpretation can lead to inappropriate management strategies if the underlying nutritional issues are not addressed.
            </p>
            <p>
                Furthermore, certain nutrient deficiencies can trigger cascading effects, exacerbating PD symptoms or hasten the decline of the condition. For example, deficiencies in vitamins B12, folate, and vitamin D have been implicated in PD and can affect neurological function and overall health. Inadequate intake of essential nutrients can also impair mitochondrial function, increase oxidative stress, and compromise neurotransmitter synthesis and signaling, all of which are implicated in PD pathophysiology.
            </p>
            <p>
                Additionally, levodopa/carbidopa therapy can reduce vitamin B6 levels, which is essential for the synthesis of neurotransmitters.
            </p>
            <p>
                It's crucial to build a comprehensive plan that strikes a balance between supplementation, nutrition, lifestyle, and regular monitoring to slow disease progression.
            </p>
            <p>
                Don't just "talk to your doctor", collaborate with a team of healthcare professionals with multiple specialties to create individualized treatment plans that include nutrition, lifestyle, supplementation, and medication. Regularly test and monitor status with symptoms and biochemical markers to assess the effectiveness of interventions and make adjustments as needed.
            </p>
            <p>
                <dfn>Antifibrillogenics</dfn> mitigate formation of Œ±-synuclein fibrils. Anti-aggregants aim to prevent the accumulation of fibrils and other misfolded proteins into lewy bodies. By preventing the formation of Œ±-synuclein fibrils and aggregates, these compounds address the underlying pathology of Parkinson's disease at a more fundamental level, potentially offering therapeutic benefits in managing the condition.
            </p>
            <p>
                Preventing fibril aggregation (<dfn>anti-aggregant</dfn>): These treatments focus on inhibiting the aggregation of Œ±-synuclein fibrils into Lewy bodies, potentially slowing the spread of pathology and neurodegeneration.
            </p>
            <p>
                It is necessary to work with doctors who focus on what works. Focus on the facts and evidence, consider risk/reward, and work on total health. Avoid doctors who won't look at the evidence you present them.
            </p>
            
            <h4>What Do Doctors Miss?</h4>
            <p>
                Doctors typically prioritize symptoms over addressing the underlying causes. Specifically, they tend to focus on the dopamine pathway with medications like levodopa/carbidopa, to enhance dopamine levels in the brain, and COMT inhibitors, to inhibit its breakdown by catechol-O-methyltransferase (COMT).
            </p>
            <p>
                Approaches to mitigating the underlying cause can extend longevity, improve quality of life, and reduce the dependence on medication which is not without side effects. Address these key areas for a more comprehensive approach to managing PD. (For solutions, see: <a href="#problem-list">Problem List</a>)
            </p>
            <ul>
                <li class="senolytic">Senescence: Senolytics</li>
                <li class="mitochondrial">Mitochondrial health: Mitophagy and mitogenesis</li>
                <li class="neuroprotective">Neuroprotective measures</li>
                <li class="neuroinflammation">Anti-inflammatory: Reducing neuroinflammation</li>
                <li class="cytotoxicity">Reducing cytotoxicity</li>
                <li class="multiple-pathways">Addressing Dopaminergic, serotonergic, and GABAergic systems</li>
                <li class="fibrils">Preventing fibril formation and aggregation</li>
                <li class="sleep">Sleep management</li>
                <li class="total-health">
                    Overall health promotion
                </li>
            </ul>

            <p>
                Many approaches overlap more than one problem area and have synergistic benefits. For example, 5-HTP is converted into serotonin in the brain. It inhibits the release of glutamate, mitigates oxidation modulates dopamine
                release, improves mitochondrial function, and improves sleep, which improves overall health, leading to a better sense of well-being and better exercise capacity and recovery.
            </p>
            -->
    </section>

    <section id="etiological-problems">
		<h3>The Best Approach</h3>
		<p>
			The best possible individual results can be predicted by a comprehensive, evidence-based approach. Care that is etiologically sound, evidence-based, patient-centered, integrated, and comprehensive should be investigated, and skepticism should be applied regarding the veracity of claims made by all healthcare providers.
		</p>

		<!-- TODO: Move to new peptides section? p>
			Peptide therapy, by practitioner in-home visits, can be used (SS-31, AICAR, Epitalon, Pinealon).
		</p -->
		
		<p>
			Here are some approaches to target underlying problem areas:
		</p>
		<dl id="problems-list">
			<dt class="antifibrillogenic">Antifibrillogenic</dt>
			<dd>Preventing fibril formation of Œ±-synuclein</dd>

			<dt class="anti-aggregant">Anti-aggregant</dt>
			<dd>Preventing aggregation of fibril and other junk</dd>

			<dt class="anti-ischemic">Anti-ischemic</dt>
			<dd>Promoting blood flow deep within the brain</dd>

			<dt class="senolytic">Senolytic</dt>
			<dd>Targeting senescent cells</dd>

			<dt class="mitochondrial">Mitochondrial</dt>
			<dd>Promoting mitochondrial health (mitogenesis, mitophagy)</dd>

			<dt class="sleep">Sleep</dt>
			<dd>Addressing insomnia</dd>

			<dt class="dopaminergic">Helps DRT side-effects</dt>
			<dd>Mitigating side effects of dopaminergic treatments (e.g., dyskinesia, impulse control disorders)</dd>

			<dt class="neuroprotective">Neuroprotective</dt>
			<dd>Protecting neuronal structure and function</dd>

			<dt class="antioxidant">Antioxidant</dt>
			<dd>Oxidative stress causes Œ±-synuclein aggregation and neuroinflammation in PD. <cite class="reflink"><a href="#s-j-won">S.J. Won</a></cite></dd>

			<dt class="anti-inflammatory">Anti-inflammatory</dt>
			<dd>Reducing inflammation</dd>

			<dt class="neurorestorative">Neurorestorative</dt>
			<dd>Promoting recovery and regeneration of neural tissue</dd>
		</dl>
		<!-- p>
			Supplements, peptides, therapies, drugs, and stem cells can mitigate &alpha;-synuclein overexpression, reduce mutant &alpha;-synuclein, strengthen the mitochondria, reduce the side effects of LD/dopa decarboxylase (DDC), decrease the need for LD/dopa decarboxylase, reduce ROS, improve mood, improve sleep, improve recovery.
		</p -->

		<h4>References</h4>
		<ol class="reference-list">
			<li id="s-j-won">
				<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774295/"
				title="Neuronal Oxidative Stress Promotes Œ±-Synuclein Aggregation In Vivo"
				target="_blank"
				>Neuronal Oxidative Stress Promotes Œ±-Synuclein Aggregation In Vivo</a>, Seok Joon Won, et al.
				<p>
				
				</p>
			</li>
		</ol>
	</section>
    <section id="treatment-plan">
        <h2>
           Treatment Starter Plan
        </h2>
        <p>
            The Treatment Starter Plan is a structured, customizable framework for self-directed management of Parkinson's Disease with a health-optimization mindset. 
        </p>
        <ol>
            <li>Adopt a mindset to maximize health.
            <li>Get <a href="#genetic-testing">genetic testing</a>.
            <li>Learn health (<a href="#introduction-to-health">basic overview</a>).
            <li>Learn <a href="#introduction-to-pd">Parkinson's Disease</a>.
            <li>Learn about <a href="#food-and-supplements">supplements</a> and get started with the <a href="#how-to-build-a-supplement-plan">Supplement Starter Plan</a>.
            <li>Get a <a href="#pbm">Red Light Therapy</a> device and learn how to use it.
            <li>Look into <a href="#hormonal-interventions">Hormonal Interventions</a>.
            <li>Build a <a href="#care-team">Care Team</a>.
            <li>Develop an <a href="#exercise">exercise</a> plan.
            <li>Consider early <a href="#dbs">Deep Brain Stimulation (DBS)</a> for longevity.
            <li>Look into cellular treatments like <a href="#gene-therapy">Gene Therapy</a>, <a href="#nad-injection">NAD+ Injections</a>, and <a href="#msc">Stem Cells</a>. 
            <li>Continue to revise.
        </ol>
 
        <p>
            The <a href="#care-team">care team</a> prioritizes patient needs over their own. For this to be effective, a thorough, detailed understanding of the condition and treatments is essential.
        </p>
        
        <h4>Question Assumptions</h4>
        <p>
            Recognized experts may lack thoroughness. Therefore, it is important to question the methods used to reach conclusions, learn the underlying principles, and apply critical thinking to make sound, informed decisions.
        </p>
        
        <p>
            Before attempting to answer any question, examine the framing or assumptions inherent in it, and evaluate the underlying assumptions, biases, and implications embedded within the question itself. Question the question.
        </p>

        <p>
            Start by questioning the question. Carefully evaluate the risks and benefits of each step outlined above. What is missing, misleading, or wrong?
        </p>
    </section>
        
    <section id="treatments">
        <h2>Detailed Treatments</h2>
        <section id="medications">
            <h3>Medications</h3>
            
            <h4>Standard of Care Medications</h4>
            <p class="call-out">
                Parkinson's disease is generally treated with symptomatic management. That includes:&mdash;
            </p>
            
            <ul>
                <li>Levodopa/Carbidopa (Dopamine Agonists)</li>
                <li>COMT Inhibitors</li>
                <li>MAO-B Inhibitors</li>
                <li>Anticholinergics ‚ùå WARNING: Cognitive impairment.</li>
            </ul>
            <p>
                Levodopa/Carbidopa are dopamine agonists. COMT inhibitors prevent the breakdown of dopamine. Both classes of drugs exhibit dopaminergic side effects.
            </p>
            
            <h4>Criticism of Standard of Care</h4>
               
            <p>
				Standard of Care practices generally fall short in addressing the complexities of various medical conditions, including neurological disorders like PD.
			</p>
			
			<p>
				Medical schools and institutions often have long-standing traditions and biases toward conventional treatments. This bias is reinforced through outdated curricula, faculty influence, and institutional culture that prioritize traditional industry solutions over innovative approaches.
			</p>
			<p>
				Government policies and regulations often shape medical practice and can create conflicts of interest. For example, the FDA‚Äôs accelerated approval of Aduhelm in 2021, despite mixed trial results, was criticized due to concerns over industry influence and lobbying by Biogen
			</p>
			<p>
				Pharmaceutical funding creates conflicts of interest that permeate medical institutions. Students, often unaware of the bias, are encouraged to win teacher favor and earn good grades by adopting industry-supported ideologies while avoiding questioning the establishment or exploring other approaches.
			</p>
			<p>
				For example, the <a href="https://www.nice.org.uk/guidance/ng71/chapter/Recommendations#pharmacological-management-of-motor-symptoms" target="_blank">NICE guidelines</a> recommend the use of anticholinergics for managing PD symptoms, despite their known negative effects on cognitive function, membrane integrity, and synaptic plasticity (for more, see: <a href="#cholinergics">cholinergics</a>). These recommendations highlight the broader issue of prioritizing pharmaceuticals over patient-centric care, pushing reliance on drugs and limiting opportunities for optimizing health beyond symptom management.
			</p>

			<h5>Anticholinergics</h5>
			<p>
				Standard of care recommendations include drugs that do not address underlying pathologies and may cause physical damage. Anticholinergics, such as Benztropine, are still recommended for managing symptoms like incontinence in PD, despite their well-established potential to impair cognitive function, affect neuronal transmission, and disrupt synaptic plasticity. The mechanisms behind their side effects, including memory problems and confusion, are well-documented. <cite class="reflink"><a href="#campbell">Campbell</a>, <a href="#yasumasa">Yasumasa</a></cite>
			</p>
			
			<p>
				While dopamine replacement therapy (DRT) is commonly used to manage motor symptoms, its overreliance can lead to long-term complications such as motor fluctuations and dyskinesias, which will be discussed further below. These examples highlight the limitations of standard treatment approaches and the need for strategies that address underlying pathologies, minimize harmful effects, and optimize health.
			</p>

			<h5>Supplementation</h5>
			<p>				
				Conversely, they oppose the use of over-the-counter supplements, specifically mentioning CoQ10, Vitamin E (unspecified form), and creatine ‚Äî all of which have shown efficacy in neurodegenerative conditions, without prior consultation with a healthcare professional. Given that healthcare professionals are not trained in health optimization, such inquiries will likely result in denial of efficacy and refusal to look at evidence. This reflects a broader reluctance within the medical community of "not invented here" to eschew non-prescription treatments, often resulting in a dependency on conventional pharmaceuticals.
			</p>
			
			<p>
			Discouraging safe and potentially beneficial supplements while promoting anticholinergics reflects an incentive to maintain the status quo of pharmaceutical reliance and healthcare control over self-empowerment and patient health optimization.
			</p>
			
			<h5>Genetic Testing</h5>
			<p>
				Moreover, identifying PD gene mutations, especially in early-onset cases, can provide crucial information for prognosis and influence treatment decisions, particularly in cases initially suspected to be psychogenic. Despite this, genetic testing is not part of the standard of care.
			</p>

            <section id="dopamine-agonists">
                <h4>Dopamine Replacement Therapy &mdash; Overview</h4>
            
                <p>
                    Dopamine replacement therapy (DRT) for PD commonly includes levodopa/carbidopa (LD/DDC inhibitor) and MAO-B inhibitors. 
                </p>
                
                <p>
                    Replenishing dopamine levels in the brain helps alleviate motor symptoms such as tremors, rigidity, and bradykinesia (slowness, freezing), improving patients' quality of life. However, dopamine replacement therapy has other effects, good and bad.
                </p>
            
                <h4>Impact of Dopamine Agonists</h4>

                <h5>Fibrillization Inhibition</h5>
                <p>
                    Dopamine agonists inhibit fibrillization by reacting with the Œ±-synuclein. This is an advantage, as fibrils contribute to cellular damage, senescent cells, and neurodegeneration. <cite class="reflink"><a href="#dorszewska">dorszewska</a></cite>
                </p>

                <h5>Problems</h5>
                <p>
                    Dopamine's antifibrillogenic effects are good but its interaction with Œ±-synuclein also contributes to cellular damage and neurodegeneration. <cite class="reflink"><a href="#mor">mor</a>, <a href="#thompson">thompson</a></cite>
                </p>
                <p>
                   Dopaminergic modulation must therefore be carefully balanced to achieve optimal neuroprotection. Better neuroprotection and healthspan can be achieved through the multi-faceted approach described in the <a href="#treatment-plan">Treatment Starter Plan</a>. 
                </p>

                <h5>Neurochemical and Vitamin Imbalances</h5>
                <p>
                    Dopamine agonists also deplete active vitamin B6 levels in the body. They do this by irreversibly binding to and permanently deactivating pyridoxal 5‚Äô-phosphate (P5P), the active form of vitamin B6. This leads to various side effects and exacerbates the progression of the disease, as B6 is essential for dopamine synthesis and is involved in other metabolic pathways.
                </p>

                <h5>Progressive Neurodegeneration</h5>
                <p>
                    Dopamine is but one of many neurochemical systems in the midbrain. Focusing solely on the dopaminergic system without considering other neurotransmitter systems leads to progressive neurodegeneration (PN) exacerbating motor and non-motor symptoms.
                </p>
                
                <h5 class="diagram-header">DRT Neurodegeneration Cycle Diagram</h5>
                <div id="drt-diagram" class="diagram">
                    <div class="concept">
                        <h6>Dopamine Agonists</h6>
                        <p>Dopamine agonists inhibit fibrillization by interacting with Œ±-synuclein.</p>
                        <div class="arrow"></div>
                    </div>
                
                    <div class="concept">
                        <h6>Fibrillization Inhibition</h6>
                        <p>Stops cellular damage, senescence, and neurodegeneration. 
                        </p>
                        <div class="arrow"></div>
                    </div>
                
                    <div class="concept">
                        <h6>Problems</h6>
                        <p>Dopamine interacts with Œ±-synuclein causing non-fibrillar oligomers, cell damage and neurodegeneration.</p>
                        <div class="arrow"></div>
                    </div>
                
                    <div class="concept">
                        <h6>Harmful Cycle</h6>
                        <p>The cycle continues with increased dopamine use leading back to cell damage and neurodegeneration.</p>
                    </div>
                </div>

                <h4>Dopamine Replacement Therapy &mdash; Summary</h4>
                <p>
                    DRT should be used at the minimum effective dose (MED). This can be done using a holistic approach to address neuroprotection, neurorestoration, antioxidation, and mitochondrial health.
                </p>
                
                <h5>References</h5>
                <ol class="reference-list">
					<li id="campbell">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697587/"
							title="The cognitive impact of anticholinergics: A clinical review"
							target="_blank"
							>The cognitive impact of anticholinergics: A clinical review</a>, Noll Campbell, et al.
                    </li>
                	<li id="yasumasa">
                        <a href="https://www.sciencedirect.com/science/article/pii/S096999611100283X"
                        title="Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model"
                        target="_blank"
                        >Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model</a>, Yasumasa Yoshiyama, et al.
                    </li>
                    
                    <li id="dorszewska">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958954/"
                        title="Molecular Effects of L-dopa Therapy in Parkinson‚Äôs Disease"
                        target="_blank"
                        >Molecular Effects of L-dopa Therapy in Parkinson‚Äôs Disease</a>, Jolanta Dorszewska, et al.
                        <p>
                        
                        </p>
                    </li>
                    
                    
                    <li id="thompson">
                        <a href="https://www.stressmarq.com/alpha-synuclein-oligomers-dopamine-stabilization-and-neurodegeneration/"
                        title="Alpha Synuclein Oligomers: Dopamine Stabilization and Neurodegeneration"
                        target="_blank"
                        >Alpha Synuclein Oligomers: Dopamine Stabilization and Neurodegeneration</a>, Patricia Thompson.
                        <p>
                        
                        </p>
                    </li>
                    <li id="mor">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379109/"
                        title="The usual suspects, dopamine and alpha synuclein, conspire to cause neurodegeneration"
                        target="_blank"
                        >The usual suspects, dopamine and alpha synuclein, conspire to cause neurodegeneration</a>, Danielle E. Mor, et al.
                        <p>
                        
                        </p>
                    </li>
                </ol>
            </section>           
            <section id="comt-inhibitors">   
                <h4>COMT Inhibitors</h4>
                
                <p>
                    COMT inhibitors are a class of medications that prolong the effect of levodopa by inhibiting the breakdown of dopamine in the brain. They work by blocking the action of the enzyme catechol-O-methyltransferase (COMT), which breaks down catecholamines, including dopamine, norepinephrine, and epinephrine, resulting in sustained levels of these catecholamines.
                </p>
                <p>
                    Tolcapone, a COMT inhibitor, has been associated with a higher risk of liver damage, which can be severe in some cases.
                </p>
                <p>
                    Entacapone, another COMT inhibitor, has been linked to an increased risk of dyskinesias and other dopaminergic side effects.
                </p>
            </section>
            <section id="mao-b-inhibitors">
                 <h4>MAO-B Inhibitors</h4>
                 <p>
                    Problems with MAO-B Inhibitors, such as side effects, dietary restrictions, and potential interactions with other medications, have contributed to a decline in their use.
                 </p>
            </section>

            <section id="synuclean-d-and-minzasolmin">
                <h4>SynuClean-D and Minzasolmin üß™</h4>
                <p>
                SynuClean-D and Minzasolmin are in the research phase. There are outlets for research chemicals, and there are ongoing clinical trials.
                <p>
                    https://sciencebeta.com/synuclean-d-parkinsons/
                </p>
                <ol>
                    <li>
                        <h4>SynuClean-D Can Revert Neurodegeneration Caused By Parkinson's</h4>
                        <p>
                            SynuClean-D inhibits &alpha;-synuclein aggregation, disrupts amyloid fibrillization, prevents degeneration of dopaminergic neurons (<a href="https://pubmed.ncbi.nlm.nih.gov/30249646/"><abbr title="Proceedings of the National Academy of Sciences">reference</abbr></a>), and inhibits &alpha;-synuclein aggregation.
                        </p>
                        <p>
                            SynuClean-D is available as a research chemical. It is being studied in a Phase 2 clinical trial of 450 early-stage PD patients with an expected completion date in mid-2024.
                        </p>
                    </li>
                    <li>
                        <h4>Minzasolmin</h4>
                        <p>
                            Minzasolmin is a misfolding inhibitor, whereas SynuClean-D is an aggregation inhibitor. While Minzasolmin is in clinical development for Parkinson‚Äôs disease, SynuClean-D is primarily mentioned as a research compound.
                        </p>
                        <p>
                           Patients with Parkinson‚Äôs disease can apply to participate in clinical trials for Minzasolmin. The clinical trial information is available on ClinicalTrials.gov (ID: NCT04658186; EudraCT Number 2020-003265).
                        </p>
                    </li>
                </ol>
                <h4>Summary</h4>
                <p>
                    Minzasolmin and SynuClean-D both seem promising in inhibiting the misfolding and aggregation of &alpha;-synuclein aggregation respectively. Ask your team about clinical trials or apply to participate directly with those trials' clinicians.
                </p>
            </section>
        </section>
        <section id="hormonal-interventions">
            <h3>Hormonal Interventions</h3>
            <section id="hrt">
                <h4 class="neuroprotective">Estrogen</h4>
            
                <h5>Early Menopause and PD</h5>
                <p>
                    Early menopause has been observed with statistical significance across women with PD. Postmenopausal HRT has been associated with a reduced PD risk in several studies. It has been repeatedly shown that more women without PD used postmenopausal estrogen compared with women with PD. The neuroprotective effects of estrogen replacement have shown positive results in animal models of PD, and in early menopausal women with PD. <cite class="reflink"><a href="#l-currie">L. Currie</a>, <a href="#d-brann">D. Brann</a></cite>
                </p>
                
                <p>
                    A 2023 study published in Alzheimer's Research & Therapy found HRT introduction is associated with improved delayed memory and larger entorhinal and amygdala volumes, but in <abbr title="Apolipoprotein E allele 4">APOE4</abbr> carriers only. APOE4 is associated with increased Œ±-synuclein pathology in humans with PD. <cite class="reflink"><a href="#r-saleh">R. Saleh</a></cite>
                </p>
                <p>
                    A retrospective chart review of a computerized patient database was performed at Columbia-Presbyterian. The review included only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa. This research found a positive association between estrogen use and lower symptom severity in women with early PD who were not yet taking L-dopa. This indicates that estrogen therapy may be beneficial for women with early PD who entered menopause early and have not yet started <abbr title="Dopamine Replacement Therapy">DRT</abbr>. <cite class="reflink"><a href="#r-pullman">R Saunders-Pullman</a></cite>
                </p>
                <p>
                     In a rodent model of PD, estrogen replacement reduced dopaminergic neuron loss, promoted maturation of <dfn title="the breakdown and degradation of cellular components by the cell itself">autophagy</dfn>, improved motor function and other symptoms, and slowed disease progression. <cite class="reflink"><a href="#x-li">X.Z. Li</a></cite>
                </p>
                <p>
                    The use of estrogen replacement in early menopausal women with PD is worth considering. <cite class="reflink"><a href="#m-borque">M. Borque</a></cite>
                </p>
                
                <h5>Osteocalcin ‚Äî Estrogen's Effects on Osteoblasts</h5>
                <p>
                    Estrogen stimulates osteoblasts, which produce osteocalcin (OCN). Some of that OCN is then carboxylated in a vitamin K-dependent process, resulting in carboxylated OCN and some is undercarboxylated OCN (ucOCN). Carboxylated OCN improves bone strength.
                </p>
                <p>
                     Undercarboxylated OCN acts as a hormone in the body and brain. OCN crosses the blood-brain barrier and has been shown to reach the midbrain and brainstem and influence brain functions such as memory and cognition. <cite class="reflink"><a href="#obri">A. Obri</a></cite>
                </p>
                
                <p>
                    The reduction in osteocalcin production during menopause, including uncarboxylated osteocalcin, can lead to decreased neuroprotection and cognitive functions.
                </p>
                
                <h5>Risks of HRT in Women</h5>
                <p>
                    The risks of estrogen replacement therapy include vascular disease and stimulation of estrogen-responsive cancer, and should not be taken without measured risk and medical supervision. Alternatives to increasing osteocalcin levels include high-impact and weight-bearing exercise, and supplementation of vitamin K, magnesium, strontium, collagen, sleep, and vitamin D.
                </p>
                
                <h4>Testosterone</h4>
                <p>
                    Testosterone is also neuroprotective, and 5-10% of it converts to estradiol via aromatase. Thus, <abbr title="Testosterone Replacement Therapy">TRT</abbr> can be used in men to raise testosterone to <em>optimal</em> levels (~800 ng/dL), resulting in a greater amount of aromatization to estradiol. <cite class="reflink"><a 
             href="#v-e-bianchi">V.E. Banchi</a></cite>
                </p>
                
                <h4>References</h4>
                
                <ol class="reference-list">
                    <li id="l-currie">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15210525/"
                        title="Postmenopausal estrogen use affects risk for Parkinson disease"
                        target="_blank"
                        >Postmenopausal estrogen use affects risk for Parkinson disease</a>, Lillian J Currie, et al.
                    </li>
                    <li id="d-brann">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2048656/"
                        title="Neurotrophic and Neuroprotective Actions of Estrogen: Basic Mechanisms and Clinical Implications"
                        target="_blank"
                        >Neurotrophic and Neuroprotective Actions of Estrogen: Basic Mechanisms and Clinical Implications</a>, Darrell W. Brann, et al.
                    </li>
                    <li id="r-saleh">
                        <a href="https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5"
                        title="Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer‚Äôs Disease (EPAD) cohort"
                        target="_blank"
                        >Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer‚Äôs Disease (EPAD) cohort</a>, Rasha N. M. Saleh, et al.
 
                    </li>
                     <li id="r-pullman">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10227628/"
                        title="The effect of estrogen replacement on early Parkinson's disease"
                        target="_blank"
                        >The effect of estrogen replacement on early Parkinson's disease</a>, R Saunders-Pullman, et al.

                    </li>
                    
                    <li id="x-li">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095307/"
                        title="The effects and mechanism of estrogen on rats with Parkinson‚Äôs disease in different age groups"
                        target="_blank"
                        >The effects and mechanism of estrogen on rats with Parkinson‚Äôs disease in different age groups</a>, Xue-Zhong Li, et al.
                        <p>
                        
                        </p>
                    </li>
                    <li id="obri">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958904/"
                        title="Osteocalcin in the brain: from embryonic development to age-related decline in cognition"
                        target="_blank"
                        >Osteocalcin in the brain: from embryonic development to age-related decline in cognition</a>, Arnaud Obri, et al.
 
                    </li>
                    <li id="m-borque">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356083/"
                        target="_blank"
                        title="ale/female differences in neuroprotection and neuromodulation of brain dopamine"
                        >Male/female differences in neuroprotection and neuromodulation of brain dopamine</a>, M√©lanie Bourque, et al.
                        <p>
                            This review paper concluded that exogenous 17Œ≤-estradiol and/or progesterone treatments show neuroprotective properties against nigrostriatal dopaminergic toxins while androgens fail to induce any beneficial effect.
                        </p>
                    </li>
                    
                    <li id="v-e-bianchi">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568521/"
                        title="Androgen Therapy in Neurodegenerative Diseases"
                        target="_blank"
                        >Androgen Therapy in Neurodegenerative Diseases</a>, Vittorio Emanuele Bianchi, et al.
                        <p>
                            This thorough review cites 266 references to support a wealth of information regarding the role of testosterone in neuroprotection, neuroinflammation, and neurodegeneration.
                        </p>
                        <blockquote>
                            <p>
                                <q>T improves the survival of human neurons and astrocytes, acting directly on the mitochondrial membrane, inhibiting the generation of reactive oxygen and nitrogen species, as well as sirtuin-1 expression. Conversely, its absence may contribute to neurodegenerative processes, as observed in animal models of PD and AD, and may decrease the density of spinal synapses in the hippocampus. These pathological effects were reversed following treatment with T or DHT; 17Œ≤-estradiol, likely, partially mediates these effects.</q>
                            </p>
                        </blockquote>
                    </li>
                </ol>
            </section>

            <section id="dhea">
                <h5 class="neuroprotective">Dehydroepiandrosterone (DHEA)</h5>
                <p>
                    Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal glands, the ovaries, and the brain. It is a precursor to estrogen and testosterone and is converted into estrogen and testosterone in peripheral tissues.
                </p>
                <p>
                    DHEA is also involved in the regulation of sleep, memory, and cholesterol levels.
                </p>
                <p>
                    DHEA may help protect against the progression of PD. This is due to its ability to modulate memory formation, regulate neuronal activity, and enhance or restore memory and learning processes.
                </p>
                <p>
                DHEA can signal osteoblasts both directly and via its metabolites, such as estradiol (E2) and dihydrotestosterone (DHT). It also signals chondrocytes through these metabolites. Additionally, the blood-brain axis, facilitated by osteoblast stimulation, may be a mechanism through which DHEA enhances cognitive function. <cite class="reflink"><a href="#d-kirby">D. Kirby</a></cite>
                </p>
                <p>
                    Like pregnenolone, DHEA is fat-soluble, which allows it to cross the BBB relatively easily, and is available as a dietary supplement. The recommended dosage is 100mg ED.
                </p>
                <p>
                    A study found that DHEA administration alone improved the mean Parkinsonian score (<abbr title="Unified Parkinson's Disease Rating Scale">UPDRS</abbr>) in moderately and severely impaired MPTP monkeys, a model of Parkinson‚Äôs disease. <cite class="reflink"><a href="#">D. Kirby</a></cite>
                </p>
                <p>
                    A 2006 Cochrane study found no current evidence for an improvement in memory or other aspects of cognitive function of non‚Äêdemented older people following DHEA supplements. However, a 2016 review found a positive correlation between DHEA-S blood levels and global cognition in both women and men. Other positive correlations between DHEA-S and working memory, attention, and verbal fluency were found only in women. DHEA's effects being more pronounced in women than in men may be due to its potential ability to ameliorate menopausal cognitive decline. <cite class="reflink"><a href="#j-evans">J. Evans</a>, <a href="#k-menezes">K. Menezes</a>, <a href="#s-vale">S. Vale</a></cite>
                </p>    
                
                <h4>References</h4>
                <ol class="reference-list">
                    <li id="d-kirby">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32504237/"
                        title="DHEA in bone: the role in osteoporosis and fracture healing"
                        target="_blank"
                        >DHEA in bone: the role in osteoporosis and fracture healing</a>, David J Kirby, et al
                    </li>
                    <li id="n-belanger">
                        <a href="https://www.sciencedirect.com/science/article/abs/pii/S0197458005003003"
                        >DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys</a>, Nancy B√©langer, et al.
                    </li>
                    <li id="j-evans">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988513/"
                        title="Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people"
                        target="_blank"
                        >Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people</a>, John Grimley Evans, et al.
                    </li>
                    <li id="k-menezes">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894834/"
                        title="Dehydroepiandrosterone, Its Sulfate and Cognitive Functions"
                        target="_blank"
                        >Dehydroepiandrosterone, Its Sulfate and Cognitive Functions</a>, Karina Junqueira de Menezes, et al.
                    </li>
                    <li id="s-vale">
                        <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0104869"
                        title="The Relationship between Dehydroepiandrosterone (DHEA), Working Memory and Distraction ‚Äì A Behavioral and Electrophysiological Approach"
                        target="_blank"
                        >The Relationship between Dehydroepiandrosterone (DHEA), Working Memory and Distraction ‚Äì A Behavioral and Electrophysiological Approach</a>, S√≥nia do Vale, et al.
                    </li>
                </ol>
            </section>
        </section>
        <section id="pregnenolone">
            <h4>Pregnenolone</h4>
            <p>
                Pregnenolone is a neurosteroid and precursor to various hormones, including cortisol, DHEA, and progesterone. Pregenolone reduces levodopa-induced dyskinesias (LIDs) without compromising L-DOPA's motor benefits.
            </p>
            <h5>Pregnenolone Dosage</h5>
            <p>
                Pregnenolone is available as a dietary supplement and is typically safe in doses ranging from 10 to 50 mg per day.
            </p>
            <p>
                Pregnenolone is fat-soluble and crosses the BBB. Once in the brain, pregnenolone can be converted into other neurosteroids, such as allopregnanolone, which have various effects on neuronal function and behavior.
            </p>                
            <p>
                Several clinical studies have investigated pregnenolone as a treatment for Parkinson‚Äôs disease. One study found that pregnenolone dose-dependently countered L-DOPA-induced dyskinesias (LIDs) without affecting L-DOPA-induced motor improvements. 
            </p>

			<h4>References</h4>
            <ol class="reference-list">
                <li>
                    <p>
                        A study found that DHEA administration alone improved the mean parkinsonian score in moderately and severely impaired MPTP monkeys, a model of Parkinson‚Äôs disease. 
                        <a href="https://www.sciencedirect.com/science/article/pii/S0014488623000547"
                        >Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease</a>
                    </p>
                </li>
            </ol>
        </section>
        <section id="dbs" class="neuroprotective">
            <h3>Deep Brain Stimulation (DBS)</h3>
            <p>
                Deep Brain Stimulation (DBS) uses electrodes implanted in the brain to deliver electrical impulses to the globus pallidus internus (GPi). This helps to regulate brain activity.
            </p>
            
            <h4>LRRK2-G2019S and DBS</h4>
            <p>
                <abbr title='Leucine-Rich Repeat Kinase 2 gene with a glycine to serine substitution at position 2019'>LRRK2-G2019S</abbr> mutations tend to have relatively good outcomes with DBS compared to other genetic types. 
            </p>
            
            <p>
                DBS of the (GPi) primarily targets the GABAergic output neurons of the basal ganglia, influencing motor output and reducing motor symptoms in PD. However, the therapeutic effects of GPi stimulation in PD extend beyond
                modulating GABAergic transmission within the basal ganglia circuitry and can indirectly impact cortical glutamatergic <em>input</em> to the basal ganglia.
            </p>
            <p>
                While GPi stimulation primarily targets the GABAergic output of the basal ganglia, the dopaminergic system a core problem in PD pathology and treatment. Dopamine depletion in the basal ganglia is a hallmark feature of
                PD and leads to motor symptoms such as bradykinesia, tremors, and rigidity, and DBS helps treat these problems.
            </p>
            <p>
                Other neurotransmitter systems affected by DBS include the serotonergic, cholinergic, noradrenergic, and glutamatergic systems. Due to the delicate balance between all these systems stimulation of the entire GPi can more
                easily achieve a positive, balanced effect, compared to medication and supplementation with l-dopa/carbidopa and supplements like 5-HTP and GABA.
            </p>
            <p>
                This normalizes basal ganglion activity resulting in reduced excitotoxicity, better neuronal function, and greater cell longevity.
            </p>
            <p>
                Medication alone leads to PN. DBS reduces the need for medication, thus mitigating PN. Supplementation further reduces the need for medication, and thus PN. A team of specialists to craft a program with DBS, medication,
                and supplementation may offer the best possible outcome with the least PN and greater longevity.
            </p>
            <p>
                Crafting a personalized treatment program that incorporates DBS, medication, and supplementation requires the expertise of a multidisciplinary team of specialists, including neurologists, movement disorder specialists,
                neurosurgeons, pharmacists, dietitians, and other healthcare professionals. This team can collaborate to tailor treatment to the individual patient's needs, optimize therapy, and minimize PN.
            </p>
        </section>
        
        <section id="gene-therapy">
            <h3>Gene Therapy</h3>

            
            <p>
                Gene therapy is designed to repair the dopamine system. The procedure involves injecting a gene into the brain.
            </p>
            
            <h3>Cell Therapies</h3>
            <p>
                <dfn>Cell replacement</dfn> is the injection of dopamine cells into the brain to replace those that are lost or dying. 
            </p>

			<h4>References</h4>
            <ol class="reference-list">
                <li>
                    <a href="https://www.parkinson.org/blog/research/gene-cell-based-therapies"
                    title="Exploring the Potential of Gene and Cell-Based Therapies in Parkinson‚Äôs"
                    target="_blank"
                    >Exploring the Potential of Gene and Cell-Based Therapies in Parkinson‚Äôs</a>, (Anonymous)
                    <p>
                    
                    </p>
                </li>
            </ol>
        </section>
        <section id="stem-cell">
            <h4 class="neuroprotective neurorestorative">Stem Cells (MSC, iPSC)</h4>
            <h5>Mesenchymal Stem Cells (MSCs)</h5>
            <p>
                Systemic injection of mesenchymal stem cells helps restore dopaminergic neurons. <cite class="reflink"><a 
         href="#h-j-park">h-j-park</a></cite>
            </p>
            
            <p>
                The concomitant use of cell therapy and photobiomodulation therapy can improve the symptoms of PD. <cite class="reflink"><a 
         href="#b-ahrabi">b-ahrabi</a></cite>
            </p>
            
            <h5>Induced Pluripotent Stem Cells (iPSCs)</h5>
            <p>
                Induced pluripotent stem cells (iPSCs) are generated by reprogramming adult somatic cells, such as skin or blood cells, to express the same genes as embryonic stem cells in a process called <dfn>induced pluripotency</dfn>.
           </p>
           <p>  
                 iPSCs can differentiate into any cell type in the body, similar to embryonic stem cells, but they are generated from adult cells, which makes them a promising source for regenerative medicine and tissue engineering. intracerebrally injected into the striatum and substantia nigra of PD patients.
            </p>
            
            <p>
                Few clinics use iPSCs. <a href="https://stemaid.com/">Stemaid</a> is one of them. Stemaid is located in San Jos√© del Cabo, Mexico. <a href="https://cynata.com/contact-us">Cynata</a> in Victoria, Australia is another. I cannot attest to anything about either of these clinics.
            </p>
            
            <h5>References</h5>
            <ol class="reference-list">
                <li id="w-chen">
                     <a href="https://pubmed.ncbi.nlm.nih.gov/30346716/"
                     title="Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease"
                     target="_blank">Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease</a>
                    <p>
                        "Stable cell sources, such as Embryonic stem cells (ESCs) and induced pluripotent stem cell (iPSCs), are far more suitable for clinical application than hfVM- and embryonic or fetal brain-derived NSCs."
                    </p>
                </li>
                <li id="h-j-park">
                 <a href="https://pubmed.ncbi.nlm.nih.gov/18665911/"
                 title="Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease."
                 >Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease.</a>, Hyun Jung Park, et al.
                 <p>
                    
                    </p>
                 </li>
                 
                <li id="b-ahrabi">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841383/"
                    title="Photobiomodulation Therapy and Cell Therapy Improved Parkinson‚Äôs Diseases by Neuro-regeneration and Tremor Inhibition"
                    target="_blank"
                    >Photobiomodulation Therapy and Cell Therapy Improved Parkinson‚Äôs Diseases by Neuro-regeneration and Tremor Inhibition</a>, Behnaz Ahrabi, et al.
                    <p>
                        This review study showed the concomitant use of cell therapy and photobiomodulation therapy can improve the symptoms of PD.
                    </p>
                </li>
             </ol>
        </section>
        <section id="exercise">
            <h3>Exercise</h3>
            
            <h4>Physiological Response in the Brain</h4>
            <p>
             <abbr title="High intensity interval training">HIIT</abbr>, more than any other type of exercise, has been shown to fight neurodegeneration. It simultaneously stimulates multiple pathways and increases cerebral blood flow. Moderate and lower intensity cardiovascular exercise. "Zone 3" and "Zone 2" respectively, and active recovery provide supplementary benefits. <cite class="reflink"><a href="#lenhart">Lenhart</a>, <a href="#s-e-lucas">S.E. Lucas</a></cite>
            </p>
            
            <p>
                <abbr title="High-Intensity Interval Training">HIIT</abbr>, high-intensity cardiovascular training, resistance training, and endurance training are respectively the most effective at increasing neurotrophins such as <abbr title="Brain-Derived Neurotrophic Factor">BDNF</abbr>, <abbr title="Nerve Growth Factor">NGF</abbr>, <abbr title="Vascular Endothelial Growth Factor">VEGF</abbr>, <abbr title="Glial Line-Derived Neurotrophic Factor">GDNF</abbr>, <abbr title="Fibroblast Growth Factor 2">FGF2</abbr>, and <abbr title="Neurotrophin-3">NT-3</abbr>. These neurotrophins help protect neurons and glial cells.
            </p>
            <p>
              Higher-intensity exercise increases the production of neuropeptides (<abbr title="Neuropeptide Y">NPY</abbr>, <dfn title="Substance P ‚Äî neuropeptide involved in various physiological processes.">Substance P</dfn>, Enkephalins) and signaling hormones (<abbr title="Insulin-like Growth Factor 1">IGF-1</abbr>, <abbr title="vascular endothelial growth factor">VEGF</abbr>, Cortisol). These effects enhance autophagy, mitochondrial function, and reduce neural apoptosis. Additionally, they improve ischemic conditions, mitigate oxidative stress, and boost insulin sensitivity and glucose uptake, leading to lower blood glucose and improved sleep.
            </p>
            
            <h4>Lower-intensity Exercise (Zone 2)</h4>   
            <p>			
				Lower intensity exercise, such as "Zone 2", is moderately low intensity aerobic exercise, such as fast walking or hiking, that occurs just below the lactate threshold and can be sustained for a long period without strain or heavy breathing. Although low-intensity exercise may not boost neurotrophic factors as acutely as high-intensity workouts, it supports overall brain health and helps maintain a baseline level of these factors for improved endurance, enhanced recovery, increased mitochondrial production, and reduced overtraining, making it an excellent addition to any fitness routine.
            </p>
            
            <h4>Proprioceptive Activities</h4>
            <p>
				Complex motor activities that require significant proprioception, such as dancing, have been shown to be beneficial and may increase blood flow to the midbrain. Further research is needed to clarify their precise effects on <abbr title="Glial Line-Derived Neurotrophic Factor">GDNF</abbr>. <cite class="reflink"><a href="#baudet">Baudet</a>, <a href="#aman">Aman</a></cite>
            </p>
           
            <h4>Peak Performance</h4>
            <p>
            	Increasing exercise intensity, VO<sub>2</sub> max, duration, and frequency leads to greater benefits. Contrary to the "minimum effective dose" approach in medicine, with exercise, more is better. By pushing the limits of exercise tolerance through training modulation and recovery strategies, individuals can maximize their neurological health. 
            </p>
            
            <h4>Limits to Exercise</h4>
            <p>
                Intense exercise, while beneficial, is physically and mentally taxing, increasing Reactive Oxygen and Nitrogen Species (RONS) and creating metabolic waste. To maximize the benefits of exercise, incorporate active recovery strategies such as mobility work, supplementation, and red light therapy to enhance exercise tolerance.
            </p>
            
            <h4>Supplementation and Recovery</h4>
            <p>
                Timing supplementation around exercise is beneficial as it enhances nutrient delivery to the brain due to increased cerebral blood flow. Pre- and intra-workout supplementation can boost performance, while post-workout supplementation aids in recovery and improves subsequent performance. Protein intake immediately after exercise can increase satiety and reduce energy intake, which helps regulate blood glucose levels. <cite class="reflink"><a href="#querido">Querido</a>, <a href="#clayton">D. Clayton</a>, <a href="#monteyne">A. Monteyne</a></cite>
            </p>
            
            <p>
                For example, <a href="#creatine">creatine monohydrate supplementation</a> increases brain creatine levels. During stress or trauma, such as intense exercise, creatine helps reduce oxidative DNA damage and restores normal brain and body creatine levels.
            </p>
            <h4>Types of Exercise</h4>
            <p>
                The categories of exercise that elicit a physiological effect on the brain include:
            </p>
            <dl>
            	<dt>HIIT  &mdash; High Intensity Interval Training
            	<dd> short periods of high-intensity effort, followed by brief periods of rest or low-intensity activity. This alternating pattern is repeated until exhaustion to maintain heart rate throughout the workout.
				</dd>
				
                <dt> HIT &mdash; High Intensity Training
                </dt>
                
                <dd> Targets strength training with high intensity and brief workouts. This improves cognitive function and brain health by increasing cerebral blood flow, <abbr title="Brain-derived Neurotrophic Factor">BDNF</abbr>, IGF-1, and osteocalcin. <cite class="reflink"><a href="#browne">Browne</a></cite>
                </dd>
                
                <dt>Zone 4 cardio</dt>
                <dd>High-intensity exercise zone,  80-90% of maximum heart rate (HRmax), Typically 2-10 minutes with a maximum sustained duration of around 15 minutes. Also known as "lactate threshold" or redline training.
                </dd>
                
                <dt> Zone 3 &mdash; Moderate-intensity cardiovascular training (70-80% of HRmax) 
                </dt>
                <dd> Enhances cerebral blood flow, metabolic, and cardiovascular health with a reduced risk of injury.
                </dd>               
                <dt> Zone 2 &mdash;¬†Low-intensity cardiovascular training
                </dt>
                <dd>  Boosts aerobic endurance and promotes recovery with minimal injury risk.
                </dd>               
            </dl>

            <h4>Active Recovery</h4>
            <p>
                Active recovery elevates heart rate, enhancing blood flow to deliver nutrients and remove waste from tissues and hasten recovery. It can address mobility issues such as tight hips and a weak core or glutes, reducing injury risk.
            </p>
            
            <p>
                Exercise increases brain blood flow, delivering oxygen and nutrients to brain cells. This triggers processes like neurogenesis, increased neurotransmitter production, and improved stress tolerance. Additionally, it boosts <abbr title="Brain-derived Neurotrophic Factor">BDNF</abbr>, promotes autophagy, reduces proinflammatory cytokines, and lowers blood sugar. These effects enhance memory, cognition, and mood, helping to counter neurodegeneration.
            </p>
            
            <p>
                This results in better memory and cognition and improved mood, countering or staving off neurodegeneration.
            </p>
            
            <h4>Mitochondrial Benefits</h4>
            <p>
                Regular exercise enhances NAD+ biosynthesis, activates AMP-activated protein kinase (AMPK) and sirtuins, and stimulates mitochondrial biogenesis. It also promotes mitochondrial turnover and mitophagy, supporting healthy mitochondrial function.
            </p>
            
            <h4>Sample Exercise Plan</h4>
            <ul>
                <li>Day 1: HIT + Zone 2 Cardio
                </li><li>Day 2: Zone 3 Cardio (40 min ergometer)
                </li><li>Day 3: HIIT + Active Recovery
                </li><li>Day 4: Zone 3 Cardio
                </li><li>Day 5: HIT + Zone 2 Cardio
                </li><li>Day 6: Zone 3 Cardio
                </li><li>Day 7: HIIT + Active Recovery
                </li>
            </ul>
            
            <h4>Summary</h4>
            <p>
            	Intense exercise counteracts neurodegeneration and enhances neurological health by increasing cerebral blood flow, promoting neurogenesis, boosting neurotransmitter production, and reducing inflammation. Different exercise types, including <abbr title="High intensity interval training">HIIT</abbr>, <abbr title="High intensity training">HIT</abbr>, Zone 3, Zone 2, offer distinct benefits. Balancing intense exercise with active recovery helps reduce injury and hasten recovery to improve exercise tolerance and maximize the results.
            </p>
            
            <h4>References</h4>
            <ol class="reference-list">
				
            	<li id="s-e-lucas">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640257/"
					title="High-intensity interval exercise and cerebrovascular health: curiosity, cause, and consequence"
					target="_blank"
					>High-intensity interval exercise and cerebrovascular health: curiosity, cause, and consequence</a>, Samuel J E Lucas, et al.
				</li>
            
            	<li id="lenhart">
					<a href="https://journals.lww.com/acsm-msse/fulltext/2019/06001/the_impact_of_varying_exercise_protocols_on.2347.aspx"
					title="The Impact of Varying Exercise Protocols on Neurogenesis and Angiogenesis in the Dentate Gyrus"
					target="_blank"
					>The Impact of Varying Exercise Protocols on Neurogenesis and Angiogenesis in the Dentate Gyrus</a>, Lenhart, Darrin.
				</li>
            	<li id="baudet">
					<a href="https://pubmed.ncbi.nlm.nih.gov/11003834/"
					title="Positive and negative interactions of GDNF, NTN and ART in developing sensory neuron subpopulations, and their collaboration with neurotrophins"
					target="_blank"
					>Positive and negative interactions of GDNF, NTN and ART in developing sensory neuron subpopulations, and their collaboration with neurotrophins</a>, C Baudet, et al.
				</li>
				<li id="aman">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309156/"
					title="The effectiveness of proprioceptive training for improving motor function: a systematic review"
					target="_blank"
					>The effectiveness of proprioceptive training for improving motor function: a systematic review</a>, Joshua E. Aman, et al.
				</li>
                <li id="querido"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/17722948/" title="Regulation of cerebral blood flow during exercise" target="_blank" rel="noopener">Regulation of cerebral blood flow during exercise</a>, Jordan S Querido, A William Sheel. 
                </li>
                <li id="clayton">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/25049135/"
                    title="The effect of post-exercise drink macronutrient content on appetite and energy intake"
                    target="_blank"
                    >The effect of post-exercise drink macronutrient content on appetite and energy intake</a>, David J Clayton, et al.
                </li>
                <li id="monteyne">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845592/"
                    title="Whey protein consumption after resistance exercise reduces energy intake at a post-exercise meal"
                    target="_blank"
                    >Whey protein consumption after resistance exercise reduces energy intake at a post-exercise meal</a>, Alistair Monteyne, et al.
                </li>
                <li id="browne">
                    <a href="https://www.sciencedirect.com/science/article/abs/pii/S0079612317300535"
                    title="Chapter 9 - Effects of acute high-intensity exercise on cognitive performance in trained individuals: A systematic review"
                    target="_blank"
                    >Chapter 9 - Effects of acute high-intensity exercise on cognitive performance in trained individuals: A systematic review</a>, Sarah E. Browne, et al.
                </li>
            </ol>
        </section>
        
        <section id="pbm">
            <h3 class="neuroprotective">Photobiomodulation (PBM)</h3>
            <p>
                Photobiomodulation (PBM) is a non-invasive, low-risk treatment to improve cellular function. PBM can be done in clinics or independently, with consumer devices.
            </p>
            <ul>
                <li>Enhances mitochondrial function and ATP production. <cite class="reflink"><a href="#m-r-hamblin1">Michael Hamblin<sup>1</sup></a></cite></li>
                <li>Increases expression <abbr title="Brain-derived Neurotrophic Factor">BDNF</abbr>. <cite class="reflink"><a href="#meng">Chengbo Meng</a></cite></li>
                <li>Reduces oxidative stress and inflammation. <cite class="reflink"><a href="#michael-r-hamblin">Michael Hamblin</a></cite></li>
                <li>Promotes neuroprotection and neuroregeneration. <cite class="reflink"><a href="#michael-r-hamblin">Michael Hamblin</a></cite></li>
                <li>Improves cognitive function in PD patients. <cite class="reflink"><a href="#nizamutdinov1">Damir Nizamutdinov<sup>1</sup></a></cite>
                <cite class="reflink"><a href="#damir-nizamutdinov">Damir Nizamutdinov</a></cite></li>
                <li>Improves sleep. <cite class="reflink"><a href="#jiexiu-zhao">Jiexiu Zhao</a></cite></li>
            </ul>
            
            <h4>Oxidative Stress and Inflammation</h4>
            <p>
            PBM inhibits hippocampal damage induced by oxidative stress and increases BDNF levels, making it suitable for treating nerve damage. <cite class="reflink"><a href="#j-c-heo">J.C. Heo</a></cite>
            </p>
            
            <h4>Ischemia and Blood Flow</h4>
             <p>
                PBM's anti-inflammatory effects mitigate inflammation from ischemic injury, reducing tissue damage and promoting healing. It increases local blood flow and oxygenation in ischemic tissues, alleviating hypoxia (low oxygen levels) and promoting tissue recovery.
            </p>
            <p>
                Ischemia can affect the delivery of therapeutic agents to the desired target in the midbrain. During ischemic events, blood flow to affected brain regions can be significantly compromised, limiting the delivery of oxygen, nutrients, and therapeutic compounds like cells (as mentioned elsewhere), melatonin, and anything crossing the BBB via passive diffusion. 
            </p>
            
            <p>
                Although numerous positive results have been observed in humans, depth penetration of the light waves is a concern. NIR light penetrates deeper than NIR, and coherent NIR (<abbr title="Light Amplification by Stimulated Emission of Radiation">laser</abbr>) even deeper. Cellular effects observed in rodents with NIR light can't be extrapolated to the much larger head thickness (and midbrain depth) of humans. <cite class="reflink"><a href="#y-lampl">Y. Lampl</a></cite>
            </p>
            <h4>Timing</h4>
            <p>
                The timing of PBM, in conjunction with the administration of substances like melatonin, may help improve delivery by mitigating the effects of ischemic inhibition on nutrient delivery to the midbrain.
            </p>
            
            <p>
                Whole body irradiation with red light improves sleep quality. Used before sleep may offer better sleep effects. <cite class="reflink"><a href="#jiexiu-zhao">Jiexiu Zhao</a></cite>
            </p>

            <h4>Frequency</h4>
            <p>
                PBM in Alzheimer‚Äôs and Parkinson‚Äôs disease models have necessitated repeated daily exposure to show beneficial results. In-home devices offer convenience, comfort, and affordability.
            </p>
            <p>
                Red light reaches the motor cortex, influences stem cell function, offers neuroprotection, restores functional activity, improves motor behaviors and reduces clinical signs, reduces <dfn title="Gliosos &mdash; when glial cells, CNS cells that support nerve cells, proliferate or hypertrophy in response to damage">gliosis</dfn>, and induces expression of trophic growth factors. 
                <cite class="reflink"><a href="#c-hamilton">C. Hamilton</a></cite>
            </p>
            
            <h4>Red Light on the Body</h4>
            <p>
                Parkinson‚Äôs disease kidney impairment happens from the start but becomes more of a problem during the later stages of the disease. Start early; don't wait.
            </p>
            <p>
                Red light improves renal function by improving renal blood flow and improving cell signaling in that area. PD impairs kidney function through &alpha;-synuclein aggregation accumulation and inflammation, autonomic nervous system (ANS) dysfunction, and dopamine depletion. Dopamine influences renal blood flow, blood pressure, and kidney function.
            </p>
            
            <h4>Near-Infrared (NIR) vs Red Light Therapy</h4>

            <p>
                Near-infrared (NIR) light has a deeper penetration depth than red light, allowing it to reach deeper tissues and organs, including the brain, without overstimulating the skin. <cite class="reflink"><a href="#t-a-henderson">T.A. Henderson</a></cite>
            </p>

            <p>
                Red light can be effective, too, but the longer duration and stronger intensity required for efficacy may overstimulate the skin. Homme LED devices that allow blending NIR and red frequencies should use lower intensity for the red frequencies to avoid burning or overstimulating the skin. This strategy can take advantage of their dermal benefits without damaging the skin while getting more intense NIR for the deep regions of the brain.
            </p>
            <p>
             Despite the large body of experimental and early clinical evidence, there is still much resistance to the use of photobiomodulation by patients and health professionals.
            </p>
            
            <h4>References</h4>
            <ol class="reference-list">
                
                <li id="m-r-hamblin1">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523874/"
                    title="title"
                    target="Mechanisms and applications of the anti-inflammatory effects of photobiomodulation"
                    >Mechanisms and applications of the anti-inflammatory effects of photobiomodulation</a>, Michael R Hamblin.
                    <p>
                        Cytochrome c Oxidase (CCO) absorbs NIR light, leading to increased <abbr title="electron transport chain">ETC</abbr> activity and greater production of ATP.
                    </p>
                </li>
                <li id="nizamutdinov1">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400541/"
                        title="Transcranial near-infrared light in treatment of neurodegenerative diseases"
                        target="_blank"
                        >Transcranial near-infrared light in treatment of neurodegenerative diseases</a>, Damir Nizamutdinov, et al.
                        <p>
                        
                        </p>
                    </li>
                <li id="meng">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705158/"
                    title="Low-Level Laser Therapy Rescues Dendrite Atrophy via Upregulating BDNF Expression: Implications for Alzheimer's Disease"
                    target="_blank"
                    >Low-Level Laser Therapy Rescues Dendrite Atrophy via Upregulating BDNF Expression: Implications for Alzheimer's Disease</a>, Chengbo Meng, et al.
                    <p>
                        Synaptogenesis was found.
                    </p>
                </li>
                <li id="jiexiu-zhao">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499892/"
                    title="Red light and the sleep quality and endurance performance of Chinese female basketball players
"
                    target="_blank"
                    >Red light and the sleep quality and endurance performance of Chinese female basketball players</a>, Jiexiu Zhao, et al.
                    <p>
                        Our study confirmed the effectiveness of body irradiation with red light in improving the quality of sleep of elite female basketball players and offered a nonpharmacologic and noninvasive therapy to prevent sleep disorders after training.
                    </p>
                </li>
                
                <li id="michael-r-hamblin"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581558/"
                    title="Transcranial photobiomodulation for the brain: a wide range of clinical applications"
                    target="_blank"
                    >Transcranial photobiomodulation for the brain: a wide range of clinical applications</a>, Michael R. Hamblin.
                    <p>
                        This review discussed the highly effective use of PBMT in treating Alzheimer‚Äôs and Parkinson‚Äôs disease models using repeated daily exposures and the mechanisms that affect the mitochondria.
                    </p>
                </li>
                
                <li id="damir-nizamutdinov"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219492/"
                    title="Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia"
                    target="_blank"
                    >Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia</a>, Damir Nizamutdinov, et al.
                    <p>
                        This placebo-controlled, randomized, double-blinded human study examined 6 min, twice daily eight weeks transcranial near-infrared (tNIR) light NIR light with wavelength of 1060-1080nm and 15,000mW, irradiance or power density= 23.1mW/cm2, ~650cm2 per treatment area compared with a sham placebo.
                    </p>

                    <p>
                        The study group showed significant improvements in cognitive functions in several tests and showed less anxiety, improved mood, energy, and positive daily routine after ~14-21 days of treatment. 
                    </p>
                    <p>
                        Patients with sham treatment did not demonstrate significant changes
                    </p>
                </li>
                
                <li id="t-a-henderson"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552256/"
                        title="Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?"
                        target="_blank"
                    >Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?</a>, Theodore A Henderson, Larry D Morries.
                    <p>
                        Higher-wattage NIR lasers can deliver therapeutic effects to greater depths of the brain without tissue heating or damage. 
                    </p>
                </li>
                    
                <li id="a-liebert">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/34215216/">Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study</a>, Ann Liebert, et al.
                    
                    <p>
                        This small study showed <abbr title="photobiomodulation">PBM</abbr> was safe and effective for symptoms of PD including mobility, cognition, dynamic balance, and fine motor skills. Improvements were maintained for as long as treatment continued, for up to one year. 
                    </p>
                </li>
                
                <li id="j-c-heo">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625994/"
                        title="Photobiomodulation (660‚Äânm) therapy reduces oxidative stress and induces BDNF expression in the hippocampus"
                        target="Photobiomodulation (660‚Äânm) therapy reduces oxidative stress and induces BDNF expression in the hippocampus"
                    >Photobiomodulation (660‚Äânm) therapy reduces oxidative stress and induces BDNF expression in the hippocampus</a>, Jin-Chul Heo, et al.
                    <p>
                        These data demonstrate that PBMT inhibits hippocampal damage induced by oxidative stress and increases the expression of BDNF in the hippocampus, a part of the brain used for learning and memory, located deep in the temporal lobe. 
                    </p>
                    <p>
                        To examine the cellular process in the hippocampus, mice were used. Although the data are impressive, the problem with extrapolating data to humans is the size of the human head is much larger, thereby damping the intensity of the NIR waves as they aim toward the deep brain regions. A possible workaround is to direct the light towards the back, to target the CSF.
                    </p>
                </li>
                
                <li id="y-lampl">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/17463313/"
                        title="Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1)"
                    target="_blank"
                    >Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1)</a>, Yair Lampl, et al.
                    <p>
                        The NeuroThera Laser System therapeutic approach involves infrared laser technology and has shown significant and sustained beneficial effects in animal models of ischemic stroke. 
                    </p>
                </li>
                <li id="c-hamilton">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128061/"
                        title="Exploring the use of transcranial photobiomodulation in Parkinson's disease patients"
                        target="_blank"
                    >Exploring the use of transcranial photobiomodulation in Parkinson's disease patients</a>, Catherine Hamilton, et al.
                    <p>
                        This study found photobiomodulation reaches the motor cortex, influences stem cell function, offers neuroprotection, restores functional activity, improves motor behaviors, reduces clinical signs of PD, reduces gliosis, and induces expression of trophic growth factors.
                    </p>
                </li>
            </ol>
        </section>
    </section>
    <section id="how-to-build-a-supplement-plan">
        <h3>How to Build a Supplement Plan</h3>
    
        <p>
            This general-purpose solution serves as a customizable starting point to address health with PD from multiple angles, targeting each of the underlying <a href="#etiological-problems">Etiological Problems</a>.
        </p>
        
        <h4>Mixing and Storing Powders</h4>
        
        <p>The mixed powders "Mitochondrial Mix", "Cacao Mix", and "Post-Workout" powders must be made in batches and should be stored in a cool, dry place with a desiccant pack (like silica gel) inside the powder to prevent clumping and contamination (mold). Silica packs commonly shipped with raw powders and supplements can be reused.
        </p>
        
        <h4>Weighing and Mixing Powders</h4>
        <p>
            A sturdy gram scale or reliable, accurate food scale that measures to the nearest 0.01g (10mg) is necessary to ensure accuracy. To help ensure proper ingredient dispersal, mix the smaller ingredients first and blend in the larger ingredients.
        </p>
            
        <h4>Daily Supplements (3x daily)</h4>
        <ol>
             <li>Ubiquinol &mdash; 300mg 
             <li>PQQ &mdash; 30mg
             <li>CDP Choline &mdash; 1000mg 
             <li>Active B Complex (Integrative Therapeutics)
             <li>Nattokinase &mdash; 100mg
             <li>Vitamin K2 &mdash; 500mcg
             <li>Methylated B Complex
             <li>Thiamine &mdash; 100mg
        </ol>

        <h4 id="mitochondrial-powder">Mitochondrial Mix Powder &mdash; 10 Days</h4>
        <p>
            This 10-day serving can be taken 2x daily; once with the morning supplements; once later.
        </p>
        <ol>
            <li>Uridine Monophosphate &mdash; 5g
            <li>Coffeeberry extract &mdash; 2.5g
            <li>NMN &mdash; 10g
            <li>NR &mdash; 5g
            <li>Niacin &mdash; 2g
            <li>Lion's Mane &mdash; 10g
            <li>Cordyceps &mdash; 10g
            <li>Matcha (ceremonial grade) &mdash; 7g
            <li>Micronized Creatine Monohydrate (CreaPure¬Æ) &mdash; 30g
            <li>Inulin &mdash; 30g
            <li>Base: Organic Greens Powder &mdash; 50g
            <li>Base: Organic Fruits Powder &mdash; 50g (e.g. "Navitas Superfood+ Immunity Blend")
        </ol>

        <h4>Cacao Mix Powder &mdash; 10 Days</h4>
        <p>
            This ~10-day serving can be taken in hot water 1-2x daily, earlier in the day. Add coconut oil and organic ginger juice</p>
        
        <p>Do not cook; add to below-boiling temperature water.
        </p>
        <ol>
            <li>Niacin &mdash; 1g
            <li>Turmeric &mdash; 5g
            <li>Matcha &mdash; 7g
            <li>Lion's Mane &mdash;10g
            <li>Cordyceps &mdash; 10g
            <li>Ceylon cinnamon &mdash; 12g
            <li>Raw Cacao &mdash; 100g
        </ol>

        <h4>Post-Workout Mixed Powder &mdash; 10 Days</h4>
        <p>This can be pre-mixed and stored in the refrigerator</p>
        <p>Mix in water with Organic Ginger Juice before drinking.</p>
        <ol>
            <li>NMN &mdash; 5g
            <li>NR &mdash; 2.5g
            <li>Niacin &mdash; 1g
            <li>Beta Alanine &mdash; 10g
            <li>HMB &mdash; 10g
            <li>Rhodiola Rosea &mdash; 2.5g
            <li>Sodium Bicarbonate &mdash; 5g
            <li>Turmeric &mdash; 7g
            <li>TMG (Betaine) &mdash; 10g
            <li>Natto powder &mdash; 5g
            <li>Lion's Mane &mdash; 10g
            <li>Inulin &mdash; 30g
            <li>Ceylon cinnamon &mdash; 12g
            <li>Micronized Creatine Monohydrate (CreaPure¬Æ) &mdash; 30g
            <li>BCAA 4:1:1 &mdash; 40g
            <li>L-Glutamine &mdash; 50g
            <li>Base: Organic Greens Powder &mdash; 50g
            <li>Organic Fruits Powder &mdash; 50g (e.g. "Navitas Superfood+ Immunity Blend")
            <li>Collagen peptides &mdash; 50g
            <li>Whey protein isolate &mdash; 300g
        </ol>

        <h4>Dinner Supplements üçΩÔ∏è</h4>
        <p>
        Fat-soluble substances are better absorbed when taken with dietary fats.
        </p>
        <ol>
             <li>Mixed Tocopherols/Tocotrienols
             <li>K2 &mdash; 500mcg
             <li>D3 &mdash; 4000 IU
             <li>Urolithin-A 1000mg
             <li>Resveratrol &mdash; 500mg
             <li>Fisetin &mdash;¬†500mg
             <li>Sulforaphane &mdash; 50mg
             <li>Quercetin &mdash; 500mg
             <li>NAC &mdash; 100mg üí§
             <li>Geranyl geraniol &mdash; 500mg
        </ol>

        <h4>Dinner Foods</h4>
        <ol>
            <li>Natto powder &mdash; 2g
            <li>Turmeric &mdash; 1.5g
            <li>Saffron &mdash; 30mg
            <li>DHA:EPA 2:1 &mdash; 5000mg (Nordic Naturals Children's DHA)
            <li>Free Range Eggs &mdash; ~2-5
        </ol>

        <h4>Sleep Supplements (7:00pm - 9:00pm) üí§</h4>
        <ol>
             <li>Melatonin (Sleep3) &mdash; 10mg
             <li>5-HTP &mdash; 100mg
             <li>GABA &mdash; 1000mg &mdash; 2000mg
             <li>Magnesium Threonate &mdash; 300mg
             <li>Chelated Magnesium &mdash; 300mg
        </ol>
        
    </section>
	<section id="food-and-supplements">
		<h3>
			Food and Supplements
		</h3>
		
		<p>
			PD affects the central, peripheral, autonomic, and enteric nervous systems. Managing This requires a comprehensive approach that includes optimizing diet for enteric and metabolic health, nutrient timing with exercise, and addressing the <a href="#problems-list">mechanisms of various issues</a>. 
		</p>
		<p>
			Many foods not only interfere with the many complex pathologies of PD, but also can contribute to the development of neuroprotective agents against it. Many supplements are derived from food sources or need dietary fats for proper absorption. This section explores targeted dietary choices and supplements to optimize health and manage PD.
		</p>
		
		<section id="food">
			<h3>
				 Dietary Strategies for Parkinson's Disease
			</h3>
			<p>
				A custom-tailored diet for PD should consider gut health, blood sugar management, and bioactives to support disease management and overall health. 
			</p>
			<p>
				To manage blood glucose, eliminate all refined sugars, reduce starch intake, and include protein (especially post-workout). Use fats rich in medium-chain triglycerides (MCTs), such as coconut oil, as alternative energy sources for the brain and to enhance absorption of fat-soluble compounds (turmeric).
			</p>
			
			<h4>Eliminating Sugar</h4>
			<p>
				Gut health can be improved by diet. Eliminating refined sugars, especially fructose and sucrose is an important first step to improving gut health and blood glucose.
			</p>
			<p>
				 High dietary sugar can alter the gut microbiota, leading to endotoxemia (leaky gut), low-grade systemic inflammation, metabolic dysregulation, and cause numerous downstream deleterious health effects. <cite class="reflink"><a href="#satokari">R. Satokari</a></cite>
			</p>
			
			<h4>Probiotics, Fiber, and Polyphenols</h4>
			<p>
				 Including probiotics (such as fermented foods), prebiotic fibers like inulin and glucomannan, and polyphenols can increase satiety and boost the production of short-chain fatty acids and postbiotics. Inulin and glucomannan can be added to pre-, intra-, and post-workout drinks.
			</p>
			
			<p>
				 Polyphenols, fermentation byproducts, bioactive peptides, and organic acids enhance gut health and short-chain fatty acid (<abbr title="short-chain fatty acid">SCFA</abbr>) production through various mechanisms. These include prebiotic effects, direct probiotic actions, microbiota modulation, and the production of beneficial fermentation byproducts and organic acids. This synergistic effect supports a balanced gut microbiome, improves digestive health, and enhances overall well-being. <cite class="reflink"><a href="#x-wang">X. Wang</a></cite>
			</p>
			
			<h4>Polyphenols and SCFA</h4>
			<p class="tweet">
				<abbr title="short-chain fatty acid">SCFA</abbr>s are fatty acids with fewer than six carbons, produced by fermenting indigestible fibers in the gut. Polyphenols like <abbr title="Epigallocatechin gallate">EGCG</abbr> from green tea boost SCFA production, enhancing anti-inflammatory effects and colon barrier integrity, reducing enteritis. <cite class="reflink"><a href="#z-wu">Z. Wu</a></cite>
			</p>
			
			<p>
				SCFAs, including acetate, propionate, and butyrate, promote a healthier gut environment by supporting epithelial integrity and the growth of beneficial microbiota. This improvement helps regulate appetite and reduces cravings for carbohydrate-rich foods, especially fructose and sucrose. Better appetite regulation leads to improved blood glucose levels, enhanced insulin sensitivity, and reduced inflammation. Reduced inflammation, in turn, contributes to better metabolic health through improved insulin sensitivity and metabolic function, lowering the risk of metabolic syndrome, and supporting balanced hormonal regulation, mitigating disease progression. <cite class="reflink"><a href="#xiong">R. Xiong</a>, <a href="#c-de-luca">C. de Luca</a></cite>
			</p>
			<!--
			
			<h4>Post-workout Nutrition</h4>
			<p>
				The post-workout shake induces satiety, reducing food cravings to keep blood sugar low. Because exercise forces maximizes uptake of nutrients, bioactive compounds, and protein, and to induce satiety
			</p>
			
			<h4>Food and the Gut-Brain Axis in Parkinson's Disease</h4>
			
			<h5>Does Gut Dysbiosis Cause PD?</h5>
			
			<p>
				In a highly-cited 2003 study, H. Braak found that intestinal inflammation and gut microbiome alterations may precede the development of PD, supporting the idea that the gut is an initial site of pathological changes. <cite class="reflink"><a href="#h-braak">H. Braak</a></cite>
			</p>
			
			<p>
				Further observations that Œ±‚Äêsynuclein was found in the enteric nervous system (ENS) of the vast majority of PD patients led to an increasing number of studies to investigate this phenomenon. However, the various methodologies between studies led to conflicting results. <cite class="reflink"><a href="#y-chao">Y. Chao</a></cite>
			</p>
			
			<p>
				Although the evidence supporting the hypothesis that synucleinopathy <em>begins</em> in the gut is inconsistent, problems in the gut-brain axis have been conclusively tied bidirectionally in PD. Mutation and aggregation of Œ±-synuclein in the <abbr title="gastrointenstinal">GI</abbr> tract spreads via the vagus nerve to the CNS leading to dopaminergic neuron degeneration. <abbr title="Dopamine Replacement Therapy">DRT</abbr> leads to gut dysbiosis, further exacerbating the problem. <cite class="reflink"><a href="#y-chao">Y. Chao</a></cite>
			</p>
			
			<p>
				Fixing gut dysbiosis with probiotics and pre-biotics is an important step towards addressing GI function. In PD patients, this problem is more common and fixing it may help protect against neurodenegeration. 
			</p>
			<p>
				Recent research has explored the potential role of probiotics in managing PD symptoms, including constipation, endothelial health, and the gut-brain axis. <cite class="reflink"><a href="#s-romano">S. Romano</a>, <a href="#a-h-tan">A.H. Tan</a></cite>
			</p>

			<h4>Insulin Resistance (IR) in PD</h4>
			<p>
				According to a 2018 study, nearly 60% of non-diabetic PD patients may have undiagnosed insulin resistance, despite having normal blood sugar levels. And although higher body mass index (BMI) was associated with increased IR, even lean PD patients showed a higher percentage (41%) of IR compared to healthy adults without PD.
			</p>
			

Studies have consistently shown that individuals with PD exhibit alterations in their gut microbiome, characterized by reduced diversity and altered composition compared to healthy individuals. This dysbiosis may contribute to the development and progression of PD symptoms.
-->
			
			<h4>References</h4>
			<ol class="reference-list">
			
				<li id="satokari">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284805/"
						title="High Intake of Sugar and the Balance between Pro- and Anti-Inflammatory Gut Bacteria"
						target="_blank"
						>High Intake of Sugar and the Balance between Pro- and Anti-Inflammatory Gut Bacteria</a>, Reetta Satokari.
				</li>
				<li id="x-wang">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220293/"
					title="Dietary Polyphenol, Gut Microbiota, and Health Benefits"
					target="_blank"
					>Dietary Polyphenol, Gut Microbiota, and Health Benefits</a>, Xiaofei Wang, et al.
				</li>
				<li id="z-wu">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424887/"
					title="Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis"
					target="_blank"
					>Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis</a>, Zhenhua Wu, et al.
				</li>
				
				<li id="xiong">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498509/"
					title="Health Benefits and Side Effects of Short-Chain Fatty Acids"
					target="_blank"
					>Health Benefits and Side Effects of Short-Chain Fatty Acids</a>, Ruo-Gu Xiong, et al.
				</li>
				<li id="c-de-luca">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246086/"
					title="Inflammation and Insulin Resistance"
					target="_blank"
					>Inflammation and Insulin Resistance</a>, Carl de Luca and Jerrold M. Olefsky.
				</li>
				<li id="h-braak">
					<a href="https://pubmed.ncbi.nlm.nih.gov/12721813/"
					title="Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen"
					target="_blank"
					>Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen</a>, H. Braak, et al.
				</li>
				
				<li id="y-chao">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477379/#B10"
					title="Gut‚ÄìBrain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease"
					target="_blank"
					>Gut‚ÄìBrain Axis: Potential Factors Involved in the Pathogenesis of Parkinson's Disease</a>, Yin-Xia Chao, et al.
				</li>
				
				<li id="s-romano">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946946/"
					title="Meta-analysis of the Parkinson‚Äôs disease gut microbiome suggests alterations linked to intestinal inflammation"
					target="_blank"
					>Meta-analysis of the Parkinson‚Äôs disease gut microbiome suggests alterations linked to intestinal inflammation</a>, Stefano Romano, et al.
				</li>
				<li id="a-h-tan">
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035463/"
					title="Probiotics for Parkinson's disease: Current evidence and future directions"
					target="_blank"
					>Probiotics for Parkinson's disease: Current evidence and future directions</a>, Ai Huey Tan, et al.
				</li>
	
			</ol>
		</section>
		<section id="supplements">
			<h3>
				Supplements
			</h3>
			<p>
				Supplements complement food and help manage PD by addressing specific <a href="#problems-list">mechanisms</a> involved in its progression. They also enhance exercise performance, aid in recovery, support better sleep, and improve overall health and well-being. An overview of each supplement, most of which have been personally experienced by the author, is provided following the legend below.
			</p>
	
			<h4>The Role of Nutrition</h4>
			<p>
				Nutritional deficiencies can exacerbate symptoms in individuals with PD and may sometimes be mistaken for progressive neurodegeneration. This misinterpretation can lead to inappropriate management strategies if the underlying nutritional issues are not addressed.
			</p>
			<p>
				Furthermore, certain nutrient deficiencies can trigger cascading effects, exacerbating PD symptoms or hastening PN. For example, deficiencies in vitamins B12, folate, and vitamin D have been implicated in PD and can affect neurological function and overall health. Inadequate intake of essential nutrients can also impair mitochondrial function, increase oxidative stress, and compromise neurotransmitter synthesis and signaling, all of which are implicated in PD pathophysiology.
			</p>
			
			<p>
				Additionally, LD/DDC inhibitor therapy can reduce vitamin B6 levels, which is essential for the synthesis of neurotransmitters.
			</p>
	
			<p>
				Don't just "talk to your doctor", your <a href="#care-team">multi-specialist team</a> must all work together on your individualized treatment plan that includes nutrition, lifestyle, supplementation, and medication. Regularly test and monitor status with symptoms and biochemical markers to assess the effectiveness of interventions and make adjustments as needed.
			</p>
			
			<p>
				Instead of "talking to your doctor", the development of an individualized treatment plan involves a multi-specialist team collaborating on nutrition, lifestyle, supplementation, medication, and regular testing and monitoring of symptoms and biochemical markers to assess and adjust interventions.
			</p>        
			<p>
				<dfn>Antifibrillogenics</dfn> mitigate the formation of Œ±-synuclein fibrils. Anti-aggregants aim to prevent the accumulation of fibrils and other misfolded proteins in Lewy bodies. By preventing the formation of Œ±-synuclein fibrils and aggregates, these compounds address the underlying pathology of Parkinson's disease at a more fundamental level.
			</p>
			<p>
				Preventing fibril aggregation (<dfn>anti-aggregant</dfn>): These treatments focus on inhibiting the aggregation of Œ±-synuclein fibrils into Lewy bodies, potentially slowing the spread of pathology and neurodegeneration.
			</p>
			<p>
				Doctors who prioritize effective treatments should be favored, and those who dismiss claims without examination avoided. Focus should be placed on facts and evidence, risk versus reward, and health optimization. 
			</p>
			
			<section id="treatment-legend">
				<h3>Treatment Legend:</h3>
				<h3>Supplement Name</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: See <a href="#problems-list">"mechanisms"</a> list.
					<li>Dose: [dose]  (üçΩÔ∏è &mdash; with food;&emsp;üí§ &mdash; at night)
					<li>Fat-soluble: [‚úÖ | ‚ùå]
					<li>ü©∏üß†BBB: Crosses blood-brain barrier [‚úÖ | ‚ùå]
					<li>Safety: [1-10]/10 ([safety confidence]% œÉ)
					<li>Efficacy: [1-10]/10 ([efficacy confidence ]% œÉ)
				</ul>
				<ul id="legend-legend">
					<li>ED &mdash; Daily
					<li>EOD &mdash; Every Other Day
					<li>BID &mdash; Twice Daily
					<li>œÉ &mdash; confidence level, 0&ndash;100%
				</ul>
			</section>
			<p>
				Eggs are a source of omega-3 fatty acids, choline, lutein, zeaxanthin, vitamin E, beta carotene, vitamin A, and selenium. Pasture-raised eggs contain more bioactive compounds and less saturated fat and cholesterol.
			</p>
			<p>
				Many plants contain phytochemicals that can improve conditions and inhibit the progression of PD.
			</p>
			<p>
				<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433754/">
					Plant Extracts and Phytochemicals Targeting &alpha;-Synuclein Aggregation in Parkinson's Disease Models
				</a>
			</p>
			<section id="glynac">
				<h4>GlyNAC (Glycine-N-Acetyl Cysteine)</h4>
				<ul>
					<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial
					<li>Dose: 3g per day üí§
					<li>Fat-soluble: ‚ùå
					<li>ü©∏üß† BBB: ‚úÖ
					<li>Safety: 9/10 (90% œÉ)
					<li>Efficacy rating: 5/10 (70% œÉ)
				</ul>
				<p>
					GlyNAC improves glutathione levels and mitochondrial function, reduces inflammation, supports neurotrophic factor expression, and improves cognitive function. <cite class="reflink"><a href="#g-lizzo">g-lizzo</a>], <a href="#p-kumar_o-osahon">p-kumar_o-osahon</a>], <a href="#p-kumar_r-sekhar">p-kumar_r-sekhar</a></cite>
				</p>
	
				<h4>Supplementation</h4>
				<p>
					 GlyNAC supplementation up to 7.2g per day is safe and well tolerated in older adults. GlyNAC is best taken at night. 
				</p>
				
				<p>
					GlyNAC improves sleep quality. The half-life of NAC in the body is about 6 hours, and the half-life of glycine is anywhere from 25-250 minutes, so taking it at night allows for optimal utilization of the amino acids. <cite class="reflink"><a href="#p-kumar_o-osahon">p-kumar_o-osahon</a></cite>
				</p>
				
				<h4>Side Effects</h4>
				<p>
					N-acetyl cysteine (NAC) can cause next-day lethargy. If experiencing this, the dose should be reduced, taken earlier in the evening, and bedtime adjusted accordingly.
				</p>
				<h4>References</h4>
				<ol class="reference-list">
				
					<li id="g-lizzo">
					  <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261343/"
					  title="A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage"
						target="_blank">A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage</a>, Giulia Lizzo, et al.
						<p>
							This double-blind RCT investigated supplementation with glycine and n-acetylcysteine (GlyNAC) at three different daily doses for 2 weeks (low dose: 2.4 g, medium dose: 4.8 g, or high dose: 7.2 g/day, 1:1 ratio) in a randomized, controlled clinical trial in 114 healthy volunteers.
						</p>
					</li>
					
					<li id="p-kumar">
						<a href="https://pubmed.ncbi.nlm.nih.gov/33783984/"
						  title="Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial"
						  target="_blank"
						  >Glycine and N-Acetylcysteine in Older Adults</a>, Premranjan Kumar, et al.
						  <p>
							  This clinical trial showed GlyNAC improves glutathione levels, mitochondrial function, and insulin sensitivity while reducing oxidative stress and inflammation.
						  </p>
					  </li>
				  
					  <li id="p-kumar_o-osahon">
						  <a href="https://www.mdpi.com/2076-3921/12/5/1042"
						  title="GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage"
						  target="_blank">GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Mice Increases Length of Life by Correcting Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic Damage</a>
					  <p>
						This placebo-controlled rodent study showed that <q>GlyNAC supplementation improves age-associated cognitive decline and supports brain health in aging by improving/correcting brain GSH deficiency, elevated OxS, mitochondrial dysfunction, abnormal mitophagy and autophagy, inflammation, impaired glucose transport/uptake, elevated genomic damage, and reversing the decline in brain neurotrophic growth factors.</q>
					  </p>
					  </li>
				  <li id="p-kumar_r-sekhar">
					  <a 
					  target="_blank"
					  title="GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging"
					  href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215265/">GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging</a>, Premranjan Kumar, et al.
					  <p>
						  This rodent study demonstrated improved age-associated cognitive decline (ACD) with GlyNAC.
					  </p>
				  </li>
				</ol>
			</section>
			<section id="creatine">
				<h4>Creatine Monohydrate</h4>
				<ul>
					<li>Mechanisms: Neuroprotective, Antioxidant
					<li>Dose: 5g ED
					<li>Fat-soluble: ‚ùå
					<li>ü©∏üß† BBB: ‚úÖ
					<li>Safety: 9/10 (90% œÉ)
					<li>Efficacy: 6/10 (65% œÉ)
				</ul>
	
				<h4>Creatine and Energy Production</h4>
				<p>
					Creatine increases mitochondrial ATP production, provides antioxidant effects, and reduces oxidative stress and mitochondrial damage. which helps it protect against neuronal damage and prevent cell death. <cite class="reflink"><a href="#c-rae">C. Rae</a>, <a href="#a-c-passaquin">A.C. Passaquin</a>, <a href="#h-arazi">H. Arazi</a></cite>
				</p>
				
				<h4>Creatine and Exercise</h4>
				<p>
					Creatine improves muscular strength, exercise recovery, mitochondrial function, and provides antioxidant effects. Because exercise plays a fundamental role in health optimization, creatine should be used with exercise to improve its performance and hasten recovery. <cite class="reflink"><a href="#h-chang">H. Chang</a></cite>
				</p>
				
				<h4>Cellular Mechanism of Action</h4>
				<p>
					Mitochondria produce energy through two different but connected pathways, the citric acid cycle and the electron transport chain (ETC). Creatine helps in this process by aiding energy production in the citric acid cycle.
				</p>
				
				<p>
					ATP (adenosine triphosphate) is the primary energy source for cells, but it can't be stored in large amounts and depletes quickly during high energy demands. When creatine monohydrate enters the cell, mitochondria convert it into creatine phosphate (CP). CP acts as a phosphate reserve, for regenerating ATP from ADP in the citric acid cycle, thereby maintaining ATP production and reducing the immediate burden on the <abbr title="electron transport chain">ETC</abbr>.
				</p>
				<p>
					The citric acid cycle uses acetyl-CoA and water, reducing <abbr title="Nicotinamide adenine dinucleotide (oxidized)">NAD+</abbr> to <abbr title="Nicotinamide adenine dinucleotide Hydrogen (reduced)">NADH</abbr>, and releasing CO<sub>2</sub>. NADH then goes to the <abbr title="electron transport chain">ETC</abbr> to produce more ATP, the cell's main energy source. By rapidly replenishing ATP, <abbr title="Creatine Phosphate">CP</abbr> helps maintain cellular energy levels and supports neuronal function, which is impacted in PD.
				</p>
				
				<h5>Creatine as Cellular Energy for Synapses</h5>
				
				<p>
					Neuronal synapses are extremely energy-intensive. The release of neurotransmitters from the presynaptic neuron requires energy provided by ATP. Creatine inside neurons holds onto phosphate molecules, just like it does is skeletal muscle cells. Creatine can donate a phosphate to ADP to create ATP which can then be used to create more energy.
				</p>
				
				<p>
					The human brain burns more glucose than other organs in the body. Although it accounts for only about 2% of the body‚Äôs total mass, the human brain uses about 20% of the body‚Äôs total energy expenditure! 
				</p>
				
				<p>
					Creatine supplementation increases brain creatine levels. During stress or trauma, such as intense exercise, creatine supplementation improves oxidative DNA injury and normalizes brain and body creatine levels. <cite class="reflink"><a href="#s-forbes">S. Forbes</a></cite>
				</p>
	
				<p>
					A 2023 review study published in Sports Medicine found long-term high-dosage creatine supplementation increases brain creatine stores, improves cognition and memory, especially in older adults or during times of metabolic stress (e.g. sleep deprivation), improves aspects of recovery from traumatic brain injury in children, and has the potential to reduce symptoms of depression and anxiety. <cite class="reflink"><a href="#d-candow">D. Candow</a></cite>
				</p>
				
				<h4>Creatine and PD</h4>
				
				<p>
					Creatine has shown neuroprotection in PD patients with cognitive decline via creatine transporter uptake. In a rodent model, high-dosage creatine was shown to exert anti-inflammatory, antioxidative, and anti-aggregant effects on Œ±-synucleinopathy. <cite class="reflink"><a href="#y-leem">Y. Leem</a></cite> <cite class="reflink"><a href="#h-chang">H. Chang</a></cite>
				</p>
				
				<p>
					A long-term, multicenter, double-blind, parallel-group, placebo-controlled, 1:1 randomized efficacy trial for 10g of creatine in PD patients showed benefit to the <abbr title="Unified Parkinson's Disease Rating Scale">UPDRS</abbr> both at 1 year and at 18 months, but eventually terminated early with no determined harm or benefit. <cite class="reflink"><a href="#k-kieburtz">K. Kieburtz</a></cite>
				</p>
				
				<p>
					These results are not entirely disappointing. The study could have been better designed to determine a positive effect. The patients were not reported to be performing intense exercise, although some may have.
				</p>
					
				<p>
					<abbr title="High Intensity Interval Training">HIIT</abbr> exercise significantly mitigates and may partially reverse progressive neurodegeneration. However, high-intensity exercise also depletes brain creatine, which impacts neurological function. 
				</p>
				<p>             
					Had the patients in this study been assigned to a <abbr title="High Intensity Interval Training">HIIT</abbr> regimen, they would have benefitted from the exercise. HIIT depletes creatine levels and may deplete brain creatine levels. Creatine supplementation might result in less exercise-induced depletion of creatine, less oxidative damage caused by the exercise, and better exercise recovery (allowing for more frequent training). Such a design might have revealed a more significant benefit to the 10g ED creatine supplementation. However, despite the study's design, beneficial effects were observed at 1 year and at 18 months. <cite class="reflink"><a href="#b-laat">B. Laat</a></cite>
				</p>
				
				
				<h4>Supplementation</h4>
				
				<p>
					Taking creatine with food improves absorption. Eating increases the production of insulin-like growth factor-1 (IGF-1), which helps facilitate creatine uptake. Because dosages recommended for neurological function tend to be much higher, in excess of 20g per day, those with impaired kidney function might consider a more moderate dose as a compromise. 
				</p>
				 
				<h4>Safety and Efficacy</h4>
				<p>
					Creatine is commonly used with minimal adverse effects reported in clinical studies.
				</p>
				<p>
					Creatine supplementation alone may not significantly slow the progression of Parkinson's disease, especially not in the later stages. But its neuroprotective and antioxidant effects contribute to overall disease management when used as part of a comprehensive treatment approach, particularly in combination with exercise, to stave off disease progression in the early stages of the disease. Because creatine helps with exercise recovery, its use allows for more frequent training to enjoy the benefits of exercise.
				</p>
				<h4>References</h4>
				<ol class="reference-list">
					<li id="c-rae">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1691485/"  title="Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial."
						target="_blank"
						>Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial</a>, Caroline Rae, et al
						<p>
							Creatine supplementation had a significant positive effect on both working memory (backward digit span) and intelligence (Raven's Advanced Progressive Matrices), both tasks that require speed of processing. 
						</p>
					</li>
	
					<li id="h-chang">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844727/" title="The potential role of creatine supplementation in neurodegenerative diseases"
						target="_blank"
						>The potential role of creatine supplementation in neurodegenerative diseases</a>, Hyukki Chang, et al.
						<p>
							This review study concluded creatine supplementation had neuroprotective effects in animal models and in vitro studies of certain neurodegenerative diseases, but that clinical trials failed to reproduce favorable outcomes.
						</p>
					</li>
					<li id="a-c-passaquin">
						<a href="https://www.sciencedirect.com/science/article/abs/pii/S0960896601002735" title="Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice"
						target="_blank"
						>Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice</a>, Anne-Catherine Passaquin , et al.
						<p>
							This study found creatine supplementation in mice improves muscle health and may provide a scientific basis for its use as adjuvant therapy in Duchenne muscular dystrophy.
						</p>
					</li>
					
					<li id="h-arazi">
						<a href="https://www.mdpi.com/2072-6643/13/3/869" 
						title="Creatine Supplementation, Physical Exercise and Oxidative Stress Markers: A Review of the Mechanisms and Effectiveness"
						target="_blank"
						>Creatine Supplementation, Physical Exercise and Oxidative Stress Markers</a>, Hamid Arazi, et al.
						<p>
							This review study concluded creatine's antioxidant mechanisms include reduced <abbr title="Reactive Oxygen Species">ROS</abbr> and <abbr title="Reactive Nitrogen Species">RNS</abbr>, and that creatine can maintain mitochondrial integrity, increase creatine phosphate (CP) resources, act as a cellular energy buffer, and protect two important cellular targets, mtDNA and RNA, from oxidative damage. 
						</p>
					</li>
	
					<li id="y-leem">
						<a href="https://pubmed.ncbi.nlm.nih.gov/38262563/"
						title="Creatine supplementation with exercise reduces Œ±-synuclein oligomerization and necroptosis in Parkinson's disease mouse model"
						target="_blank"
						>Creatine supplementation with exercise reduces Œ±-synuclein oligomerization and necroptosis in Parkinson's disease mouse model</a>, Yea-Hyun Leem, et al.
						<p>
							These authors found that creatine supplementation with exercise has anti-inflammatory, antioxidative, and anti-Œ±-synucleinopathy effects, thereby reducing necroptotic cell death in a PD mouse model.
						</p>
					</li>
					
					<li id="s-forbes">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912287/"
						title="Effects of Creatine Supplementation on Brain Function and Health"
						target="_blank"
						>Effects of Creatine Supplementation on Brain Function and Health</a>, Scott C. Forbes, et al.
						<p>
						
						</p>
					</li>
					
					<li id="d-candow">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721691/"
						title="&ldquo;Heads Up&rdquo; for Creatine Supplementation and its Potential Applications for Brain Health and Function&rdquo;"
						target="_blank"
						>&ldquo;Heads Up&rdquo; for Creatine Supplementation and its Potential Applications for Brain Health and Function&rdquo;</a>, Darren G. Candow, et al.
						<p>
						
						</p>
					</li>
					
					<li id="k-kieburtz">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349346/"
						title="Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease"
						target="_blank"
						>Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease</a>, Karl Kieburtz, et al.
						<p>
							This results of this RCT found benefits at 12 months and 18 months, but did not support the use of creatine monohydrate in patients with Parkinson disease. However, they also found that its use at 10g ED was not harmful.
						</p>
					</li>
					
					<li id="b-laat">
						<a href="https://www.nature.com/articles/s41531-024-00641-1"
						title="Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson‚Äôs disease"
						target="_blank"
						>Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson‚Äôs disease</a>, Bart de Laat, et al.
						<p>
						
						</p>
					</li>
				</ol>
			</section>
			
			<section id="cacao">
				<h4>Raw Cacao</h4>
				
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, anti-ischemic, antioxidant, anti-inflammatory
					<li>Dose: 7g ED ‚òÄÔ∏è
					<li>Fat-soluble: ‚úÖ (Theobromine, caffeine, and flavonoids are somewhat fat-soluble. The Fatty Acids and Phytosterols are very fat-soluble)
					<li>ü©∏üß†BBB: ‚úÖ
					<li>Safety: 9/10 (70% œÉ)
					<li>Efficacy:2/10 (40% œÉ)
				</ul>
				
				<p>
					Raw cacao is made from cold-pressed, unroasted cocoa beans, which preserves the nutritional content, in contrast to cocoa, which is heavily processed, roasted at high temperatures, and often has added sugar. 
				</p>
				
				<h4>Health Benefits</h4>
				<p>
					Cacao's flavonoids improve blood flow, lower blood pressure, and reduce heart disease risk. Increased brain blood flow and theobromine noticeably improve cognitive function. Anandamide in cacao helps regulate mood and alleviate depression. Flavonoids reduce chronic inflammation and overall disease risk. Additionally, cacao provides magnesium, manganese, and phosphorus for bone health, and about 20% fiber to support digestion and satiety.
				</p>
				
				<h4>Cognitive Benefits</h4>
				<p>
					Studies on raw cacao show cognitive improvement in healthy individuals of various ages. A 2024 single-blind study from Japan examined the cognitive effects of high versus low polyphenol cacao. The high polyphenol group showed improvements in mental and physical fatigue, stress, boredom, sleepiness, motivation, healing, enjoyment, relaxation, concentration, and willingness after two sets of cognitive performance tests. <cite class="reflink"><a href="#r-lalonde">R. Lalonde</a>, <a href="#a-sasaki">A. Sasaki</a></cite>
				</p>
				
				<h4>Preparation</h4>
				<p>
					To maximize the health benefits of cacao, it should be consumed in its raw or minimally processed form, such as raw cacao paste or powder. Heat processing degrades beneficial flavonoids and other nutrients, reducing its overall nutritional value. Therefore, it is important to minimize heat exposure during preparation. Additionally, added sugar not only diminishes the potential health benefits but also contributes to the formation of advanced glycation end-products (AGEs), which are associated with aging and various chronic diseases. For optimal health, it's advisable to choose unsweetened, high-quality cacao products.
				</p>
				
				<p>
					Cacao powder contains fat-soluble compounds but can be dissolved in hot water as a beverage with fats like coconut oil added.
				</p>
				<h4>Stimulatory Effects</h4>
				<p>
					Cacao contains theobromine (dimethylxanthine), a stimulant similar to caffeine but less methylated. Both bind to adenosine receptors in the brain, increasing activity and alertness, and can interfere with sleep. Therefore, it is advisable to avoid consuming cacao later in the day.
				</p>
	
				<h4>References</h4>
				<ol class="reference-list">
					<li id="a-sasaki">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10780455/"
						title="Cacao Polyphenol-Rich Dark Chocolate Intake Contributes to Efficient Brain Activity during Cognitive Tasks: A Randomized, Single-Blinded, Crossover, and Dose-Comparison fMRI Study"
						target="_blank"
						>Cacao Polyphenol-Rich Dark Chocolate Intake Contributes to Efficient Brain Activity during Cognitive Tasks: A Randomized, Single-Blinded, Crossover, and Dose-Comparison fMRI Study</a>, Akihiro Sasaki, et al.
					</li>
					
					 <li id="r-lalonde">
						<a href="https://pubmed.ncbi.nlm.nih.gov/35993474/"
							title="
Cocoa Flavanols and the Aging Brain"
							target="_blank"
							>Cocoa Flavanols and the Aging Brain</a>, Robert Lalonde, Catherine Strazielle.
						</li>
				</ol>
			</section>
				
			<section id="cinnamon">
				<h3>Cinnamon</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antidiabetic
					<li>Dose: 4g ED
					<li>Fat-soluble: ‚úÖ (cinnamaldehyde and eugenol are moderately fat-soluble)
					<li>ü©∏üß†BBB: ‚úÖ
					<li>Safety: 9/10 (90% œÉ)
					<li>Efficacy: 3/10 (60% œÉ)
				</ul>
				
				<p>
					Cinnamon is a spice obtained from the inner bark of several species of trees. Ceylon cinnamon is preferred, as it contains no coumarin, a natural carcinogen. Cinnamon contains both water-soluble and fat-soluble compounds. Cinnamon's fat-soluble compounds include cinnamaldehyde and epicatechin and its water-soluble compounds include procyanidin type-A trimer, cinnamic acid, and various flavonoids. 
				</p>
				
				<h4>Antidiabetic Effects</h4>
				<p>
					Cinnamon exhibits anti-hyperglycemic properties, with the most significant effects observed in Ceylon cinnamon. These effects are species-specific.  <cite class="reflink"><a href="#n-j-hayward">N.J. Hayward</a></cite>
				</p>
				
				<p>
					It does this by mimicking insulin receptor kinase, increasing glucose uptake, and glycogen synthase activity, and increasing GLP-1 concentrations. <cite class="reflink"><a href="#n-kizilaslan">n-Kizilaslan</a>, <a href="#j-hlebowicz">J. Hlebowicz</a></cite>
				</p>
				
				<p>
					A 2006 randomized, placebo-controlled, double-blind study an an aqueous solution of cinnamon found improvements on fasting blood glucose and systolic blood pressure, and improvements in body composition in men and women with the metabolic syndrome. <cite class="reflink"><a href="#ziegenfuss">T. Ziegenfuss</a></cite>
				</p>
				
				<h4>Neuroprotective Effects</h4>
				<p>
					Glucose metabolism is impaired in Parkinson's Disease (PD). Improved glucose response and blood glucose levels from cinnamon's antidiabetic effects may benefit PD patients. <cite class="reflink"><a href="#a-marques">A. Marques</a></cite>
				</p>
				<p>
					Ingested cinnamon metabolizes to sodium benzoate (NaB). Both cinnamon and NaB upregulate neuroprotective molecules (Parkin and DJ-1) and protect the nigrostriatum in a mouse model.  <cite class="reflink"><a href="#s-khasnavis">S. Khasnavis</a></cite>
				</p>
				
				<h4>Supplementation</h4>
				
				<p>
					Translating the mouse dosage of the Khasnavis to human dosage, using the study's 100 mg/kg to a 12x k-factor results in 1.2 g/kg. For a 50 lb human, this equates to 60 grams of cinnamon daily ‚Äî an impractical amount. Consuming 3g daily is only 5% of the suggested dose, offering minimal neuroprotection. This small dose can be achieved by adding cinnamon to premixed powders such as the cacao mix, post-workout protein mix, and to golden milk. Consuming CinnulinPF can achieve more optimal levels. <cite class="reflink"><a href="#e-angelopoulou">D. Patel</a></cite>
				</p>
				
				<h4>References</h4>
				<ol class="reference-list">
				
					<li id="ziegenfuss">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2129164/"
						title="Effects of a Water-Soluble Cinnamon Extract on Body Composition and Features of the Metabolic Syndrome in Pre-Diabetic Men and Women"
						target="_blank"
						>Effects of a Water-Soluble Cinnamon Extract on Body Composition and Features of the Metabolic Syndrome in Pre-Diabetic Men and Women</a>, Tim N Ziegenfuss, et al.
					</li>

					<li id="n-j-hayward">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900266/"
						title="Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion"
						target="_blank"
						>Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion</a>, Nicholas J. Hayward, et al.
					</li>
					
					<li id="n-kizilaslan">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425402/"
						title="The Effect of Different Amounts of Cinnamon Consumption on Blood Glucose in Healthy Adult Individuals"
						target="_blank"
						>The Effect of Different Amounts of Cinnamon Consumption on Blood Glucose in Healthy Adult Individuals</a>, Nildem Kizilaslan
						<p>
							3‚Äì6‚Äâg of cinnamon consumption was found to affect certain blood parameters of individuals positively. 
						</p>
					</li>
					
					<li id="s-khasnavis">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167597/e"
						title="Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease"
						target="_blank"
						>Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease</a>, Saurabh Khasnavis, et al.
						<p>
						
						</p>
					</li>
					
					<li id="j-hlebowicz">
						<a href="https://pubmed.ncbi.nlm.nih.gov/19158209/"
						title="Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects"
						target="_blank"
						>Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects</a>, Joanna Hlebowicz, et al.
						<p>
							Ingestion of 3 g cinnamon reduced postprandial serum insulin and increased GLP-1 concentrations without significantly affecting blood glucose, GIP, ghrelin concentration, satiety, or GER in healthy subjects. The results indicate a relation between the amount of cinnamon consumed and the decrease in insulin concentration.
						</p>
						
						<p>
							(<dfn>GIP</dfn>, is a <dfn>glucose-dependent insulinotropic polypeptide</dfn>, an <dfn>incretin</dfn> hormone secreted by <dfn title="K Cells or GIP cells are enteroendocrine cells found in the small intestine">K cells</dfn> in the upper small intestine in response to nutrient ingestion, particularly glucose.)
					</li>
					
					<li id="a-marques">
						<a href="https://pubmed.ncbi.nlm.nih.gov/29866628/"
						title="Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?"
						target="_blank"
						>Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?</a>, Ana Marques, et al.
						<p>
							Glucose control is impaired in moderate to advanced non-diabetic PD patients, due to impaired adaptive insulin response which may be a novel non-motor consequence of PD-associated dysautonomia.
						</p>
					</li>
					
					<li id="d-patel">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708487/"
						title="Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson‚Äôs disease via astrocytic GDNF"
						target="_blank"
						>Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse
	Model of Parkinson‚Äôs Disease Via Astrocytic GDNF</a>, Dhruv Patel, et al.
	
						<p>
							In this mouse model of <dfn title="1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a protoxin that can cause parkinsonism similar to PD">MPTP</dfn>-induced PD, mice were treated with either cinnamon or NaB dissolved in 0.5% methylcellulose at individual doses (100 mg/kg, orally) once daily for 7 days, and following behavior analysis the mice were sacrificed for biochemical studies.
						</p>
					</li>
	
				</ol>
			</section>
			<section id="cavracrol">
				<h4>Carvacrol</h4>
				<p>
				</p>
				
				<ol>
					<li>
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681233/#B67-biomolecules-09-00271
						">Role of Dietary Supplements in the Management of Parkinson‚Äôs Disease
	</a>
					</li>
				</ol>
				<p>
					Established that carvacrol is also able to inhibit acetylcholinesterase activity, with positive effects on memory and cognitive performance in PD.
				</p>
			</section>
			<section id="lions-mane">
				<h3>Lion's Mane</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neurorestorative
					<li>Dose: 1000mg ED
					<li>Fat-soluble: ‚úÖ
					<li>ü©∏üß†BBB: ‚úÖ
					<li>Safety: 9/10 (90% œÉ)
					<li>Efficacy: 7/10 (80% œÉ)
				</ul>
				
				<p>
					Lion‚Äôs Mane contains fat-soluble bioactive compounds hericenones and erinacines that have been shown to increase <abbr title="Brain-derived neurotrophic factor">BDNF</abbr> and Nerve Growth Factor (NGF) stimulate the growth of brain cells, improve memory, and boost cognitive function. <cite class="reflink"><a href="#koichiro-mori">koichiro-mori</a></cite><cite class="reflink"><a href="#i-chen-li">i-chen-li</a></cite><cite class="reflink"><a href="#sarah-docherty">sarah-docherty</a></cite>
				</p>

				<h4>Lion's Mane in PD</h4>
				<p>
					Lion‚Äôs mane stimulates neurite outgrowth, promotes neurogenesis, and improves cognitive function in individuals with Parkinson‚Äôs disease. <cite class="reflink"><a href="#koichiro-mori">koichiro-mori</a></cite><cite class="reflink"><a href="#i-chen-li">i-chen-li</a></cite><cite class="reflink"><a href="#sarah-docherty">sarah-docherty</a></cite><cite class="reflink"><a href="#puei-lene-lai">puei-lene-lai</a></cite>
				</p>
			
				<h4>Supplementation</h4>
				<p>
					Lion's mane is safe and well-tolerated in doses commonly listed on reputable supplements, 1-3 grams daily.
				</p>
				
				<h4>References</h4>
				<ol class="reference-list">
					<li id="koichiro-mori">
						<a href="https://pubmed.ncbi.nlm.nih.gov/18844328/"
						title="Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial"
						target="_blank"
						>Improvement of Cognitive Functions by Oral Intake of Hericium erinaceus</a>, Koichiro Mori, et al.
						<p>
							This double-blind, parallel-group, placebo-controlled RCT found that elderly men and women with mild cognitive impairment who took Lion's mane mushroom extract for 16 weeks showed significant improvements in cognitive function compared to the placebo group.
						</p>
					</li>
					<li id="i-chen-li">
						[i-chen-li] <a href="https://pubmed.ncbi.nlm.nih.gov/32581767/"
						title="Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study"
						target="_blank"
						>Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study</a>, I Chen Li, et al.
						<p>
							This double-blind RCT found that elderly men and women who took a daily 350mg capsule containing 5 mg/g erinacine A (active ingredient) demonstrated better cognitive performance and functioning.
						</p>
					</li>
					<li id="sarah-docherty">[sarah-docherty]
						<a href="https://www.mdpi.com/2072-6643/15/22/4842"
						title="The Acute and Chronic Effects of Lion‚Äôs Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study">Lion‚Äôs Mane Supplementation on Cognitive Function, Stress, and Mood in Young Adults</a>, Sarah Docherty, et al.
						
						<p>
							The findings tentatively suggest that Hericium erinaceus may improve performance speed and reduce subjective stress in healthy, young adults.
						</p>
					</li>
					
					<li id="puei-lene-lai">[puei-lene-lai]
						<a href="https://www.mdpi.com/2072-6643/15/22/4842"
						title="Neurotrophic Properties of the Lion‚Äôs Mane
	Medicinal Mushroom, Hericium erinaceus (Higher
	Basidiomycetes) from Malaysia">Neurotrophic Properties of the Lion‚Äôs Mane
	Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia</a>, Puei-Lene Lai, et al
						
						<p>
							The extract contained neuroactive compounds that induced the secretion of extracellular NGF in NG108-15 cells, thereby promoting neurite outgrowth activity.
						</p>
					
					</li>
				</ol>
			</section>
			
			<section id="cordyceps" class="neuroprotective anti-inflammatory">
				<h3>Cordyceps</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Anti-inflammatory, Mitochondrial, Antioxidant</li>
					<li>Dose: ~3g EDÔ∏è</li>
					<li>ü©∏üß†BBB: ‚úÖ</li>
					<li>Safety: 7/10 (90% œÉ)</li>
					<li>Efficacy: 5/10 (80% œÉ)</li>
				</ul>                
				<p>
					Cordycepin, a bioactive component of Cordyceps militaris, reduces neuroinflammation by regulating cytokine production. <cite class="reflink"><a href="#y-sun">y-sun</a></cite>
				</p>
				
				<h4>BBB</h4>
				<p>
					Cordycepin of (2‚Ä≤-Deoxyadenosine) is a small molecule (<abbr title="molecular weight">MW</abbr> ~251 <abbr title="Daltons &ndash; unit of molecular mass">Da</abbr>) that can cross the BBB and improve its tight junction. <cite class="reflink"><a href="#j-yuan">j-yuan</a></cite>
				</p>
				
				<h4>Immunomodulation</h4>
				<p>
					Beta-glucans, a type of polysaccharide found in the cell walls of many mushrooms including Cordyceps, are potent immunomodulators. <cite class="reflink"><a href="#c-cerletti">c-cerletti</a></cite>
				</p>
				
				<p>
					Both cordycepin and adenosine can be used to mitigate excessive inflammation. <cite class="reflink"><a href="#s-shin">s-shin</a></cite> <cite class="reflink"><a href="#s-j-jung">s-j-jung</a></cite>
				</p>
				<ol class="reference-list">
					<li id="y-sun">
						<a 
						title="Neuroprotective effects of natural cordycepin on LPS-induced Parkinson‚Äôs disease through suppressing TLR4/NF-Œ∫B/NLRP3-mediated pyroptosis"
						target="_blank"
	href="https://www.sciencedirect.com/science/article/pii/S1756464620304989"
						>Neuroprotective effects of natural cordycepin on LPS-induced Parkinson‚Äôs disease through suppressing TLR4/NF-Œ∫B/NLRP3-mediated pyroptosis</a>, Ying Sun, et al.
						<p>
							Found cordycepin exerts neuroprotective effects via an anti-apoptotic mechanism based on the mitochondrial pathway in a rotenone-induced PD rat model. It suppresses inflammatory cytokines that lead to <dfn>pyroptosis</dfn>, or <dfn>"fiery falling"</dfn>, which describes the bursting of pro-inflammatory chemical signals from the dying cell.
						</p>
						<p>
							Toll-like receptor 4 (TLR4) is involved in the innate immune response and inflammation. Activation of TLR4 triggers downstream signaling pathways, including <abbr title="Nuclear factor kappa-light-chain-enhancer of activated B cells ">NF-Œ∫B</abbr> activation. Cordycepin inhibits TLR4 activation, diminishing inflammatory responses in the brain.
						</p>
						<p>
							Cordycepin inhibits the activation of the <abbr title="NOD-, LRR- and pyrin domain-containing protein 3) &mdash; immune system protein">NLRP3</abbr> inflammasome. This inhibition reduces the production and release of IL-1Œ≤ and IL-18, potent mediators of inflammation-induced neurotoxicity.
						</p>
					</li>
					
					<li id="j-yuan">
						<a 
							title="Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats"
							target="_blank"
	href="https://pubmed.ncbi.nlm.nih.gov/27646481/"
							>Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats</a>, Jing Yuan, et al.
							
						<p>
							Cordycepin has protective effects against brain damage induced by <abbr title="Traumatic Brain Injury">TBI</abbr>. Its protection of BBB integrity is likely achieved through the recovery of tight junction proteins, inhibition of local inflammation, and prevention of <abbr title="NADPH oxidase, an enzyme that reduces NADPH, increasing inflammation">NOX</abbr> activity.
						</p>
					</li>
					
					 <li id="s-shin">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816959/"
						title="Role of Cordycepin and Adenosine on the Phenotypic Switch of Macrophages via Induced Anti-inflammatory Cytokines"
						target="_blank"
						>Role of Cordycepin and Adenosine on the Phenotypic Switch of Macrophages via Induced Anti-inflammatory Cytokines</a>, Seulmee Shin, et al.
						
						<p>
							This in-vitro study found cordycepin and adenosine regulated the phenotypic switch on macrophages and suggested that cordycepin and adenosine may potentially be used as immunomodulatory agents in the treatment of inflammatory disease.
						</p>
						<p>
							By interacting with immune cells such as macrophages and dendritic cells, cordycepin and adenosine promote <dfn title="A process by which a cell engulfs a particle, such as a bacterium, dead cell, or foreign substance, and digests it">phagocytosis</dfn> and enhance immune responses against pathogens.
						</p>
					</li>
					
					<li id="c-cerletti">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308413/"
						title="Edible Mushrooms and Beta-Glucans: Impact on Human Health"
						target="_blank">Edible Mushrooms and Beta-Glucans: Impact on Human Health</a>, Chiara Cerletti, et al.
					</li>
					
					<li id="s-j-jung">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441223/"
						title="Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial"
						target="_blank"
						>Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial</a>, Su-Jin Jung, et al.
						<p>
							The results of this randomized and double-blind clinical trial suggest that CBG-CS-2, a strain of Cordyceps (Paecilomyces hepiali), is safe and effective for enhancing cell-mediated immunity in healthy adults.
						</p>
					</li>
				</ol>
			</section>
			
			<section id="turmeric" class="neuroprotective antifibrillogenic">
				<h3>
					Turmeric 
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotection, Anti-inflammatory, Antifibrillogenic, Anti-aggregation
					<li>Dose: 2-5 g daily üçΩÔ∏è üí§
					<li>ü©∏üß†BBB: <cite class="reflink"><a href="#n-sharma">N. Sharma</a></cite>
					<li>Safety: 8/10 (80% œÉ)
					<li>Efficacy: 7/10 (70% œÉ)
				</ul>
				
					<p>
						Turmeric, a rhizome of the Curcuma longa plant, contains curcumin as its primary active compound. While curcumin is the most researched, other curcuminoids also offer health benefits. In this guide,the terms <em>curcumin</em> and <em>turmeric</em> are used interchangeably.
					</p>
					
					<p>
						Curcumin crosses the blood-brain barrier to reach deep brain structures, including the midbrain, where it directly exerts beneficial effects. 
					</p>
	
					<h4>How Turmeric Helps PD</h4>
					<p>
						Turmeric promotes neuroprotection and neurogenesis. <cite class="reflink"><a href="#s-mishra">S Mishra</a></cite>
					</p>
	
					<p>
						Curcumin inhibits Œ±-synuclein aggregation by inhibiting oxidative stress, replenishing <abbr title="Glutathione">GSH</abbr> levels, and preventing glial-associated inflammatory response. By preventing misfolding and aggregation, curcumin inhibits fibril formations that damage neurons and lead to neurodegeneration. <cite class="reflink"><a href="#n-sharma">N. Sharma</a></cite> <cite class="reflink"><a href="#x-geng">X. Geng</a></cite>
					</p>
					
					<p>
						Curcumin rescues Œ±-synuclein from aggregation by increasing its <dfn>reconfiguration rate</dfn>. Œ±-synuclein is prone to aggregation because it misfolds and, subsequently, its reconfiguration rate is slow enough to expose hydrophobic residues on the same time scale that bimolecular association occurs. Œ±-synuclein misfolding exposes hydrophobic regions of the protein that are normally hidden in the correctly folded protein. These exposed hydrophobic areas can then interact with similar regions on other proteins, leading to aggregation, and eventually forming Lewy bodies. Curcumin mitigates this problem by preventing the misfolding. <cite class="reflink"><a href="#b-ahmad">B. Ahmad</a></cite>
					</p>
					
					<h4>Supplementation (Eating Turmeric)</h4>
					<p>
						Turmeric is generally safe at 1-10 g daily. However, very high doses may cause stomach upset or kidney strain, while lower doses may not be effective. <cite class="reflink"><a href="#h-ghodsi">H. Ghodsi</a></cite>
					</p>
	
					<h4>Challenges with Curcumin Absorption</h4>
					<p>
						Curcumin pills are convenient but poorly absorbed and rapidly metabolized. To improve absorption, frequent turmeric consumption throughout the day with fatty foods, black pepper or long pepper, and phosphatidylserine, fixes these problems.
					</p>
				
					<h4>Self-Emulsifying Drug Delivery Systems SEDDS</h4>
					<p> 
						Self-Emulsifying Drug Delivery Systems (SEDDS) are lipid-based formulations that create emulsions to improve the oral bioavailability of lipophilic substances like curcumin. The increased bioavailability means that a greater effect can be achieved without increasing the dose, thereby reducing the risk of side effects from overconsumption.
					</p>
				
					<h4>Enhancing Absorption with Food</h4>
					<p>                         
						Turmeric is good in curries with coconut oil, eggs, and in the cacao mix, when blended with coconut oil or butter. Such food formulations offer better absorption, acting as a SEDDS. Turmeric can be added to other dishes, like soups, andor blended into warm milk as <dfn>"golden milk"</dfn> with saffron, cinnamon, and other spices, or mixed into mustard as a garnish. 
					</p>
					
					<p>
						Piperine and piper longumine, from black pepper and long pepper, respectively, also increase turmeric bioavailability, and the latter is also senolytic. <cite class="reflink"><a href="#k-kesarwani">K. Kesarwani</a></cite>
					</p>
					
					<h4>Safety Concerns</h4>
					
					<p>
						Turmeric thins the blood, which may increase the risk of bleeding, especially in individuals taking blood-thinning medications or those with bleeding disorders or who are planning surgery. It may interact with blood thinners, diabetes medications, and medications that reduce stomach acid production.
					</p>
					<p>
						Excessive turmeric intake (over 10 g per day) may cause gastrointestinal issues or increase the risk of kidney stone formation, especially in those prone to kidney stones or with a history of kidney problems.
					</p>
	
					<h4>
						Curcumin References:
					</h4>
					<ol class="reference-list">
						<li id="n-sharma">
							<a href="https://pubmed.ncbi.nlm.nih.gov/29027056/" 
							title="Curcumin affords neuroprotection and inhibits Œ±-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model"
							target="_blank">Curcumin neuroprotection and anti- Œ±-synuclein aggregation rodent PD model</a>, Neha Sharma, et al.
							<p>
							   This rodent study found curcumin significantly improved inflammation, improved the glutathione system (GSH, <dfn title="Glutathione disulfide">GSSG</dfn>, and redox ratio), and prevented iron deposition in the dopaminergic neurons prevented Œ±-synuclein aggregates in the dopaminergic neurons
							</p>
						</li>
						
						<li id="s-mishra">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781139/"
							title="The effect of curcumin (turmeric) on Alzheimer's disease: An overview"
							target="_blank"
							>The effect of curcumin (turmeric) on Alzheimer's disease: An overview</a>, Shrikant Mishra and Kalpana Palanivelu.
							<p>
							
							</p>
						</li>
						<li id="x-geng">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372469/" 
							title="A novel curcumin oil solution can better alleviate the motor activity defects and neuropathological damage of a Parkinson‚Äôs disease mouse model"
							target="_blank">A novel curcumin oil solution can better alleviate the motor activity defects and neuropathological damage of a Parkinson‚Äôs disease mouse model</a>, Xiwen Geng, et al.
							
							<p>
								This rodent study provided comprehensive strong evidence regarding the effect of a novel curcumin oil solution on preventing movement disorders. This confirmed <dfn>n vivo</dfn> that the curcumin oil solution has higher bioavailability than curcumin alone.
							</p>
							<p>
								Curcumin had a greater protective effect on dopaminergic neurons in the compact part of the substantia nigra along with the PD process according to pathological evaluation.
							</p>
						</li>
						
						<li id="b-ahmad">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308736/" 
							title="Curcumin Prevents Aggregation in Œ±-Synuclein by Increasing Reconfiguration Rate"
							target="_blank">Curcumin Prevents Aggregation in Œ±-Synuclein by Increasing Reconfiguration Rate</a>, Basir Ahmad and Lisa J. Lapidus.
							<p>
								This rodent study found curcumin rescues the protein from aggregation by increasing the reconfiguration rate into a faster regime.
							</p>
						</li>
						<li id="h-ghodsi">
							<a href="https://www.sciencedirect.com/science/article/abs/pii/S0303846722001810?via%3Dihub" 
							title="Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial"
							target="_blank">Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial</a>, Hamidreza Ghodsi, et al.
							
							<p>
								This human study tested the effects of a novel <dfn>nanomicelle</dfn> curcumin preparation. Although it was well-tolerated, it was not successful in improving quality of life and clinical symptoms of PD patients.
							</p>
							
							<p>
								The problem with this study is they did not test the absorption of their novel <dfn>nanomicelle</dfn> curcumin. They did not prove that curcumin doesn't work, only that their <dfn>nanomicelle</dfn> preparation failed for unknown reasons.
							</p>
						</li>
						
						<li id="k-kesarwani">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634921/"
							title="Bioavailability enhancers of herbal origin: An overview"
							target="_blank"
							>Bioavailability enhancers of herbal origin: An overview</a>, Kritika Kesarwani and Rajiv Gupta.
						</li>
					</ol>
					
					<h4>Turmeric Products</h4>
					
					<ul class="product-list">
						<li>
							<figure>
								<img alt="Frontiers Bulk Turmeric" src="img/frontiers_turmeric-sm.png">
								<figcaption>
									<p>
										<a href="https://www.amazon.com/Frontier-Bulk-Turmeric-Powder-Trade/dp/B006K0C1RE">Frontier Co-op Organic Fair Trade Ground Turmeric Root 1lb</a>
									</p>
								</figcaption>
							</figure>
						</li>
						<li>
							<figure>
								<img src="img/turmeric-mykind.jpeg" alt="MyKind Turmeric">
								<figcaption>
									 <p>
										<a
										href="https://www.amazon.com/gp/product/B07NXQHXV3/ref=as_li_tl?ie=UTF8&amp;camp=1789&amp;creative=9325&amp;creativeASIN=B07NXQHXV3&amp;linkCode=as2&amp;tag=garrettsmit02-20&amp;linkId=143e5904cc8bab43c355acfc7eed8bc2"
									>Garden of Life, MyKind Organics, Extra Strength Turmeric
										</a>
									</p>
								</figcaption>
							</figure>
						</li>
						<li>
							<figure>
								<img src="img/curcumin.jpeg" alt="CurcuGreen Curcumin">
								<figcaption>
									<p>
										<a href="https://www.amazon.com/gp/product/B01ELXB3MA/ref=as_li_tl?ie=UTF8&tag=garrettsmit02-20&camp=1789&creative=9325&linkCode=as2&creativeASIN=B01ELXB3MA&linkId=ab05fa8195a7a04384554288ef47d9bd">Curcumin as BCM-95&reg; (CURCUGREEN&reg;)</a>
									</p>
								</figcaption>
							</figure>
						</li>
					</ul>
			</section>
			<section id="saffron">
				<h3>
					Saffron
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antioxidant, Sleep</li>
					<li>Dose: ~30mg of Saffron (8-10 threads) üçΩÔ∏èüí§</li>
					<li>ü©∏üß†BBB: ‚úÖ <cite class="reflink"><a href="#y-bian">Y. Bian</a></cite></li>
					<li>Fat-soluble: ‚úÖ/‚ùå Partially (safranal is fat-soluble; crocin and picrocrocin are water-soluble)
					<li>Safety: 9/10 (95% œÉ)</li>
					<li>Efficacy: 6/10 (60% œÉ)</li>
				</ul>
				<p>
					Saffron is a spice made from the red stigmas or "threads" of the Crocus flower used in South Asian and Middle Eastern medicine as an <dfn title="substance that induces menstrual flow, even if it is delayed or absent.">emmenagogue</dfn>, general tonic, aphrodisiac and nerve stimulant in low doses either in tea or in meals.
				</p>
				
				<p>
					Saffron has antioxidant, anti-inflammatory, and neuroprotective effects. Scientific research shows its beneficial effects on improving mood and sleep, enhancing cognitive function, and supporting cardiovascular health. The primary active components, such as crocin and picrocrocin, are water-soluble, while safranal, responsible for saffron's aroma, is fat-soluble.
				</p>
				
				<h4>Sleep</h4>
				<p>
				A 28-day, parallel-group, double-blind <abbr title="randomized controlled trial">RCT</abbr> A 28-day, parallel-group, double-blind RCT recruited sixty-three healthy adults aged 18‚Äì70 with self-reported sleep problems were randomized to receive either saffron or a placebo. Results showed that saffron was associated with greater improvements in the Insomnia Severity Index (ISI), Restorative Sleep Questionnaire (RSQ), and the Pittsburgh Sleep Diary (PSD) and was well-tolerated with no reported adverse effects. <cite class="reflink"><a href="#a-lopresti">A. Lopretsi</a></cite>
				</p>
				
				<h4>Saffron in Neurodegenerative Disease</h4>
				
				<p>
					Saffron has been proven to alleviate the symptoms of AD and its effects on PD are of continuing research, particularly for its antidepressant and anxiolytic effects. <cite class="reflink"><a href="#y-bian">Y. Bian</a></cite>
				</p>
				<p>
					A 2024 review found that saffron's compounds inhibit neuroinflammation and excitotoxic pathways, modulate autophagy and apoptosis, attenuate oxidative damage, and activate defensive antioxidant enzymes, providing neuroprotection against neurodegenerative diseases. <cite class="reflink"><a href="#hamedani">S. G.-Hamedani</a></cite>
				</p>
				
				<p>
					A 2019 rodent model study found saffron had a neuroprotective
effect and could be recommended as a possible therapeutic agent to prevent neurotoxicity allied to heavy metals and related neurodegenerative disorders like PD. <cite class="reflink"><a href="#tamegart">L. Tamegart</a></cite>
				</p>
				
				<p>
					Saffron inhibits damage and inflammation to astrocytes, a type of glial cell, through multiple pathways. Its active compounds modulate oxidative stress, reduce pro-inflammatory cytokine production, and support the maintenance of cellular integrity, thereby protecting astrocytes from injury and dysfunction. <cite class="reflink"><a href="#maqbool">Maqbool</a></cite>
				</p>
				<p>
					Glial cells, and specifically astrocytes, support the function and survival of neurons. Astrocytes can release neurotransmitters, such as glutamate and ATP, which can influence neuronal activity.
				</p>
				<p>
					Glial scar formation is a common pathological feature in various central nervous system (CNS) diseases, including PD. In PD, the glial scars form around damaged dopaminergic neurons, blocking their repair.
				</p>

				<h4>Supplementation</h4>
				<p>
					Some of the compounds in saffron are fat-soluble, while others are water soluble. Saffron can be drunk with turmeric and cinnamon in golden milk. Excessive amounts may cause bloating and gas and gut microbiota may positively affect the gut-brain axis, therefore, it's a good idea to consume saffron with prepared food.
				</p>
				
				<figure class="flex-row">
					<img src="img/saffron-liquid-sm.png" alt="saffron in water">
					<figcaption style="margin-left: 1rem">
						<h5>DIY Saffron Extract</h5>
						<p>Place dry saffron in a jar and add water for an easy and convenient aqueous ready for daily use.
						</p>
					</figcaption>
				</figure>
				<!--
				
				<h4>
						Saffron Productss
				</h4>
				<ul class="product-list">
					<li>
						<a href=""></a>
					</li>
					<li>
						<figure>
							<img src="" alt="">          
							<figcaption>
								<p>
									<a href=""
									target="_blank"></a>
								</p>
							</figcaption>
						</figure>
					</li>
				</ul>
				
					<a    href="https://www.amazon.com/gp/product/B07Q23DCZC/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07Q23DCZC&amp;linkId=a89eecbeabe1c12666d9093201834fce"
					title=""
					>Saffron Extract Supplements
					</a>
				</div>
				<p>
					<img src="img/saffron.jpeg" title="saffron">
				</p>
				<div>
					Turmeric and Saffron can also be prepared together as a warm night drink of golden milk with a calming effect. Both can be purchased online.
				</div>
				<div>
					<strong>
						Turmeric and Saffron Product:
					</strong>
					<a
						href="https://www.amazon.com/gp/product/B07BH6KBN4/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07BH6KBN4&amp;linkId=5726ef5550d5890bb7fd0e237f6a7791"
					>
						Turmeric Latte with Saffron
					</a>
				</div>
				<p>
					<img src="img/turmeric-latte.jpeg" alt="turmeric latte" />
				</p>
			-->
				<h5>
						Saffron References:
				</h5>
				<ol class="reference-list">
				
					<li id="hamedani">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827773/"
						title="Therapeutic effects of saffron and its components on neurodegenerative diseases"
						target="_blank"
						>Therapeutic effects of saffron and its components on neurodegenerative diseases</a>, Sahar Golpour-Hamedani, et al.
					</li>
					
					<li id="y-bian">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573929/"
						title="Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside"
						target="_blank"
						>Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside</a>, Yaqi Bian, et al.
						<p>
							This review study discussed the neuroprotective effects of crocin and crocetin, and that both could provide neuroprotection by reducing AŒ≤ aggregation.
						</p>
					</li>
					<!--li id="n-skladnev">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361500/"
						title="Neuroprotective properties of dietary saffron: more than just a chemical scavenger?"
						target="_blank"
						>Neuroprotective properties of dietary saffron: more than just a chemical scavenger?</a>, Nicholas V. Skladnev, et al.
						<p>
							This review study discussed the mechanism of actions of saffron to induce dose-dependent neuroprotective response.
						</p>
					</li -->
					<li id="l-tamegart">
						<a href="https://pubmed.ncbi.nlm.nih.gov/30573341/"
						target="_blank"
						title="Crocus sativus restores dopaminergic and noradrenergic damages induced by lead in Meriones shawi: A possible link with Parkinson's disease"
						>Crocus sativus restores dopaminergic and noradrenergic damages induced by lead in Meriones shawi: A possible link with Parkinson's disease</a>, Lahcen Tamegart, et al.
						<p>
							This rodent study showed that movement disorder caused by Pd (lead)-induced damage to dopaminergic and noradrenergic systems in the midbrain was reversed by saffron (crocus sativus).
						</p>
					</li>
					<li id="a-lopresti">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849671/"
						title="Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial"
						target="_blank"
						>Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial
	</a>, Adrian L Lopresti, et al.
						<p>
							This 28-day, parallel-group, double-blind, randomized controlled trial included sixty-three healthy adults aged 18-70 with self-reported sleep problems. Subjects were randomized to receive either saffron extract (saffron; 14 mg twice daily) or a placebo.
						</p>
						<p>
							Conclusions: Saffron intake was associated with improvements in sleep quality in adults with self-reported sleep complaints.
						</p>
					</li>
					<li id="s-r-rao">
						<a href="https://pubmed.ncbi.nlm.nih.gov/26705857/"
						target="_blank"
						title="Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism"
						>Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism</a>, Sriranjini Venkat Rao, et al.
						<p>
							This drosophila model of parkinsonism study showed the neuroprotective effects of saffron and crocin. It concluded that these effects may be largely attributable to its antioxidant action and recommended saffron be exploited as a supplementary therapeutic agent in PD and other oxidative stress-mediated neurodegenerative conditions.
						</p>
					</li>
					<li id="maqbool">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526642/"
                        title="Potential Role of Phytochemical Extract from Saffron in Development of Functional Foods and Protection of Brain-Related Disorders"
                        target="_blank"
                        >Potential Role of Phytochemical Extract from Saffron in Development of Functional Foods and Protection of Brain-Related Disorders</a>, Zahra Maqbool, et al.
                    </li>
				</ol>
			</section>
			
			<section id="coconut-oil">
				<h3>
					Coconut Oil
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
					<li>Dose: ~30 ml of Coconut Oil per day üçΩÔ∏è </li>
					<li>ü©∏üß†BBB: ‚úÖ (coconut oil itself does not cross the BBB, but MCFAs do)</li>
					<li>Fat-soluble: ‚úÖ
					<li>Safety: 9/10 (95% œÉ)</li>
					<li>Efficacy: 6/10 (60% œÉ)</li>
				</ul>
				
				<p>
					Coconut oil is extracted from the meat of mature coconuts. It is high in saturated fats and commonly used in cooking and food preparations.
				</p>
				
				<p>
					Rich in lauric acid and <abbr title="medium-chain triglyceride">MCTs</abbr>, coconut oil supports heart health by increasing HDL and providing antimicrobial effects. Lauric acid, a 12-carbon variety, may contribute to its positive effects on HDL. <abbr title="medium-chain triglyceride">MCTs</abbr> boost energy and enhance metabolic health, which can improve brain function and aid conditions like AD, PD, and MS. Additionally, coconut oil supports fat loss, nutrient absorption, and gut health.
				</p>
				
				<h4>Metabolic Health Effects</h4>
				<p>
					A 2018 double-blind RCT investigated the effects of various vegetable oils, including coconut, safflower, chia, and soybean (placebo) oils, on obese women following a hypocaloric diet.
				</p>
				<p>
					The coconut oil group showed significant improvements in cardiovascular risk factors, including reduced abdominal adiposity, decreased waist circumference, decreased waist-to-height ratio, lower blood glucose and glycated hemoglobin levels, reduced body fat, and increased lean mass. <cite class="reflink"><a href="#oliveira-de-lira">Oliveira de Lira</a></cite>
				</p>
				
				<p>
					The increase in lean mass was likely due to MCTs, which provide quick energy, enhance exercise performance, and stimulate muscle growth without promoting fat storage. Maintaining or increasing lean mass supports metabolic health and cardiovascular outcomes. The quick energy boost also makes coconut oil a good pre-workout option.
				</p>
				
				<h4>Mitigating PD</h4>
				
				<p>A 2022 review study found that coconut oil improves PD through multiple pathways, mediating oxidative stress, neuroinflammation, mitochondrial dysfunction, apoptosis, and excitotoxicity in various in vitro and in vivo models. Dietary intake of coconut oil has also been associated with a reduced incidence of PD. During digestion, coconut oil is broken down into smaller molecules, such as ketone bodies (KBs). These KBs can cross the <abbr title="blood-brain barrier">BBB</abbr> and serve as an alternative energy source for the brain, making coconut oil a significant natural remedy for neurodegenerative conditions. <cite class="reflink"><a href="#deepika">deepika</a></cite>
				</p>
				
				<p>
					Coconut oil has been shown to reduce obesity, improve insulin resistance, and support metabolic health. These improvements can reduce inflammation, enhance mitochondrial function, and increase cerebral blood flow. These effects may help explain how coconut oil potentially benefits neurodegenerative disorders such as AD, PD, and MS. <cite class="reflink"><a href="#oliveira-de-lira">Oliveira de Lira</a>, <a href="#ibrahim">Ibrahim</a></cite>
				</p>
				
				<h4>Mitochondrial Effects</h4>
				<p>
					Although progressive damage to dopaminergic neurons in the substantia nigra is a primary etiological pathway in PD, mitochondrial dysfunction and oxidative stress contribute substantially to its pathogenesis. Coconut oil's <abbr title="medium-chain triglyceride">MCTs</abbr> are metabolized into glycerol and medium-chain fatty acids, which support mitochondrial <abbr title="adenosine triphosphate">ATP</abbr> production and may enhance mitochondrial biogenesis. <cite class="reflink"><a href="#ying-wang">Ying Wang</a></cite>
				</p>

				<p>
					A 2020 rodent model study even showed that coconut oil helped neural function and mitigated the effects of L-dopa supplementation, lending its use as a potential strategy to reduce reliance on <abbr title="dopamine replacement therapy">DRT</abbr>. <cite class="reflink"><a href="#shehata">Shehata</a></cite>
				</p>
				<!-- strong>
					Coconut Oil Product:
				</strong>
				<a href="https://www.amazon.com/gp/product/B00CQ7TNDK/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00CQ7TNDK&amp;linkId=f32fa29138420ac8f79b25b5f9f8849f"
				>Dr. Bronner's - Organic Virgin Coconut Oil</a>
				<p>
					<img src="img/coconut-oil.jpeg" alt="coconut oil" />
				</p-->
				
				
				<h4>References</h4>
				<ol class="reference-list">
				
					<li id="oliveira-de-lira">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073593/"
                        title="Supplementation-Dependent Effects of Vegetable Oils with Varying Fatty Acid Compositions on Anthropometric and Biochemical Parameters in Obese Women"
                        target="_blank"
                        >Supplementation-Dependent Effects of Vegetable Oils with Varying Fatty Acid Compositions on Anthropometric and Biochemical Parameters in Obese Women</a>, Luciene Oliveira de Lira, et al.
                    </li>
					
					<li id="deepika">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36208039/"
                        title="Neuroprotective role of coconut oil for the prevention and treatment of Parkinson's disease: potential mechanisms of action"
                        target="_blank"
                        >Neuroprotective role of coconut oil for the prevention and treatment of Parkinson's disease: potential mechanisms of action</a>, 
                    </li>
					<li id="ibrahim">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36208039/"
                        title="Beneficial Effects of Coconut Oil in Treatment
of Parkinson‚Äôs Disease"
                        target="_blank"
                        >Beneficial Effects of Coconut Oil in Treatment
of Parkinson‚Äôs Disease</a>, K. S. Ibrahim and E. M. El-Sayed.
                    </li>
                    <li id="ying-wang">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805166/"
                        title="Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism"
                        target="_blank"
                        >Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism</a>, Ying Wang, et al.
                    </li>

	
					<li id="shehata">
						<a href="https://pubmed.ncbi.nlm.nih.gov/32707436/"
                        target="_blank"
                        title="Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil"
						>Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil</a>, Ahmed M Shehata, et al.
					</li>
                    
				</ol>
			</section>
			<section id="ginger">
				<h4>
					Ginger
				</h4>
				<div>
					Ginger, a member of the same family of rhizomes as turmeric, contains several phenolic compounds, including shogaol. Gingerol and shogaol protect dopaminergic neurons.
				</div>
				<div>
					<strong>
						Ginger References:
					</strong>
				</div>
				<ol>
					<li>
						<a href="https://pubmed.ncbi.nlm.nih.gov/23811724/"
						>6-Shogaol, an active compound of ginger, protects dopaminergic neurons in Parkinson's disease models via anti-neuroinflammation.</a>
						<p>
	
						</p>
					</li>
					<li>
						2)
						<a href="https://nhsjs.com/2021/extractions-of-6-shogaol-and-6-gingerol-from-ginger-zingiber-officinale-on-the-protection-of-dopaminergic-neurons-in-a-parkinsons-disease-model/">
							Extractions of 6-Shogaol and 6-Gingerol from Ginger (Zingiber officinale) on the Protection of Dopaminergic Neurons in a Parkinson's Disease Model
						</a>
					</li>
				</ol>
			</section>
			<section id="egcg">
				<h3>
					Matcha
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
					<li>Dose: 2-5g</li>
					<li>ü©∏üß†BBB: (The concentrated L-theanine can bypass the BBB‚Äôs natural barriers and reach the brain, where it is believed to have a positive impact on sleep, focus, learning, and symptoms of anxiety.) </li>
					<li>Fat-soluble: ‚ùå </li>
					<li>Safety: 8/10 (85% œÉ)</li>
					<li>Efficacy: 5/10 (80% œÉ)</li>
				</ul>
				
				<p>
					Matcha is a finely ground Japanese green tea powder rich in bioactives, including lutein, vitamin K, and polyphenols, particularly catechins like epigallocatechin gallate (EGCG). EGCG exhibits potent antioxidant and neuroprotective effects that help mitigate oxidative stress, neuroinflammation, and neurodegeneration.
				</p>
				
				<h4>Cognitive Effects</h4>
				
				<p>
					A 2020 randomized, double-blind, placebo-controlled trial over 12 weeks on 15 men and 39 women found that Matcha improved cognitive function (<abbr title="Montreal Cognitive Assessment">MoCA</abbr> test), with the effects being more pronounced in women than in men, especially in the cognitive domain of language. Researchers speculated that this may be associated with physiological changes that accompany estrogen loss and menopause in elderly women, attributing the potential effects to matcha's EGCG, vitamin K, and lutein content. <cite class="reflink"><a href="#k-sakurai">Sakurai</a></cite>
				</p>
				
				<h4>Metabolic Effects</h4>
				<p>
					A 2017 review found that EGCG exhibited a wide range of therapeutic properties including anti-atherosclerosis, anti-diabetes, anti-inflammatory, and antioxidant effects. The reduction in plasma glucose and inflammatory markers and the inhibition of <abbr title="Reactive Oxygen Species">ROS</abbr> generation have multiple benefits to cardiopulmonary and neurological health. <cite class="reflink"><a href="#q-y-eng">Eng</a></cite>
				</p>
	
				<p>
					Low-dose EGCG and caffeine, two components of matcha, elicit substantial synergistic anti-obesity effects by improving gut microbiota and enhancing short-chain fatty acid (SCFA) production. The gut microbiota regulates obesity and metabolic disorders through various physiological pathways, including SCFAs and their receptors. These effects on the gut microbiota may help explain the metabolic and cognitive benefits associated with matcha consumption. <cite class="reflink"><a href="#zhu">Zhu</a></cite>
				</p>
				
				<h4>Anti-aggregant Effects</h4>
				<p>
					EGCG has been shown to inhibit the ability of preformed oligomers, such as oligomers of Œ±-synuclein, to increase the permeability of vesicles (small, membrane-bound structures within cells that contain fluid and are enclosed by a lipid bilayer), which can lead to cell damage and induce cytotoxicity in rat brain cells. This in vitro and rodent model evidence warrants further investigation in humans. <cite class="reflink"><a href="#lorenzen">Lorenzen</a>, <a href="#y-xu">Xu</a></cite>
				</p>
				
				<h4>Ceremonial Grade Matcha</h4>
				<p>
					Ceremonial grade matcha is made from the youngest tea leaves with higher concentrations of chlorophyll and lower fluoride content compared to culinary grade matcha made from older leaves, which accumulate fluoride from the soil as they grow.
				</p>
				
				<h4>Fluoride and Oxalates Warning</h4>
				<p>
					Matcha also has moderate levels of oxalates with younger leaves having higher oxalate concentrations than older leaves. Oxalates can contribute to inflammation and kidney damage. Moderate amounts of quality ceremonial grade matcha are safe for drinking (10 g of matcha contains approximately 60 mg of oxalate). Those seeking a much higher dose of EGCG and lutein without the fluoride and oxalate can consider supplemental EGCG.
				</p>
				
				<h4>Matcha Preparation</h4>
<ul>
    <li><strong>Grade:</strong> Use ceremonial grade matcha for higher polyphenols and less caffeine and fluoride.</li>
    <li><strong>Timing:</strong> Consume in the morning or early afternoon to avoid nighttime caffeine effects.</li>
    <li><strong>Water Temperature:</strong> Heat water to 160‚Äì175¬∞F (70‚Äì80¬∞C; well below boiling) to preserve polyphenols.</li>
    <li><strong>Milk:</strong> Avoid milk to maintain polyphenol effectiveness.</li>
</ul>

				<!-- h4>
					Product:
				</h4>
				<img src="img/cytokine-suppress.png" alt="cytokine suppress" />
				<h4>
					<a
						href="https://www.amazon.com/gp/product/B00FPOF0ME/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00FPOF0ME&amp;linkId=ed2f547390cfaadd1c5ca40695bf1d3a"
					>
						Life Extension Cytokine Suppress
					</a>
				</h4 -->
				
				<h4>References</h4>
				<ol class="reference-list">
					<li id="k-sakurai">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760932/"
                        title="Effects of Matcha Green Tea Powder on Cognitive Functions of Community-Dwelling Elderly Individual"
                        target="_blank"
                        >Effects of Matcha Green Tea Powder on Cognitive Functions of Community-Dwelling Elderly Individual</a>, Keisuke Sakurai, et al.
                    </li>
                    
					<li id="lorenzen">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118093//"
						target="_blank"
						title="How Epigallocatechin Gallate Can Inhibit Œ±-Synuclein Oligomer Toxicity in Vitro"
						>How Epigallocatechin Gallate Can Inhibit Œ±-Synuclein Oligomer Toxicity in Vitro</a>, Nikolai Lorenzen, et al.
					</li>
                    
					<li id="y-xu">
						<a href="https://pubmed.ncbi.nlm.nih.gov/27364962/"
						title="Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson‚Äôs Disease"
						target="_blank">Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson‚Äôs Disease</a>, Yan Xu, et al.
						<p>
							This study found EGCG significantly decreased the number of cerebral SNCA aggregates and their activity in mice.
						</p>
					</li>
	
					<li id="q-y-eng">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28864169/"
                        title="Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases"
                        target="_blank"
                        >Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases</a>, Qian Yi Eng, et al.
                    </li>
                    
                    <li id="zhu">
                        <a href="https://pubs.rsc.org/en/content/articlelanding/2021/fo/d0fo01768j"
                        title="Combined use of epigallocatechin-3-gallate (EGCG) and caffeine in low doses exhibits marked anti-obesity synergy through regulation of gut microbiota and bile acid metabolism"
                        target="_blank"
                        >Combined use of epigallocatechin-3-gallate (EGCG) and caffeine in low doses exhibits marked anti-obesity synergy through regulation of gut microbiota and bile acid metabolism</a>, Ming-zhi Zhu, et al.
                    </li>
                    
					<li>
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867908/"
						title="EGCG remodels mature Œ±-synuclein and amyloid-Œ≤ fibrils and reduces cellular toxicity"
						>remodels mature &alpha;-synuclein and amyloid-&beta; fibrils and reduces cellular toxicity</a>, Jan Bieschke, et al.
					</li>
				</ol>
			</section>
			<section id="ginsenoside">
				<h3>
					Ginseng
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Anti-inflammatory, Antioxidant, Mitochondrial</li>
					<li>Dose: 200 - 400 mg pre-workout ‚òÄÔ∏è</li>
					<li>ü©∏üß†BBB: ‚úÖ Ginsenosides can cross the blood-brain barrier, but transport may be poor. <cite class="reflink"><a href="#y-n-zhao">Zhao</a></cite></li>
					<li>Safety: 8/10 (75% œÉ)</li>
					<li>Efficacy: 6/10 (60% œÉ)</li>
				</ul>
				<p>
					Ginseng is a traditional herbal medicine used for energy and vitality, metabolic (<abbr title="blood glucose">BG</abbr>) and cardiovascular health, stress relief, sexual dysfunction, and cancer protection. Its ginsenoside components, primarily Rb1 and Rg1, and saponins have shown neuroprotective effects, alleviating PD symptoms and slowing disease progression.
				</p>
								
				<h4>Ginseng in PD</h4>
				<p>
					Ginseng exhibits improved motor function and increased dopamine levels in PD models. These neuroprotective effects are explained by reduced oxidative stress, inflammation, and neuronal apoptosis, with no significant toxicity observed in most studies. <cite class="reflink"><a href="#he">He</a>, <a href="#l-song">Song</a>, <a href="#zaafan">Zaafan</a>, <a href="#van-kampen">van-kampen</a>, <a href="#jh-choi">Choi</a></cite>
				</p>
				
				<p>
					Ginsenoside Rb1 inhibits fibrillation, oligomerization, and toxicity of Œ±-synuclein, and disaggregates preformed fibrils.  <cite class="reflink"><a href="#y-heng">Heng</a>, <a href="#ardah">Ardah</a></cite>
				</p>
				
				<h4>Supplementation</h4>
				<p>
					Ginseng's energizing effects make it suitable pre-workout or earlier in the day. Fermented ginseng offers significantly better absorption with higher ginsenoside concentration, compared to the low oral absorption of non-fermented ginsenosides (0.1 ‚Äì 3.7%). <cite class="reflink"><a href="#j-ryu">Ryu</a></cite> Start with 200-400 mg daily, gradually increasing the dose as needed. Select a high-quality product with clear labeling.
				</p>
				
				<h4>Side Effects</h4>
				<p>
					Side effects may include a mildly elevated heart rate, increased blood pressure, as well as insomnia if consumed in the evening. Ginseng may enhance the activity of MAOIs, which could allow for reductions in medication dosage. Consult a healthcare professional for potential interactions and monitoring. <cite class="reflink"><a href="#l-liu">l-liu</a></cite>
				</p>
				
				<h4>
					Products
				</h4>
				<ul class="product-list">
					<li>
						<figure>
							<img src="img/acetyl-l-carnitine.jpeg" alt="">
						
							<figcaption>
								<p>
									<a
						target="_blank"
						href="https://www.amazon.com/gp/product/B00KDSZ6XU/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00KDSZ6XU&amp;linkId=d82ad47963e6dede78ec44e2184a1d36"
					>ILHWA Korean Ginseng Concentrated Pure Extract</a>
								</p>
							</figcaption>
						</figure>
					</li>
				</ul>
				
				<h4>References</h4>
				<ol class="reference-list">
					<li id="y-n-zhao">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29576053/"
                        title="Qualitative detection of ginsenosides in brain tissues after oral administration of high-purity ginseng total saponins by using polyclonal antibody against ginsenosides"
                        target="_blank"
                        >Qualitative detection of ginsenosides in brain tissues after oral administration of high-purity ginseng total saponins by using polyclonal antibody against ginsenosides</a>, Yu-Nan Zhao, et al.
                    </li>
					<li id="he">
                        <a href="https://ncbi.nlm.nih.gov/pmc/articles/PMC8027743/"
                        title="Effect of ginsenoside-Rg1 on experimental Parkinson's disease: A systematic review and meta-analysis of animal studies"
                        target="_blank"
                        >Effect of ginsenoside-Rg1 on experimental Parkinson's disease: A systematic review and meta-analysis of animal studies</a>, Yi-Bo He, et al.
                    </li>
                    <li id="l-song">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366755/"
                        title="A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease"
                        target="_blank"
                        >A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease</a>, Liang Song, et al.
                    </li>
					<li id="zaafan">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31198107/"
                        title="The Protective Effect of Korean Red Ginseng Against Rotenone-Induced Parkinson's Disease in Rat Model: Modulation of Nuclear Factor-Œ∫Œ≤ and Caspase-3"
                        target="_blank"
                        >The Protective Effect of Korean Red Ginseng Against Rotenone-Induced Parkinson's Disease in Rat Model: Modulation of Nuclear Factor-Œ∫Œ≤ and Caspase-3</a>, Mai A Zaafan, et al.
                    </li>
                    <li id="van-kampen">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/14637121/"
                        title="title"
                        target="_blank"
                        >title</a>, Jackalina Van Kampen, et al.
                    </li>
                    
                    <li id="jh-choi">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026382/"
                        title="title"
                        target="_blank"
                        >title</a>, Jong Hee Choi, et al.
                    </li>
                    <li id="y-heng">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26723869/"
                        title="Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting Œ±-synuclein abnormalities in the substantia nigra"
                        target="_blank"
                        >Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting Œ±-synuclein abnormalities in the substantia nigra</a>, Yang Heng, et al.
                    </li>
					<li id="ardah">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882765/"
						title="Ginsenoside Rb1 inhibits fibrillation and toxicity of &alpha;-synuclein and disaggregates preformed fibrils"
                        target="_blank"
						>Ginsenoside Rb1 inhibits fibrillation and toxicity of &alpha;-synuclein and disaggregates preformed fibrils.</a>, Mustafa T. Ardah, et al.
					</li>
					
					<li id="j-ryu">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659629/"
                        target="_blank"
                        title="The bioavailability of red ginseng extract fermented by Phellinus linteus"
						>The bioavailability of red ginseng extract fermented by Phellinus linteus</a>, Jae Sik Ryu, et al.
					</li>
					
					<li id="l-liu">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755186/"
                        title="Functional compounds of ginseng and ginseng-containing medicine for treating cardiovascular diseases"
                        target="_blank"
                        >Functional compounds of ginseng and ginseng-containing medicine for treating cardiovascular diseases</a>, Lanchun Liu, et al.
                    </li>
				</ol>
			</section>
			<section id="acetyl-l-carnitine">
				<h3>Acetyl-L-Carnitine (ALCAR)</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
					<li>Dose: 1.5 - 2g pre-workout ‚òÄÔ∏è</li>
					<li>ü©∏üß†BBB: ‚úÖ ALCAR can easily cross the blood-brain barrier, which allows it to target brain cells more effectively than free L-carnitine.<cite class="reflink"><a href="#akihiro-inano">akihiro-inano</a></cite></li>
					<li>Safety: 8/10 (75% œÉ)</li>
					<li>Efficacy: 6/10 (60% œÉ)</li>
				</ul>
				
				
				<p>
					Acetyl-L-Carnitine (ALCAR) is a modified form of L-Carnitine, an amino acid that transports fatty acids into the mitochondria for energy conversion, making it an excellent fat-burning supplement.
				</p>
				
				<h4>Blood-Brain Barrier</h4>
				<p>
					ALCAR‚Äôs acetyl group allows it to cross the blood-brain barrier more effectively than L-carnitine, enhancing brain energy metabolism and cognitive function.
				</p>
				
				<h4>How ALCAR Works</h4>
				<p>
					ALCAR facilitates the transport of fatty acids into mitochondria, boosting energy production and reducing oxidative stress. This helps boost brain energy and neurotransmitter activity. Therapeutic benefits may include improved cognitive function, potential support for depression, and reduced oxidative stress, and fat loss.
				</p>
				
				<h4>Performance and Recovery</h4>
				<p>
					Forms of l-carnitine, including ALCAR, improve exercise performance and recovery. A 2018 study published in the Journal of Exercise Nutrition and Biochemistry found that L-carnitine supplementation enhances exercise performance while attenuating blood lactate and oxidative stress responses to resistance training. <cite class="reflink"><a href="#koozehchian">Koozehchian</a></cite>
				</p>
				
				<p>
					A comprehensive 2018 review in Nutrients analyzed multiple studies across various populations, concluding that l-carnitine intake improves recovery after exercise, alleviates muscle injury, and reduces markers of cellular damage and free radical formation accompanied by attenuation of muscle soreness. Studies in older adults further showed that l-Carnitine supplementation can lead to increased muscle mass accompanied by a decrease in body weight and reduced physical and mental fatigue.
				</p>
				
				<h4>Metabolic Health</h4>
				<p>
					A 2021 review study investigated the effects of L-Carnitine, ALCAR, and Propionyl-L-Carnitine (PLCAR) on body mass in type 2 diabetes mellitus (T2DM) patients. After reviewing several studies, they concluded that 2 g/day l-carnitine for at least 2 weeks to affect body mass in T2DM patients, and no differentiating effects were found in acetyl-l-carnitine or propionyl-l-carnitine groups. <cite class="reflink"><a href="#dd-wang">Wang</a></cite>
				</p>
				
				<h4>Neurological Effects</h4>

				<p>
					ALCAR protects dopaminergic neurons by reducing neuroinflammation, apoptosis, astrogliosis (damage to  astrocytes (glial cells)), and oxidative stress. ALCAR has shown neuroprotective effects in rodent models of PD, both in vitro and in vivo, protecting cells against the accumulation of alpha-synuclein. <cite class="reflink"><a href="#s-a-majd">Majd</a>, <a href="#burks">S Burks</a></cite> 
				</p>
				<p>
					A 1990 study on PD patients showed that 2g of ALCAR improved the H-reflex and enhanced sleep architecture, including spindle activity, in non-placebo subjects.
				</p>
				<p>
					Researchers found that the 2 g of supplemental ALCAR improved the H-response, sleep stages, and spindling in test (non-placebo) subjects. The H-response, or Hoffmann reflex, is a muscle reflex response to specific nerve stimulation, characterized by distinct latency and amplitude. Spindling refers to brain wave activity occurring during <abbr title="Non-rapid eye movement sleep">NREM</abbr> sleep, particularly in stages N2 (lighter sleep) and N3 (deeper sleep). <cite class="reflink"><a href="#puca">Puca</a></cite>
				</p>
				
				<p>
					A later 2018 multicenter, randomized double-blind, placebo-controlled 28 day clinical trial studied the efficacy of 1500 mg ALCAR per day in patients with dementia-associated with cerebrovascular disease. Although the study excluded patients with PD, researchers found that 1.5g of ALCAR significantly improved cognitive assessment. <cite class="reflink"><a href="#ys-yang">ys-yang</a></cite>
				</p>
				
				<p>
					A 2022 randomized, observational, double-blind, placebo-controlled study on ALCAR scheduled prefrail elderly patients. 92 patients received 3 months of treatment with ALCAR at 1.5 grams or placebo, twice daily, and then 3 months of follow-up. They found that ALCAR treatment delayed the incidence and severity of onset of degenerative disorders of the elderly in prefrail subjects with improvement in memory and cognitive processes. <cite class="reflink"><a href="#malaguarnera">Malaguarnera</a></cite>
				</p>
				
				<p>
					ALCAR supports exercise performance and recovery, mitochondrial health, cognitive function, and fat loss. Cognitive function is improved in elderly and some cognitive function, likely due to its ability to aid mitochondrial energy production, which may have potential benefit for PD.
				</p>
				
				<h4>Supplementation</h4>
				<p>
					Taking 1.5 - 2 g ALCAR pre-workout enhances exercise performance. Intense exercise increases cerebral blood flow, potentially enhancing ALCAR uptake in the brain. It is avoid taking ALCAR before sleeping, as its stimulating effects may interfere with sleep. 
				</p>
				
				<h4>Products</h4>
				<ul class="product-list">
					<li>
						<figure>
							<img src="img/acetyl-l-carnitine.jpeg" alt="">
						
							<figcaption>
								<p>
									<a href="https://www.amazon.com/gp/product/B07BLMSWGN/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07BLMSWGN&amp;linkId=d5ce891282e299fedbd0358e75eafd91">Superior Labs | Acetyl L-Carnitine 1000mg</a>
								</p>
							</figcaption>
						</figure>
					</li>
				</ul>
	
				<h5>References</h5>
				<ol class="reference-list">
					<li id="akihiro-inano">
						<a href="https://pubmed.ncbi.nlm.nih.gov/14595704/"
						target="_blank"
						>Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2</a>, Akihiro Inano, et al.
					</li>
	
					<li id="koozehchian">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343764/"
                        title="Effects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained malese"
                        target="_blank"
                        >Effects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained males</a>, Majid S. Koozehchian, et al.
                    </li>
					<li id="s-a-majd">
						<a href="https://pubmed.ncbi.nlm.nih.gov/28199883/"
						target="_blank"
						>Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat</a>, Siamak Afshin-Majd, et al.
					</li>
					<li id="burks">
                        <a href="https://www.sciencedirect.com/science/article/abs/pii/S0304394019301703"
                        title="Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson‚Äôs disease mouse model: Endothelial and microglial effects"
                        target="_blank"
                        >Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson‚Äôs disease mouse model: Endothelial and microglial effects</a>, Susan Burks, et al.
                    </li>
					<li id="dd-wang">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606643/"
                        title="The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients"
                        target="_blank"
                        >The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients</a>, Dong-Dong Wang, et al.
                    </li>
                    <li id="fielding">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872767/"
                        title="l-Carnitine Supplementation in Recovery after Exercise"
                        target="_blank"
                        >l-Carnitine Supplementation in Recovery after Exercise</a>, Roger Fielding, et al.
                    </li>
					<li id="puca">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2387661/"
                        title="Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease"
                        target="_blank"
                        >Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease</a>, F M Puca, et al.
                    </li>
                    
                    <li id="ys-yang">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427993/"
                        title="A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease"
                        target="_blank"
                        >A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease</a>, YoungSoon Yang, et al.
                    </li>
                    <li id="malaguarnera">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36043711/"
                        title="Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial"
                        target="_blank"
                        >Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial</a>, Giulia Malaguarnera, et al.
                    </li>
			   </ol>
			</section>
			
			<section id="r-ala">
				<h3>Alpha-Lipoic Acid (ALA)</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
					<li>Dose:  250-500 mg ED ‚òÄÔ∏è</li>
					<li>ü©∏üß†BBB: ‚úÖ ALCAR can easily cross the blood-brain barrier, which allows it to target brain cells more effectively than free L-carnitine.<cite class="reflink"><a href="#j-liu">J. Liu</a></cite></li>
					<li>Safety: 7/10 (75% œÉ)</li>
					<li>Efficacy: 6-7/10 (70% œÉ)</li>
				</ul>
	
				<p>
					Alpha-Lipoic Acid (ALA) improves mitochondrial function and reduces oxidative damage. <cite class="reflink"><a href="#j-liu">J. Liu</a></cite>
				</p>
				
				<h4>Supplement Forms: s- and r-Enantiomers, and Binding</h4>
	
				<p>
					Most research on ALA uses both s- and r-isoforms. The naturally occurring r-form has higher absorption and bioavailability than the synthetically produced s-form. <cite class="reflink"><a href="#b-salehi">B. Salehi</a></cite>
				</p>
				
				<h5>Na-r-ALA &mdash; Increased Absorption</h5>
				<p>
					Despite its advantages, free-form r-ALA is still prone to polymerization. Na-r-ALA (sodium-bound r-ALA) is comparatively more stable, less prone to polymerization, and has better absorption compared to free-form r-ALA. Lysine R-lipoate may offer greater absorption compared to r-ALA. <cite class="reflink"><a href="#d-a-carlson">D.A. Carlson</a></cite>
				</p>
	
				<h4>How R-ALA Works</h4>
				
				<p>
					R-ALA activates <abbr title="AMP-activated protein kinase">AMPK</abbr> which stimulates mitophagy. This leads to mitochondrial biogenesis and improved mitochondrial function. It increases glucose uptake and decreases glucose production in the liver, resulting in enhanced insulin sensitivity and reduced oxidative stress. <cite class="reflink"><a href="#y-wang">Y. Wang</a>, <a href="#w-j-lee">W. J. Lee</a></cite>
				</p>
				
				<h4>R-ALA in Parkinson's Disease</h4>
				<p>
					 Insulin resistance (IR) is commonly associated with an increased risk of developing Parkinson‚Äôs disease. IR leads to elevated brain glucose, which damages brain cells and accelerates neurodegeneration. <cite class="reflink"><a 
			 href="#e-hogg">E. Hogg</a></cite>
				</p>
				
				<h5>Iron in Parkinson's Disease</h5>
				<p>
					Alpha-synuclein pathology disrupts iron homeostasis in PD. High iron levels harm dopaminergic neurons, inducing cell death and leading to more severe motor deficits with mutant Œ±-synuclein. <cite class="reflink"><a 
			 href="#f-jia">f-jia</a>, <a 
			 href="#p-lingor">p-lingor</a></cite>
				</p>
				
				<p>
					ALA's improvement to mitochondrial function and antioxidant status make ideal for PD. <cite class="reflink"><a href="#j-liu">J. Liu</a></cite>
				</p>
				<p>
					R-ALA decreases intracellular <abbr title="Reactive Oxygen Species">ROS</abbr> and iron levels. <cite class="reflink"><a 
			 href="#s-tai">S. Tai</a></cite>
				</p>
				
				<p>
					Overexpression of Œ±-synuclein inhibits <abbr title="Adenosine 5‚Ä≤ Monophosphate-Activated Protein Kinase">AMPK</abbr> activity, contributing to the neurodegenerative process in PD. ALA increases AMPK, which improves mitochondrial function &mdash; a problem in PD. A rodent model experiment showed that treatment with acetyl-L-carnitine or Œ±-lipoic acid improved motor performance, reduced oxidation, and improved ATP production. <cite class="reflink"><a href="#w-bobela">W. Bobela</a>, <a 
			 href="#s-zaitone">S. Zaitone</a>, <a href="#h-zhang">H. Zhang</a></cite>
				</p>
				
				<h4>Synergy: Na-r-ALA, Creatine, ALCAR, and Carbohydrates</h4>
				
				<p>
					R-ALA, an antioxidant, helps protect the mitochondria from damage, allowing them to function more efficiently. <cite class="reflink"><a 
			 href="#h-zhang">H. Zhang</a></cite>
				</p>
				<p>
					Combining ALCAR, r-ALA, and creatine amplify each other's effects, making this combination a potent pre-workout mitochondrial activator. <cite class="reflink"><a href="#d-g-burke">D.G. Burke</a></cite>
				</p>
				<h4>Side Effects</h4>
				<p>
					Gastrointestinal upset can occur. Some individuals experience this when taking Na-r-ALA on a full stomach, but not when taking r-ALA in the morning with water and fruit.
				</p>
				
				<h4>Products</h4>
				<ul class="product-list">
					<li>
						<figure>
							<img src="img/mitochondrial-optimizer.jpeg" alt="mitochondrial optimizer">          
							<figcaption>
								<p>
									<a href="https://www.amazon.com/gp/product/B006L8DWSC/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B006L8DWSC&amp;linkId=c6c8f2664db42d477f10657223837e34"
									>Life Extension Mitochondrial Energy Optimizer with PQQ</a>
								</p>
							<p>
								Note: This product contains Taurine, which is
								<a href="https://journeywithparkinsons.com/2018/04/05/neuroprotection-with-taurine-in-a-parkinsons-model-system/">neuroprotective </a> and
								<a href="https://pubmed.ncbi.nlm.nih.gov/26004911/">found to be suppressed in PD patients on L-Dopa</a>.
							</p>
							</figcaption>
						</figure>
					</li>
					
					<li>
						<figure>
							<img src="img/r-ala.jpeg" alt="r-Alpha Lipoic Acid" height="280">
							<figcaption>
							<p>
								<a
	href="https://www.amazon.com/gp/product/B0027YKO1C/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B0027YKO1C&amp;linkId=ebcbfd85708db0064877b27b10629629"
								>Life Extension Super R-Lipoic Acid, 240mg
								</a>
							</p>
							</figcaption>
						</figure>
					</li>
				</ul>
				<h4>References</h4>
				<ol class="reference-list">
					<li id="j-liu">
						<a href="https://pubmed.ncbi.nlm.nih.gov/17605107/"
						title="The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview"
						target="_blank"
						>The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview</a>, Jiankang Liu.
						<p>
							This review study found ALA improves upon the age-associated decline of memory, mitochondrial structure and function, age-associated increase of oxidative damage, and antioxidation. 
						</p>
						<p>
							The also found that <q>co-administration of LA with other mitochondrial nutrients, such as acetyl-L-carnitine and coenzyme Q10, appears more effective in improving cognitive dysfunction and reducing oxidative mitochondrial dysfunction &hellip;</q>
						</p>
					</li>
					
					<li id="b-salehi">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723188/"
						title="Insights on the Use of Œ±-Lipoic Acid for Therapeutic Purposes"
						target="_blank"
						>Insights on the Use of Œ±-Lipoic Acid for Therapeutic Purposes</a>, Bahare Salehi, et al.
						<p>
							The R enantiomer of ALA shows better pharmacokinetic parameters, including increased bioavailability as compared to its S enantiometer.
						</p>
					</li>
						
					<li id="d-a-carlson">
						<a href="https://pubmed.ncbi.nlm.nih.gov/18069903/"
						title="The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects"
						target="_blank"
						>The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects</a>, David A Carlson, et al.
						<p>
							Na-r-ALA is less prone to polymerization, completely soluble in water, and displays significantly higher <dfn title="maximum serum concentration">Cmax</dfn> and <abbr title="Area Under the Curve">AUC</abbr> values and decreased time to maximum concentration (Tmax) and T1/2 values than RLA or rac-LA.
						</p>
					</li>
					
					<li id="y-wang">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882509/"
						title="Alpha-lipoic acid increases energy expenditure by enhancing AMPK-PGC-1Œ± signalling in the skeletal muscle of aged mice"
						target="_blank"
						>Alpha-lipoic acid increases energy expenditure by enhancing AMPK-PGC-1Œ± signalling in the skeletal muscle of aged mice</a>, Yi Wang, et al.
						<p>
						
						</p>
					</li>
					<li id="w-j-lee">
						<a href="https://pubmed.ncbi.nlm.nih.gov/15913551/"
						title="Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle"
						target="_blank"
						>Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle</a>, Woo Je Lee, et al.
						<p>
							This study suggests that ALA-induced improvement of insulin sensitivity is mediated by activation of AMPK and reduced triglyceride accumulation in skeletal muscle.
						</p>
					</li>                   
					
					<li id="e-hogg">
						<a href="https://pubmed.ncbi.nlm.nih.gov/29614702/"
						target="_blank"
						title="High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease"
						>High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson's Disease</a>, Elliot Hogg, et al.
						
						<p>
							The study revealed nearly 60% of the non-diabetic study participants may have undiagnosed insulin resistance &mdash; despite having normal blood sugar levels.
						</p>
					</li>
	
					<li id="f-jia">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897504/"
						target="_blank">High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein</a>, Fengju Jia, et al.
							
						<p>
							These results suggested high dietary iron supplement could induce nigral dopaminergic neuron lesions in A53T mice, which might be due to the vulnerability of SN to accumulate iron.
						</p>
					</li>
					<li id="p-lingor">
						<a title="Alpha-synuclein and iron: two keys unlocking Parkinson's disease"
						target="_blank"
						href="https://pubmed.ncbi.nlm.nih.gov/28168622/">
							Alpha-synuclein and iron: two keys unlocking Parkinson's disease</a>, Paul Lingor, et al.
							
						<p>
							This short review focuses on two disease mechanisms: alpha-synuclein pathology and dysfunction of iron homeostasis, as well as their intricate interaction.
						</p>
					</li>
	
					<li id="s-tai">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330090/"
						title="Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation by Regulating Iron Metabolism in a Parkinson‚Äôs Disease Model Induced by 6-OHDA"
						target="_blank">Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation in PD Model</a>, Shengyan Tai, et al.
						
						<p>
							This PD-induced rodent model showed that ALA could provide significant protection from 6-OHDA-induced cell damage in vitro by decreasing the levels of intracellular reactive oxygen species and iron. 
						</p>
					</li>
					
					<li id="w-bobela">
						<a href="https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0220-x"
						title="Modulating the catalytic activity of AMPK has neuroprotective effects against Œ±-synuclein toxicity"
						target="_blank"
						>AMPK activation mitigates Œ±-synuclein toxicity</a>, Wojciech Bobela, et al.
						<p>
							Researchers modulated AMPK activity to overexpress AMPK. Overexpression of AMPK mitigated Œ±-synuclein toxicity in nigral dopamine neurons.
						</p>
					</li>
					<li id="s-zaitone">
						<a href="https://pubmed.ncbi.nlm.nih.gov/21958946/"
						title="Acetyl-L-carnitine and Œ±-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy"
						target="_blank">Acetyl-L-carnitine and Œ±-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy</a>, Sawsan A Zaitone, et al.
						<p>
							Treatment with acetyl-L-carnitine or Œ±-lipoic acid improved the motor performance and reduced the level of lipid peroxides in rat brains as compared to rotenone group. Further, ATP production was enhanced along with acetyl-L-carnitine treatments (p‚â§0.05). 
						</p>
					</li>
					<li id="h-zhang">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837594/"
						title="Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease"
						target="_blank"
						>Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease</a>, Hongyu Zhang, et al.
						<!-- p>
							This in vitro study revealed that pretreatment with combined ALA and ALCAR increased mitochondrial biogenesis and decreased production of <abbr title="reactive oxygen species">ROS</abbr> through the up-regulation of <abbr title="Peroxisome Proliferator-activated Receptor-gamma Coactivator 1 alpha">PGC-1a</abbr> as a possible underlying mechanism.
						</p>
						<p>
							<abbr title="the peroxisome proliferator-activated receptor-gamma coactivator 1 alpha">PGC-1a</abbr> is a transcriptional coactivator that regulates various cellular energy metabolism, mitochondrial biogenesis, and cellular stress responses. 
						</p-->
					</li>
					
					<li id="d-g-burke">
						<a href="https://pubmed.ncbi.nlm.nih.gov/14669930/"
						title="Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration"
						target="_blank"
						>Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration</a>, Darren G Burke, et al.
						<p>
							This small human trial found that co-ingestion of alpha-lipoic acid with creatine and a small amount of sucrose can enhance muscle total creatine content as compared to the ingestion of creatine and sucrose or creatine alone.
						</p>
					</li>
				</ol>
			</section>
			
			<section id="gaba-5-htp-melatonin">
				<h3>GABA, 5-HTP, and Melatonin</h3>
				<p>
					GABA, 5-HTP, and melatonin can help PD patients through multiple neurological pathways. They're grouped because they all promote sleep and should all be taken at night.
				</p>
				<h4>Dopaminergic, Serotonergic, and GABAergic Systems</h4>
				<p>
					PD affects the dopaminergic, serotonergic, and GABAergic systems, which are interdependent. Doctors typically focus on the dopaminergic system, leading to imbalances in other systems, nutrient deficiencies, and progressive neurodegeneration (PN).
				</p>
				
				<p>
					Addressing only the dopaminergic system without considering the broader neurochemical landscape results in inadequate management of PD symptoms, exacerbates non-motor symptoms, and leads to treatment-related complications.
				</p>
	
				<h4>Comprehensive PD Management</h4>
				<p>
					A comprehensive approach to PD must consider not only the direct effects of medications but also their broader implications for nutritional status and metabolic function for improved outcomes and quality of life.
				</p>
				
				<h4>Medical Team Awareness</h4>
				<p>
					All medical team members must understand the broader implications of PD treatments to prevent nutrient depletion and exacerbation of neurodegeneration.
				</p>
				<section id="gaba">
					<h3>GABA</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Sleep, Dopaminergic side-effects
						<li>Dose: 1000mg üí§</li>
						<li>ü©∏üß†BBB: ‚ùå
						<li>Safety: 7/10 (75% œÉ)
						<li>Efficacy: 6/10 (70% œÉ)
					</ul>
					<p>
						GABA is an inhibitory neurotransmitter that regulates dopaminergic neuron activity in the brain. 
					</p>
					
					<h4>GABA and Sleep</h4>
					<p>
						GABA supplementation improves sleep by interacting with neurotransmitter systems in both the enteric nervous system (ENS) of the gastrointestinal tract and peripheral nervous system (PNS) receptors in the brainstem. This interaction influences the vagus nerve, leading to relaxation and better sleep quality.
					</p>
	
					<h4>GABA and Dopaminergic Side Effects</h4>
					<p>
						In Parkinson‚Äôs disease, the loss of GABAergic neurons in the substantia nigra contributes to motor symptoms.
					</p>
	
					<p>
						Dyskinesia is a common side effect of long-term treatment with levodopa in Parkinson‚Äôs disease. GABA supplementation at 1000mg daily has the potential to help regulate dopamine release and likely ameliorate dyskinesia. 
					</p>
					
					<p>
						Non-pharmacological approaches, such as physical therapy and deep brain stimulation (DBS) targeting GABAergic circuits, may also help manage motor complications.
					</p>
					
					<ul>
					
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366437/"
								title="GABA and l-theanine mixture decreases sleep latency and improves NREM sleep"
								target="_blank"
							>GABA and l-theanine mixture decreases sleep latency and improves NREM sleep in rats</a>
							
							<p>
								Researchers demonstrated that GABA and l-theanine together enhance sleep activity more effectively than either alone, likely through changes in GABA and glutamate receptor expression.
							</p>
						</li>
						
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031986/"
								title="Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial"
								target="_blank"
							>Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial</a>
							
							<p>
								This small double-blind RCT shows that treatment with 300mg unpolished-rice-germ-derived GABA improved both subjective sleep quality and objective sleep efficiency in patients with insomnia, with no severe adverse events.
							</p>
						</li>
						<li>
							<a href=""
							title="The Role of the GABAergic System in Diseases of the Central Nervous System"
							target="_blank">GABAergic System in CNS Diseases</a>
						<p>
							This review study discusses how the decline in dopamine production impairs neurotransmission in the substantia nigra and reduces GABAergic function, leading to lower GABA+/creatine levels in the occipital cortex of individuals with Parkinson's disease.
						</p>
						</li>
						<li>
							<a href="https://content.iospress.com/articles/journal-of-alzheimers-disease/jad120535"
							title="GABA Attenuates Amyloid Toxicity by Downregulating its Endocytosis and Improves Cognitive Impairment"
							target="_blank"
							>GABA Attenuates Amyloid Toxicity by Downregulating its Endocytosis and Improves Cognitive Impairment</a>
							<p>
								GABA reduces amyloid toxicity by downregulating amyloid-Œ≤ (AŒ≤) endocytosis, improving cognitive impairment. High levels of GABA decrease AŒ≤-induced cytotoxicity in wild-type mice through the receptor for advanced glycation end-products.
							</p>
						</li>
						
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/12948617/"
							title="Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy
	"
							target="_blank">GABA(A) receptors correlated to vagus nerve stimulation</a>
							<p>
								In this comparative study, researchers concluded that stimulating the vagus nerve increased GABA(A) receptor density. GABAergic activation affects the vagus nerve, contributing to the regulation of sleep and relaxation."
							</p>
						</li>
						
					</ul>
				</section>
				<section id="5-htp">
					<h4>5-HTP (5-Hydroxytryptophan)</h4>
	
					<p>
						5-HTP is converted into serotonin in the brain, promoting relaxation and sleep.
					</p>
					<p>
						Changes in serotonin signaling happen in the early stages of Parkinson's. It is imperative to work on this system as early as possible. Do not wait for GI symptoms to develop.
					</p>
					<p>
						Dopamine Replacement Therapy (DRT) commonly used to treat Parkinson‚Äôs can cause involuntary movements; <dfn>"L-DOPA-induced dyskinesia (LID)"</dfn>. 5-HTP supplementation helps balance and restore serotonin to reduce the severity of these symptoms by modulating serotonin levels and dopamine release.
					</p>
					
					<p>
						Parkinson's disease affects not only the dopaminergic system but also other neurotransmitter systems, including the serotonergic system, by the same mechanisms (mitochondrial dysfunction, aggregation, etc). This leads to progressive degeneration of serotonergic terminals associated with the ANS (Autonomic Nervous System), the development of non-motor symptoms, and complications like GI dysfunction, a common problem in PD, and may be related to visual hallucinations in some patients.
					</p>
					<p>
						DRT depletes vitamin B6 levels, essential for nerve health and neurotransmitter synthesis. This problem impacts nerves directly and <em>also</em> leads to multiple neurotransmitter systems failure, further damaging nerves (and with the unpleasant symptom of neuropathy) (B-12 causes neuropathy, too).
					</p>
					<p>
						Metabolic pathways involving neurotransmitters are complex. The complexities of these delicate interactions, as shown in the figure "Competitive Neurotransmitter Inhibitors", are well-handled in healthy individuals, but disrupted in PD and disrupted further by <abbr title="Dopamine Replacement Therapy">DRT</abbr>. <cite class="reflink"><a href="#a-munoz">a-munoz</a></cite> <cite class="reflink"><a href="#m-hinz">m-hinz</a></cite>
					</p>   
					
					<p>
						To elaborate, the aforementioned pathways include Dopamine, norepinephrine, epinephrine, glutathione, S-adenosylmethionine (SAMe), methionine, cysteine, tryptophan, serotonin, and vitamin B6 affect each other and contribute to neurological function, oxidative stress regulation, mood regulation, and overall health. 
					</p>
					<p>
						Minimizing <abbr title="Dopamine Replacement Therapy">DRT</abbr> and supporting other neurotransmitter systems avoids the impossible challenge of micromanaging every neurotransmitter pathway.
					</p>
					<p>
						Diet, supplementation, and regular monitoring must be balanced to slow disease progression.
					</p>
					
					<figure>
						<img src="img/5-htp-competitive-inhibitors.jpeg" alt="Diagram of Competitive Neurotransmitter Inhibitors"
						class="block-image">
						<figcaption>
							<p>
								<strong>Competitive Neurotransmitter Inhibitors:</strong> 5-HTP is converted into serotonin in the brain. It inhibits the release of glutamate, mitigates oxidation, and modulates dopamine release.
							</p>
						</figcaption>
					</figure>
	
					<p>
						The effects of PD on the serotonergic system are vastly understated. Several studies have shown serotonergic dysfunction in Parkinson's disease is associated with the development of motor and non-motor symptoms and complications. <cite class="reflink"><a href="#m-politis"></a></cite>
					</p>
	
					<p>
						5-HTP has been shown to have neuroprotective effects in various animal models of neurodegenerative diseases, including PD. It reduces oxidative stress, inflammation, and mitochondrial dysfunction, all of which contribute to PN (Progressive Neurodegeneration).
					</p>
					<h5>Serotonin and 5-HTP References</h5>
					<ol class="reference-list">
						<li id="m-politis">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201695/"
							title="Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability"
							target="_blank"
							>Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability</a>, Marios Politis and Clare Loane.
							<p>
								This study confirms the lack of any autoregulatory feedback control in serotonergic neurons to regulate L-DOPA-derived dopamine release contributes to L-DOPA-induced dyskinesia (LID).
							</p>
						</li>
	
						<li id="a-munoz">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289026/"
							title="Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson‚Äôs Disease and Adverse Effects of L-DOPA"
							target="_blank"
							>Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson‚Äôs Disease and Adverse Effects of L-DOPA</a>, Ana Mu√±oz, et al.
							<p>
							Parkinson‚Äôs disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. However, other non-dopaminergic neuronal systems such as the serotonergic system are also involved. Serotonergic dysfunction is associated with non-motor symptoms and complications, including anxiety, depression, dementia, and sleep disturbances. 
							</p>
							<p>
								The lack of any autoregulatory feedback control in serotonergic neurons to regulate L-DOPA-derived dopamine release contributes to the appearance of L-DOPA-induced dyskinesia (LID). 
							</p>
						</li>
	
						<li id="m-hinz">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827589/"
							title="Parkinson‚Äôs disease managing reversible neurodegeneration (retracted)"
							target="_blank"
							>Parkinson‚Äôs disease managing reversible neurodegeneration (retracted)</a>, Marty Hinz, et al.
							<p>
								This study explains the interactions between serotonin and dopamine along with their precursors in synthesis, transport, and metabolism. 
							</p>
							<p>
								The study was retracted for conflict of interest, not factual inaccuracies.
							</p>
						</li>
					</ol>
				</section>
			
				<section id="melatonin">
					<h4>Melatonin</h4>
					<ul class="treatment-rating">
						<li>Mechanisms: Neuroprotective, Antioxidant, Anti-inflammatory, Mitochondrial, Anti-ischemic</li>
						<li>Dose: 10mg per day üí§ </li>
						<li>ü©∏üß†BBB: ‚úÖ</li>
						<li>Safety: 9/10 (90% œÉ)</li>
						<li>Efficacy: 8/10 (85% œÉ)</li>
					</ul>
					<p>
						Melatonin is a hormone produced by the pineal gland, a small endocrine gland located in the midbrain between the two hemispheres.
					</p>
				
					<h5>Neuroprotective</h5>
					<p>
						Melatonin protects neurons against oxidative stress, a problem exacerbated by Parkinson's Disease (PD) that leads to progressive neurodegeneration (PN). It interacts with nuclear receptors and signaling pathways to regulate gene transcription. This causes an increase in the production of superoxide dismutase (SOD), glutathione peroxidase, and glutathione reductase.
					</p>
					
					<p>
						 Neuroinflammation leads to increased ROS production. Increased ROS production contributes to neuronal damage which perpetuates further neuroinflammation. Melatonin reduces inflammation, thereby reducing oxidative stress.
					</p>
					
					<p>
						Melatonin directly scavenges free radicals, reducing the oxidative burden on cells and allowing antioxidant enzymes to function more efficiently.
					</p>
					<p>
						Melatonin receptors MT1 and MT2 in the substantia nigra are reduced in PD patients. Supplementing melatonin helps amend this deficit.
					</p>
	
					<p>
						Melatonin's neuroprotective effects, bolstered by its anti-inflammatory effects, may contribute to the preservation of MT1 and MT2 receptors and contribute to neuroprotection.
					</p>
	
					<h5>Vasodilation Effects</h5>
					<p>                
						Brain ischemia, a common problem in PD, occurs when blood flow and oxygen supply are restricted to various parts of the brain. Worse, ischemia to the substantia nigra exacerbates the problem of decreased dopamine output. This impairs mitochondrial function, leading to energy depletion and cell death.
					</p>
				
					<p>
						Melatonin has vasodilatory effects, relaxing blood vessels, and improving blood flow. This may help improve perfusion to ischemic brain regions, potentially reducing tissue damage and promoting recovery. 
					</p>
					
					<figure>
						<img src="img/ischemia-pathophysiology.png" alt="Diagram of ischemia pathophysiology in PD" class="block-image">
						<figcaption>
							<p>
								Ischemia pathophysiology at four stages: energy failure, excitotoxicity, oxidative stress, and inflammation. <img src="img/ischemia-mechanism-icon.jpeg" alt="icon for diagram"> Represents the site of melatonin action
							</p>
						</figcaption>
					</figure>
	
				
					<h5>Mitoprotective</h5>
					<p>
						Melatonin protects mitochondrial function and integrity, mitigating cellular damage caused by ischemia.
					</p>
					<h5>Supplementation</h5>
					<p>
						Melatonin is safe to take. Excessive doses over 10-15mg may cause next-day tiredness and headache.
	
	
					<p>
						Time-released formulations help maintain melatonin levels for a longer period. The reduced peak concentration helps maintain sleep throughout the night.
					</p>
					
					<h5>
						Product
					</h5>
					<figure>
					<img src="img/sleep3.png" alt="Sleep3 &mdash; Nature's Bounty Sleep3 Melatonin 10mg, Maximum Strength 100% Drug Free Sleep Aid, Dietary Supplement, L-Theanine & Nighttime Herbal Blend Time Release Technology, 60 Tri-Layered Tablets">
					<figcaption>
						<p>
							<a
								href="https://www.amazon.com/gp/product/B07PXT5LYR/ref=ppx_yo_dt_b_search_asin_title?ie=UTF8&psc=1;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07DJJXPDD&amp;linkId=fcbfe06c3bf2c5b2709c3b7afef8459"
								>Sleep3 &mdash; Nature's Bounty &mdash; Time-released Melatonin &mdash; 10mg</a>
						</p>
					</figcaption>
					</figure>
					
					<h5>Melatonin References</h5>
					<ol class="reference-list">
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/10668453/"
					>Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and 
					parkinsonism</a>
					
							<p>
								Melatonin easily crosses the BBB and stimulates a variety of antioxidative enzymes including superoxide dismutase, glutathione peroxidase and glutathione reductase. 
						</li>
	
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/16179266/"
							title="Role of Melatonin in Neurodegenerative Diseases"
							target="_blank">Role of Melatonin in Neurodegenerative Diseases</a>
							<p>
							This review concluded that melatonin preserves mitochondrial homeostasis, reduces free radical generation, e.g., by enhancing mitochondrial glutathione levels, and safeguards proton potential and ATP synthesis by stimulating complex I and IV activities.
							</p>
						<li>
							<a href="https://www.parkinsonalliance.org/grantsgiven/2000-23/"
							target="_blank"
							title="Superoxide Dismutase Activity in Early and Advanced Parkinson's Disease">Superoxide Dismutase Activity in Early and Advanced Parkinson's Disease</a>
							<p>
								 A defect in SOD activity develops over time in PD.
							</p>
						</li>
						<li>
							<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2020.00053/full"
							title="Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson‚Äôs Disease Severity"
							target="_blank"
							>[Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson‚Äôs Disease Severity</a>
							<p>
								&ldquo;Superoxide dismutase (SOD) is one of the most important antioxidant enzymes both inside and outside cell membranes, and it catalyzes the dismutation of superoxide radicals (O2‚àí) to hydrogen peroxide (H2O2), which is converted to water and oxygen by catalase and glutathione peroxidase.&rdquo;
							</p>
						</li>
					</ol>
				</section>
			</section>
			<section id="quinones">
				<h3>
					Mitochondrial Quinones (PQQ, CoQ10, K2) 
				</h3>
				
				<p>
					The three mitochondrial quinones are PQQ, CoQ10, and Menaquinone (MK-4 and MK7, also known as "vitamin k2"). These fat-soluble substances are <dfn>electron transporters</dfn> that help the mitochondria generate ATP, used for cellular energy. Their supplementation has shown health benefits, especially for athletic performance and when mitochondrial function is impaired, however they each serve more specific roles.
				</p>
				
				<p>
					These mitochondrial quinones promote mitochondrial biogenesis, improving ATP production, and reduce oxidative stress. Their combined supplementation has shown synergistic effects, improving mitochondrial efficiency, reducing fatigue, and enhancing overall cellular health.
				</p>
				
				<section id="pqq">
					<h3>Pyrroloquinoline Quinone (PQQ)</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Antifibrillogenic, Anti-aggregant, Anti-ischemic, Mitochondrial, Neuroprotective, Antioxidant, Anti-inflammatory, Neurorestorative</li>
						<li>Dose: 40-200mg per day üçΩÔ∏è </li>
						<li>ü©∏üß†BBB: ‚ùå (?)</li>
						<li>Safety: 9/10 (90% œÉ)</li>
						<li>Efficacy: 8/10 (85% œÉ)</li>
					</ul>
	
					<p>
						Pyrroloquinoline Quinone (PQQ) is a naturally occurring coenzyme manufactured by bacteria, found in plants in tiny amounts, and utilized by mammalian cells as an important nutritional growth factor. PQQ is not produced endogenously in humans.
					</p>
	
					<p>
						PQQ activates the signaling pathway involving the transcription factor PGC-1Œ± (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), which promotes the formation of new mitochondria. This increases the number and efficiency of mitochondria in cells, improving cellular energy production. <cite class="reflink"><a href="#w-chowanadisai">W. Chowanadisai</a>, <a href="#p-hwang">P. Hwang</a></cite>
					</p>
	
					<h4>Brain Health</h4>
					<p>
						Neurologically, PQQ increases blood flow to the cerebral cortex, protects against cell damage, promotes nerve growth factor (NGF) production, and prevents neurodegeneration caused by oxidative stress. These combined effects improve upon cognitive deficits from oxidative damage and senescence, and enhance memory, attention, cognition, learning, and mood. <cite class="reflink"><a href="#k-ohwada">K. Ohwada</a>, <a href="#k-shiojima">K. Shiojima</a>, <a href="#m-tamakoshi">M. Tamakoshi</a>, <a href="#k-ikemoto">K. Ikemoto</a></cite>
					</p>
					
					<h4>Cardiovascular Health</h4>
					<p>
						 By reducing oxidative stress and inflammation, PQQ supports endothelial function and protects against damage to blood vessels. PQQ has been shown to improve LDL levels, probably by the enzyme <abbr title="AMP-activated protein kinase">AMPk</abbr>, which regulates blood lipid levels, and to significantly decrease the levels of plasma C-reactive protein and <abbr title="interleukin 6">IL-6</abbr>. <cite class="reflink"><a href="#c-harris">C. Harris</a>, <a href="#m-nakano">M. Nakano</a>, <a href="#y-huang">Y. Huang</a></cite> 
					</p>
				
					<p>
						PQQ helps prevent the formation of &alpha;-synuclein fibrils in vitro. However, these antifibrillogenic effects in humans, from supplementation, are unproven and questionable, as PQQ's ability to cross the BBB has not been established. 
						<cite class="reflink"><a href="#m-kobayashi">M. Kobayashi</a>, <a href="#j-kim">J. Kim</a></cite> 
					</p>
					
					<h4>Blood-Brain Barrier (BBB)</h4>
					<p>
						PQQ's cognitive and neurological effects could be achieved either through indirect mechanisms, undetermined transport proteins might facilitate the passage of PQQ across the BBB, metabolites that can cross the BBB and exert beneficial effects on brain function, or a combination of things. 
					</p>
					<p> 
						PQQ's effects do involve enhanced systemic energy metabolism, reduced inflammation, increased antioxidant capacity, stimulation of neurotrophic factors, improved vascular health, and gut-brain axis modulation. These systemic effects create a more favorable environment for brain health, indirectly supporting cognitive function, whether or not PQQ itself crosses the BBB.
					</p>
					
					<h4>Supplementation</h4>
					<p>
						Although many studies show benefit at 20 or 30 mg, 40 &ndash; 200 mg per day of PQQ is safe. It is fat-soluble and best taken with other fat-soluble supplements and food.
					</p>
					<p>
						In 2017, the European Food Safety Authority (EFSA) Panel on Dietetic Products determined a No Observed Adverse Effect Level (NOAEL) of 100mg/kg per day for 90 days. For a 50kg woman, this translates to a dose of 5g per day. Other studies have investigated PQQ's benefits and safety using similar dosages.
					</p>
					<p>
						Given the vast multitude of benefits that occur on the cellular level and the incredibly high safety threshold, a recommended dose of PQQ is 40 &ndash; 200mg per day. There are no known contraindications.  Dose-dependent effects have been observed in rodents with <abbr title="Traumatic Brain Injury">TBI</abbr>. It is recommended to start with a more moderate dose of 40 mg per day and gradually increase. <cite class="reflink"><a href="#l-zhang">L. Zhang</a></cite>
					</p>
					
					<h4>Side Effects</h4>
					<p>
						Mild headaches and insomnia may be experienced when PQQ is taken at night. Higher doses (e.g., 100-200 mg per day) are well-tolerated and may provide more pronounced effects.
					</p>
					
					<h4>PQQ References</h4>
	
					<ol class="reference-list">                    
						<li id="w-chowanadisai">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804159/" 
								title="Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expressions"
								target="_blank">Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1Œ± Expression</a>, Winyoo Chowanadisai, et al.
							<p>
								This in vitro study shows that PQQ enhances mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression.
							</p>
						</li>
						<li id="p-hwang">
							<a href="https://pubmed.ncbi.nlm.nih.gov/31860387/" 
								title="Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men"
								target="_blank">Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men</a>, Paul S Hwang, et al.
							<p>
								This small six week study found PQQ supplementation increases mitochondrial biogenesis by way of significant elevations in PGC-1Œ± protein content in previously untrained men, though it did not improve their performance.
							</p>
						</li>
						<li id="k-ohwada">
							<a href="https://pubmed.ncbi.nlm.nih.gov/18231627/" 
								title="PQQ prevents cognitive deficit in rats"
								target="_blank">PQQ prevents cognitive deficit caused by oxidative stress in rats</a>, Kei Ohwada, et al.
							<p>
								This rodent study indicates that PQQ supplementation markedly improved the memory deficit and can prevent cognitive deficits in rats induced by oxidative stress.
							</p>
						</li>
						<li id="y-shiojima">
							<a href="https://pubmed.ncbi.nlm.nih.gov/34415830/"
							title="Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study"
							target="_blank"
							>Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study</a>, Yoshiaki Shiojima, et al.
							<p>
							
							</p>
						</li>
						<li id="m-tamakoshi">
							<a href="https://pubmed.ncbi.nlm.nih.gov/36807425/"
							title="Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults"
							target="_blank"
							>Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults</a>, Masanori Tamakoshi, et al.
							<p>
								 In the logistic regression analysis that included the results of all cognitive tests, the changes due to PQQ intake of 20 mg ED for 12 weeks were observed at 8 and 12 weeks in the young and old groups, respectively.
							</p>
						</li>
						<li id="k-ikemoto">
							<a href="https://pubmed.ncbi.nlm.nih.gov/38735721/"
							title="The effects of pyrroloquinoline quinone disodium salt on brain function and physiological processes"
							target="_blank"
							>The effects of pyrroloquinoline quinone disodium salt on brain function and physiological processes</a>, Kazuto Ikemoto, et al.
							<p>
								PQQ was found to suppress skin moisture loss and increase PGC-1Œ± expression. Co-administration of PQQ and coenzyme Q10 further enhanced these effects. 
							</p>
						</li>
						<li id="c-harris">
							<a href="https://pubmed.ncbi.nlm.nih.gov/24231099/"
							title="Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects"
							target="_blank"
							>Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects</a>, Calliandra B Harris, et al.
							<p>
							
							</p>
						</li>
						<li id="m-nakano">
							<a href="https://pubmed.ncbi.nlm.nih.gov/26226960/" 
								title="Effects of Pyrroloquinoline Quinone Disodium Salt Intake on the Serum Cholesterol Levels of Healthy Japanese Adults"
								target="_blank">PQQ intake effects on serum cholesterol levels</a>, Masahiko Nakano, et al.
							<p>
								This study showed the effects of PQQ disodium salt (BioPQQ‚Ñ¢) on serum TG and cholesterol levels in humans after 6 and 12 wk of treatment at an oral dosage of 20 mg/d. 
							</p>
							<p>
								PQQ suppressed the LDL-chol level, which is an important finding because a high level of this lipid is a risk factor for various lifestyle-related diseases.
							</p>
						</li>
						<li id="m-kobayashi">
							<a href="https://pubmed.ncbi.nlm.nih.gov/16962995/" 
								title="Pyrroloquinoline quinone (PQQ) prevents fibril formation of Œ±-synuclein"
								target="_blank">PQQ prevents fibril formation of alpha-synuclein</a>, Masaki Kobayashi, et al.
							<p>
								This study demonstrates that PQQ inhibits the fibril formation of alpha-synuclein, which is significant in neurodegenerative diseases.
							</p>
						</li>
						<li id="j-kim">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881056/" 
								title="The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein"
								target="_blank">PQQ inhibits amyloid formation and cytotoxicity</a>, Jihoon Kim, et al.
							<p>
								This study showed that PQQ dramatically inhibits the fibril formation of C-terminal truncated alpha-synuclein 110119, and 133 as well as the mixtures of full-length alpha-synuclein with these truncated variants. Moreover, PQQ decreases the cytotoxicity of truncated alpha-synuclein.
							</p>
						</li>
	
						<li id="y-huang">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509087/" 
								title="P\Biological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice"
								target="_blank">PQQ effects on liver damage in Bmi-1 knockout mice</a>, Yuanqing Huang, et al.
							<p>
								This study found that a moderate dose of PQQ significantly protected the liver from deleterious effects by inhibiting oxidative stress and participating in DNA damage repair.
							</p>
						</li>
	
						<li id="q-geng">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329928/"
							title="Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence"
							target="_blank"
							>Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence</a>, Qinghe Geng, et al.
							<p>
							
							</p>
						</li>
						<li id="l-zhang">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303106/"
							title="The Neuroprotective Effect of Pyrroloquinoline Quinone on Traumatic Brain Injury"
							target="_blank"
							>The Neuroprotective Effect of Pyrroloquinoline Quinone on Traumatic Brain Injury</a>, Lili Zhang, et al.
							<p>
								This rodents study showed a dose-dependent response of PQQ in rodents with induced TBI from 5‚Äâmg/kg to 10 mg/kg per day, injected intraperitoneally. We can extrapolate for <abbr title="Human Equavalent Dose">HED</abbr> by dividing by 12.3, to get the respective human equivalent doses of 0.4 mg / kg, 0.57 mg/ kg, and 0.81 mg/kg. For a 60kg human, the HED dose of 0.81 mg/kg is 48 mg PQQ ED.(See: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804402/#T1">A simple practice guide for dose conversion between animals and human</a> (A. Nair, S. Jacobs)).
							</p>
						</li>
					</ol>
				</section>
				<section id="k2">
					<h3>Vitamin K2</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Mitochondrial, Neuroprotective, Antioxidant, Anti-inflammatory</li>
						<li>Dose: 2mg per day (2000 mcgs) üçΩÔ∏è </li>
						<li>ü©∏üß†BBB: ‚úÖ </li>
						<li>Safety: 9/10 (90% œÉ)</li>
						<li>Efficacy: 6/10 (50% œÉ)</li>
					</ul>
					<p>
						Vitamin K2 supports mitochondrial function by activating sirtuin 1 (SIRT1), a longevity gene that regulates mitochondrial biogenesis and helps manage oxidative stress. However, K2's biggest role is its effects on bone metabolism and the bone-brain axis. <cite class="reflink"><a href="#d-simes">D. Simes</a></cite> 
					</p>
					
					
					<h4>Blood-Brain Barrier</h4>
					<p>
						Vitamin K2's ability to cross the blood-brain barrier enables it to exert its effects within the central nervous system, including reduced oxidative stress in neurons and reduced neuroinflammation. <cite class="reflink"><a href="#a-popescu">A. Popescu</a></cite>
					</p>
					
					<h4>Bone-Brain Axis</h4>
					<p>
						Osteocalcin is a protein produced by cells in bones called osteoblasts. 
					</p>
					<p>
						K2 carboxylates osteocalcin (OCN). Carboxylated OCN (cOCN) promotes deposition of minerals such as calcium and strontium in bones, resulting in improved bone mineral density and strength. 
					</p>
				
					<p>
						K2 also stimulates osteoblastogenesis, the production of new osteoblasts, and suppresses osteoclastogenesis, leading to an increase in osteocalcin production, which further contributes to overall bone health and osteocalcin levels. <cite class="reflink"><a href="#m-yamaguchi">M. Yamaguchi</a></cite>
					</p>
					
					<p>
						Osteocalcin promotes spatial learning and memory and prevent anxiety-like behavior. This complex interplay between the bones and the central nervous system, influencing each other‚Äôs function and behavior, is known as the <dfn>bone-brain axis</dfn>. <cite class="reflink"><a href="#a-obri">A. Obri</a></cite>
					</p>
					
					<h5>Brain Calcification</h5>
					<p>
						Calcium deposits in the basal ganglia can disrupt normal movement patterns, leading to symptoms such as dystonia, tremors, and unsteady gait. 
					</p>
					<p>
						Vitamin K2 activates Matrix Gla Protein (MGP) which inhibits the calcification of soft tissues, including blood vessels, kidneys, and the brain. Activated MGP ensures that calcium is directed away from these soft tissues and towards bones, where it is needed for bone mineralization, and the reduced vascular calcification improves cerebral blood flow.
					</p>
					
					<p>
						Both carboxylated and undercarboxylated osteocalcin (ucOCN) enter the bloodstream. ucOCN, which is not bound to the bone matrix, circulates and can act on various tissues, including the brain. Reduced calcification in the brain supports cognitive function and lowers the risk of neurodegenerative diseases, while preventing vascular calcification ensures adequate cerebral blood flow and overall brain health. <cite class="reflink"><a href="#k-maresz">K. Maresz</a></cite>
					</p>
					
					<h5>Supplementation</h5>
					<p>
						Vitamin K2 supplementation is generally safe, with no known serious side effects. It has been shown to be effective and well-tolerated at doses up to 45 mg per day in women with osteoporosis. <cite class="reflink"><a href="#t-giri">T. Giri</a></cite>
					</p>
	
					<ol class="reference-list">
						 <li id="d-simes">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747195/"
							title="Vitamin K as a Powerful Micronutrient in Aging and Age-Related Diseases: Pros and Cons from Clinical Studies"
							target="_blank"
							>Vitamin K as a Powerful Micronutrient in Aging and Age-Related Diseases: Pros and Cons from Clinical Studies</a>, Dina C. Simes, et al.
						</li>
						
						<li id="a-popescu">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308377/"
							title="Vitamin K2 Holds Promise for Alzheimer‚Äôs Prevention and Treatment"
							target="_blank"
							>Vitamin K2 Holds Promise for Alzheimer‚Äôs Prevention and Treatment</a>, Alexander Popescu and Monica German.
	 
						</li>
						
						<li id="a-obri">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958904/"
							title="Osteocalcin in the brain: from embryonic development to age-related decline in cognition"
							target="_blank"
							>Osteocalcin in the brain: from embryonic development to age-related decline in cognition</a>, Arnaud Obri, et al.
						</li>
						
						<li id="m-yamaguchi">
							<a href="https://pubmed.ncbi.nlm.nih.gov/21072493/"
							title="Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-Œ∫B activation"
							target="_blank"
							>Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-Œ∫B activation</a>, Masayoshi Yamaguchi, et al.
						</li>
						<li id="k-maresz">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483258/"
							title="Growing Evidence of a Proven Mechanism Shows Vitamin K2 Can Impact Health Conditions Beyond Bone and Cardiovascular"
							target="_blank"
							>Growing Evidence of a Proven Mechanism Shows Vitamin K2 Can Impact Health Conditions Beyond Bone and Cardiovascular</a>, Katarzyna Maresz.
						</li>
						
						<li id="t-giri">
							<a href="https://pubmed.ncbi.nlm.nih.gov/30816822/"
							title="Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis"
							target="_blank"
							>Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis</a>, Tusar K Giri, et al.
						</li>
					</ol>
				</section>
				<section id="ubiquinol">
					<h3>Ubiquinol</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Mitochondrial, Antioxidant
						<li>Dose: [Recommended dose]
						<li>ü©∏üß†BBB: ‚ùå?
						<li>Safety: 8/10 (85% œÉ)
						<li>Efficacy: 7/10 (80% œÉ)
					</ul>
					<p>
						Ubiquinol is the reduced form of CoQ10. Ubiquinol is better absorbed by the body than ubiquinone, the oxidized form of CoQ10.
					</p>
					
					<p>
						CoQ10 improves mitochondrial function with exercise and improves cognitive function in chronic fatigue syndrome (CFS). <cite class="reflink"><a href="#s-fukuda">Sanae Fukuda</a></cite>
					<p>
						In Parkinson&rsquo;s, ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and is safe and well-tolerated. <cite class="reflink"><a href="#a-yoritaka">A. Yoritaka</a></cite>
					</p>
					<p>
						Previous studies using ubiquinone showed a lack of effect in PD patients. However, unlike ubiquinone, ubiquinol, the reduced form of CoQ10, is effective.
					</p>
				
					<h3>Ubiquinol in Parkinson's Disease</h3>
						
					<p>
						Mitochondrial dysfunction is one of the main factors of disease progression. Impaired mitochondrial function leads to increased oxidative stress and reduced ATP production, exacerbating neuronal damage. This dysfunction compromises cellular energy metabolism and impairs the ability of neurons to maintain their normal functions. Defective mitochondria contribute to the accumulation of toxic protein aggregates, including alpha-synuclein, leading to Lewy bodies, leading to senescence, further exacerbating neurodegeneration. <cite class="reflink"><a href="#a-ebrahimi">A. Ebrahimi</a>, <a href="#c-andreani">C. Andreani</a></cite>
					</p>
					<p>
						Addressing mitochondrial dysfunction in Parkinson's disease requires a multifaceted approach. High-dose CoQ10 supplementation is one way to improve mitochondrial function. <cite class="reflink"><a href="#m-spindler">M. Spindler</a></cite>
					</p>
					<p>
						Multiple system atrophy (MSA) is progressive neurodegeneration characterized by autonomic failure in various forms of Parkinsonism. This problem is exacerbated by decreased ubiquinone levels. Studies show that CoQ10 supplementation can reduce apoptosis in neurons derived from MSA patients. <cite class="reflink"><a href="#f-nakamoto">F. Nakamoto</a></cite>
					</p> 
					<p>
						CoQ10 transports electrons in the (<abbr title="electron transport chain">ETC</abbr>) to cross the mitochondrial inner membrane, generating cellular energy. <cite class="reflink"><a href="#m-spindler">M. Spindler</a></cite>
					</p>
	
					<h5>Supplementation</h5>
					<p>
						Ubiquinol has been demonstrated to be superior to ubiquinone. Phytosome Q10 has been shown to provide even greater absorption, but research shows strong safety and efficacy of ubiquinol, making it a reliable option for CoQ10 supplementation. <cite class="reflink"><a href="#p-langsjoen">P. Langsjoen</a>, <a href="#d-mantle">D. Mantle</a>, <a href="#g-petrangolini">G. Petrangolini</a></cite>
					</p>
					<p>
						In a study published in The Lancet, a patient with advanced Multiple System Atrophy (MSA) showed restored brain oxygen consumption after taking 1200 mg of oral ubiquinol. This finding suggests a potential benefit of high-dose ubiquinol supplementation in MSA patients to support mitochondrial function. <cite class="reflink"><a href="#j-mitsui">J. Mitsui</a></cite>
					</p>
					<h5>Products</h5>
					<ul class="product-list">
						<li>
							<figure>
								<img src="img/coq10-pqq.png" alt="Life Extension Super Ubiquinol CoQ10 with PQQ">
								<figcaption>
									<p>
										<a href="https://www.amazon.com/Life-Extension-Ubiquinol-Softgels-Bottles/dp/B00MOX1IZC/ref=sr_1_5_pp?sr=8-5" target="_blank">Life Extension Super Ubiquinol CoQ10 with PQQ, 30 Softgels. Pack of 2 Bottles</a>
									</p>
								</figcaption>
							</figure>
						</li>
						<li>
							<figure>
								<img src="img/solary-phytosome-q10.png" alt="CoQ 10 ubiquisome">
								<figcaption>
									<p>
										<a href="https://www.amazon.com/SOLARAY-CoQ-10-Phytosome-Easy-Digest/dp/B0CD2Z7TFW/ref=sr_1_5?dib=eyJ2IjoiMSJ9.cmtVvwJRdfFnIup8jBAQPfvVyJOLRy8nh2-QFBIp8FRrhaaSERHS7aUruerpkYDNNQLuYcSkt54YPUcPYAm6BK6gTaouilEq7Oba4FdcjHvzQvkLw2K1YeX0pnTSFYvjhwRqOXHnSsl2r0RoMzCilQ.5DYKhoPdVCHt_af3m1ICyUIAviwqKzsCkLSGWbQcUFg&dib_tag=se&keywords=UBIQSOME&qid=1717966723&sr=8-5">SOLARAY CoQ-10 Phytosome</a>
									</p>
								</figcaption>
							</figure>
						</li>
					</ul>
	
					<h4>
						Ubiquinol References:
					</h4>
					<ol class="reference-list">
						<li id="s-fukuda">
							<a href="https://pubmed.ncbi.nlm.nih.gov/27125909/"
							title="Ubiquinol supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome"
							target="_blank">Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndromeS</a>, Sanae Fukuda, et al.
							<p>
								This RCT showed that supplementation with ubiquinol-10 (150 mg/day) for 12 weeks improved many CFS symptoms.
							</p>
						</li>
						<li id="j-mitsui">
							<a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00097-4/fulltext"
							title="High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial"
							target="_blank">
							High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial</a>, Jun Mitsui, et al.
							<p>
								This multicenter, randomized, double-blind, placebo-controlled, phase 2 trial showed that high-dose ubiquinol was well-tolerated and improved multiple system atrophy, compared with placebo.
							</p>
						</li>
						<li id="a-ebrahimi">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632062/"
							title="[Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases]"
							target="_blank"
							>Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases</a>, Alireza Ebrahimi, et al.
							<p>
								Discusses how CoQ10 might protect the nervous system from degeneration and deterioration, mainly due to its antioxidant and energy-regulating role in mitochondria. Specifically, how CoQ10 supplementation can lead to an increment in its levels in the mitochondria.
							</p>
						</li>
						<li id="m-spindler">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785862/"
							title="Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy"
							target="_blank"
							>Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy</a>, Meredith Spindler, et al.
							<p>
								Discusses how CoQ10 supplementation may be beneficial for MSA, as for other primary CoQ10 deficiencies
							</p>
						</li>
						<li id="f-nakamoto">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155102/"
							title="The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy"
							target="_blank">Coenzyme Q10 insufficiency in patients with multiple-system atrophy</a>, Fumiko Kusunoki Nakamoto, et al.
							<p>
								This study shows a causal relationship between neuronal apoptosis and coenzyme Q10 deficiency.
							</p>
						</li>
						<li id="c-andreani">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220380/"
							title="Combination of Coenzyme Q10 Intake and Moderate Physical Activity Counteracts Mitochondrial Dysfunctions in a SAMP8 Mouse Model"
							target="_blank">
							Combination of Coenzyme Q10 Intake and Moderate Physical Activity Counteracts Mitochondrial Dysfunctions in a SAMP8 Mouse Model</a>, C. Andreani, et al.
							<p>
								This rodent study shows that ubiquinol supplementation counteracts the deleterious effects of physical exercise-derived ROS improving mitochondrial functionality in an oxidative stress model, such as SAMP8 in the presarcopenia phase
							</p>
						</li>
						<li id="a-yoritaka">
							<a href="https://pubmed.ncbi.nlm.nih.gov/26054881/"
							title="Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease"
							target="_blank">
							Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease</a>, Asako Yoritaka, et al.
							<p>
							This  double-blind, placebo-controlled RCT pilot trial showed improvement in symptoms in PD patients.
							</p>
						</li>
	
						<li id="p-langsjoen">
							<a href="https://pubmed.ncbi.nlm.nih.gov/27128225/"
							title="Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone"
							target="_blank">Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone</a>, Peter H Langsjoen, et al.
							<p>
								This small study on human volunteers showed both ubiquinol and ubiquinone increased plasma CoQ10, but the increase in CoQ10 /cholesterol ratio was significantly better after ubiquinol than ubiquinone, indicating superior bioavailability. 
							</p>
						</li>
	
						<li id="d-mantle">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278738/"
							title="Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism"
							target="_blank">Bioavailability of Coenzyme Q10</a>, David Mantle, et al. 
							<p>
								This study compares the relative bioavailability and efficacy of ubiquinone and ubiquinol forms of CoQ10.
							</p>
						</li>
						<li id="g-petrangolini">
							<a href="https://pubmed.ncbi.nlm.nih.gov/31475897/"
							title="A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers"
							target="_blank">Phytosome Q10 Formulation Improves Bioavailability in Healthy Volunteers</a>, Giovanna Petrangolini, et al.
							<p>
								This in vitro study shows that coenzyme Q10 phytosome in simulated intestinal fluids results in an improvement in oral absorption of coenzyme Q10 in healthy volunteers, three times more than the coenzyme Q10 according
							</p>
						</li>
	
					</ol>
				</section>
			</section>
			<section id="gg">
				<h3>
					Geranylgeraniol (GG)
				</h3>
				<ul class="treatment-rating">
					<li>Mechanisms: Mitochondrial, Helps DRT side-effects, Antioxidant, anti-inflammatory, Neuroprotective
					<li>Dose: 150 mg per day üçΩÔ∏è
					<li>ü©∏üß†BBB: ‚úÖ? (probably)
					<li>Safety: 9/10 (85%)
					<li>Efficacy: 5/10 (30%)
				</ul>
				<p>
					Geranylgeraniol (GG) is an essential precursor for CoQ10, vitamin K2, cholesterol, and testosterone biosynthesis. It also plays a role in protein synthesis and modification. <cite class="reflink"><a href="#h-j-ho">h-j-ho</a></cite> 
				</p>
				
				<p>
					GG is synthesized naturally within the human body through the mevalonate (cholesterol) pathway, but its production decreases with age. This decline in GG synthesis can lead to decreased production of CoQ10, vitamin K2, and testosterone. <cite class="reflink"><a href="#h-j-ho">h-j-ho</a></cite> 
				</p>
														  
				
				<p>
					GG suppresses inflammation and modifies gut microbiota composition. <cite class="reflink"><a href="#e-chung">e-chung</a></cite> 
				</p>                     
				<h4>GG and Parkinson‚Äôs Disease</h4>
				<p>
					GG can likely cross the BBB (molecules with a <abbr title="Molecular Weight">MW</abbr> &lt; 400 <abbr title="daltons">Da</abbr> can cross it and GG's MW is 268.39 g/mol) and, if it does, this would confer an advantage over supplementation of CoQ10 (MW 731 (<a href="http://www.chemspider.com/Chemical-Structure.17216048.html">chemspider</a>)) and K2
					(MW 649.0 (<a href="https://pubchem.ncbi.nlm.nih.gov/compound/Menaquinone-7"
					>pubchem</a>)). 
				</p>
				
				<p>
					Dopamine synthesis is energetically demanding, relying on cellular energy. CoQ10 acts as a vital energy substrate for brain mitochondria, supporting their function and facilitating dopamine production and GG is an obligatory substrate for CoQ10 production. <cite class="reflink"><a href="#h-j-ho">h-j-ho</a>], <a href="#b-tan">b-tan</a></cite> 
				</p>
	
				<p>
					Given the uncertainty regarding CoQ10's BBB permeability, supplementing GG may ensure CoQ10 availability in the brain.
				</p>
				<h4>Mechanism of Action</h4>
				<p>
					GG converts mevalonic acid (MVA), the precursor for cholesterol, to CoQ10, K2, and sex hormones. It protects mitochondrial function.
				</p>
				
				<p>
					CoQ10 and vitamin K2 are primarily synthesized endogenously in the body and the brain. Evidence suggests that some forms of CoQ10 and vitamin K2 can cross the BBB, however, this is not well established. 
				</p>
	
				<h4>Supplementation</h4>
				<p>
					GG extracted from annatto is used to produce GG, a fat-soluble, orally bioavailable supplement that probably crosses the BBB and aids in CoQ10 biosynthesis. 
				</p>
	
				<p>
					Supplementing geranyl geraniol is considered very safe because the body has a natural regulatory mechanism to keep levels from exceeding a healthy range.
				</p>
				
				<h4>Product</h4>
				<p>
					
				</p>
				<ul class="product-list">
					<li>
						<a href="https://www.amazon.com/Xtendlife-GG-Pure-Contains-lowering/dp/B0988TVJCH/ref=sr_1_8?sr=8-8">Xtendlife GG Pure - Geranylgeraniol</a>
					</li>
					<li>
						<figure>
							<figcaption>
								<p>
									<a href="https://www.amazon.com/Xtendlife-Xtend-Quinol-Geranylgeraniol-Supplement-Production/dp/B0CCRMH1W6/ref=sr_1_1?rdc=1&s=hpc&sr=1-1">Xtendlife Xtend-Quinol CoQ10 &amp; GG</a>
								</p>
							</figcaption>
						</figure>
					</li>
				</ul>
				
				<h4>References</h4>
				<ol class="reference-list">
					<li id="e-chung">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464510/"
						title="Beneficial effect of dietary geranylgeraniol on glucose homeostasis and bone microstructure in obese mice is associated with suppression of proinflammation and modification of gut microbiome"
						target="_blank">Beneficial effect of dietary geranylgeraniol on glucose homeostasis and bone microstructure in obese mice is associated with suppression of proinflammation and modification of gut microbiome</a>, Eunhee Chung, et al
						<p>
							This rodent study concluded that GG improves glucose homeostasis and bone microstructure in obese mice, probably via suppression of pro-inflammation and modification of microbiome composition.
						</p>
					</li>
					
					<li id="b-tan">
						<a href="https://pubmed.ncbi.nlm.nih.gov/38046949/"
						title="Potential role of geranylgeraniol in managing statin-associated muscle symptoms: a COVID-19 related perspective"
						target="_blank"
						>Potential role of geranylgeraniol in managing statin-associated muscle symptoms: a COVID-19 related perspective</a>, Barrie Tan, Kok-Yong Chin.
						<p>
							CoQ10 supplementation has not been shown to reverse  statin-associated muscle symptoms, therefore, this paper proposes GG for CoQ10 synthesis.
						</p>
					</li>
					<li id="h-j-ho">
						<a href="https://pubmed.ncbi.nlm.nih.gov/29303051/"
						title="A novel function of geranylgeraniol in regulating testosterone production"
						target="_blank"
						>A novel function of geranylgeraniol in regulating testosterone production</a>
						<p>
						</p>
					</li>
	
				</ol>
			</section>
			<section id="nattokinase">
				<h3>Nattokinase</h3>
				<p>
					Nattokinase is a proteolytic and fibrinolytic enzyme Nattokinase that reduces inflammation.
				</p>
				<p>
					Nattokinase has been shown to degrade amyloid fibrils in mice, which may help to slow down the progression of Parkinson‚Äôs disease.
				</p>
				<p>
					Nattokinase has been shown to promote the non-amyloidogenic processing of AŒ≤, which may help to reduce the accumulation of amyloid plaques in the brain.
				</p>
			</section>
			
			<section id="dha">
				<h3>
					Docosahexaenoic Acid (DHA)
				</h3>
				<ul>
					<li>Mechanisms: Anti-inflammatory, Neuroprotective, Mitochondrial
					<li>Dose: 2000 ‚Äî 5000 mg ED üçΩÔ∏è
					<li>Fat-soluble: ‚úÖ
					<li>BBB: ‚úÖ (50%)
					<li>Safety: 8/10 (80% œÉ)
					<li>Efficacy: 7/10 (95% œÉ)
				</ul>
				<p>
					Docosahexaenoic acid (DHA) is an essential omega-3 fatty acid found in eggs, fish, krill, and algae, and produced in small amounts in humans. DHA is necessary for normal brain function, for cognition, memory, and attention.
				</p>
				
				<p>
					DHA inhibits neuroinflammation by inhibiting ROS and raising glutathione levels. <cite class="reflink"><a href="#h-j-lee">H.J. Lee</a></cite>
				</p>
				
				<h4>DHA in Parkinson's Disease</h4>
				<p>
					Daily DHA has been shown to protect against core symptoms of PD in rodents, including deficits in postural stability, gait integrity, and dopamine neurochemistry in motor areas of the striatum. <cite class="reflink"><a href="#n-m-chitre">N.M. Chitre</a></cite>
				</p>
	
				<p>
					DHA exhibits a neuroprotective dose-dependent response. <cite class="reflink"><a href="#y-p-zhang">Y.P. Zhang</a></cite> 
				</p>
				
				<p>
					DHA crosses the BBB in passive diffusion. This means that relatively high plasma levels of DHA are needed to raise its brain DHA levels. When plasma DHA levels increased by 200%, <abbr title="Cerebrospinal Fluid">CSF</abbr> DHA increased by only 28%. <cite class="reflink"><a href="#i-c-arellanes">I.C. Arellanes</a></cite> 
				</p>
								
				<h4>Side Effects</h4>
				<p>
				Gastric tolerance between individuals varies. Start at 2 grams and work upwards from there. Spread consumption over time.
				</p>
				<h4>DHA Product</h4>
				<figure>
					<img src="img/childrens-dha.jpeg" title="Children's DHA">
					<figcaption>
						<p>
						<a href="https://www.amazon.com/gp/product/B004T7DYOO/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B004T7DYOO&amp;linkId=03df93bc6eab5eeabecf94de7e16e7e4"
				target="_blank"
				>Nordic Naturals Children&rsquo;s DHA, Strawberry</a>
						</p>
					</figcaption>
				</figure>
	
				<h4>DHA References</h4>
				<ol class="reference-list">
	
					<li id="h-j-lee">
						<a href="https://pubmed.ncbi.nlm.nih.gov/25545062/"
						target="_blank"
						title="Docosahexaenoic acid prevents paraquat-induced reactive oxygen species production in dopaminergic neurons via enhancement of glutathione homeostasis"
						>Docosahexaenoic acid prevents paraquat-induced reactive oxygen species production in dopaminergic neurons via enhancement of glutathione homeostasis</a>, Hyoung Jun Lee, et al.
					</li>
					<li id="n-m-chitre">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110909/">
							Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum
						</a>, Neha Milind Chitre, et al.
					</li>
					<li id="y-p-zhang">
						<a href="https://pubmed.ncbi.nlm.nih.gov/28778752/"> DHA, EPA, and their combination at various ratios differently modulated A&beta;<sub>25-35</sub>-induced neurotoxicity in SH-SY5Y cells</a>, Yong-Ping Zhang, et al.
					</li>
	
					<li id="i-c-arellanes">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502665/"
						title="Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial"
						target="_blank"
						>Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial</a>, Isabella C. Arellanes, et al.
					</li>
				</ol>
			</section>
			
			<section id="cholinergics">
				<h3>Cholinergics and Membrane Support</h3>
				
				<p>
					Cholinergic supplementation has been shown to improves cognitive function, increase physical power output, provide neuroprotection, and improve conditions of neurological disorders. Restoring phosphatidylcholine (PC) to healthy levels has been shown to combat neurological decline and reduce DRT dependence and its associated side effects. <cite class="reflink"><a href="#m-zhou">M. Zhou</a>, <a href="#m-amalric">M. Amalric</a>, <a href="#b-s-baumel">B.S. Baumel</a></cite>
				</p>
	
				<p>
					Cholinergic supplements support neuronal health by maintaining cell membrane integrity, enhancing neurotransmitter synthesis, and promoting neuroprotection. This helps sustain cognitive function and neuronal survival, particularly relevant for managing neurodegenerative conditions like PD.
				</p>
				
				<p>
					Given the interdependence between the cholinergic and dopaminergic systems, this section focuses on cholinergic supplements uridine monophosphate (UMP), CDP-Choline, alpha-GPC, and phosphatidylserine (PS). 
				</p>
				
				<h4>Cholinergic and Dopaminergic Interdependence</h4>
				<p>
					The cholinergic and dopaminergic systems interact and converge in various brain regions, including the basal ganglia and hippocampus, to regulate cognition, movement, and behavior. Disruption of these interactions contributes to the symptoms of PD.
				</p>
				
				<h4>Interactions with DRT</h4>
				<p>
					Supplementation with CDP-choline, UMP, and alpha-GPC reduces the need for DRT and should be considered and monitored under medical supervision. However, the benefits of these supplements extend beyond merely reducing the required dose of DRT. <cite class="reflink"><a href="#r-eberhardt">R. Eberhardt</a></cite>
				</p>
				
				<p>
					Phosphatidylserine (PS) levels are often decreased in idiopathic PD and its supplementation may also alleviate dopamine replacement therapy (DRT) side effects. <cite class="reflink"><a href="#g-zhai">G. Zhai</a></cite>
				</p>
	
	
				<h4>Cholinergics Example Stack</h4>
				<p>
					An example cholinergic supplement stack might include UMP and CDP-choline at 250 mg each, twice daily, 500 mg alpha-GPC pre-workout, 200 mg PS after dinner, and 3000 mg DHA daily.
				</p>
	
				<h4>Phospholipids and Alpha-Synuclein</h4>
				<p>
					Experimental evidence suggests that phospholipids alter the structure and reduce the toxicity of Œ±-synuclein oligomers. <cite class="reflink"><a href="#t-dou">T. Dou</a></cite>
				</p>
							
				<section id="uridine">
					<h3>
						Uridine Monophosphate (UMP)
					</h3>
					
					<ul>
						<li>Mechanisms: Anti-inflammatory, Neuroprotective, Mitochondrial, Helps DRT side-effects
						<li>Dose: 500mg ED 
						<li>Fat-soluble: ‚ùå
						<li>BBB: ‚úÖ 
						<li>Safety: 8/10 (80% œÉ)
						<li>Efficacy: 7/10 (85% œÉ)
					</ul>
					
					<p>
						Uridine is a type of nucleoside, a fundamental component of nucleic acids. Nucleic acids are the building blocks of life and are used for storage and transmission of genetic information.
					</p>
							
					<h4>How it Works</h4>
					<p>
						As explained under the section DHA &amp; Uridine, Uridine restores unilateral dopaminergic neurotransmission, transmission from the substantia nigra to the striatum, when that region is impacted by oxidopamine lesions in rodent models. Research shows the best results when uridine use used in conjunction with DHA and choline (more on this appears below). <cite class="reflink"><a href="#m-cansev">M. Cansev</a></cite> 
					</p>
					
					<p>
						UMP supplementation increases CDP-choline levels. As a precursor to brain phospholipids, it supports cell membrane integrity and cognitive functions such as memory and learning. <cite class="reflink"><a href="#n-agarwal">N. Agarwal</a></cite> 
					</p>
	
					<p>
						Phospholipids are phosphorus-containing compounds found in the brain involved in the regulation of various signaling pathways, including neurotransmission, synaptic plasticity, energy transfer, and nucleic acid structure.
					</p>
					
					<h4>Uridine with DHA</h4>                
					<p>
						Phosphatidylcholine (PC), the most abundant phospholipid in the brain, requires three compounds: choline; a pyrimidine such as uridine; and a polyunsaturated fatty acid (PUFA) such as DHA. <q>When all three of the nutrients are provided concurrently, the resulting increase in PC production is greater than the sum of the increases produced by giving each separately.</q> <cite class="reflink"><a href="#r-j-wurtman">R.J. Wurtman</a></cite> 
					</p>
					<p>
						DHA has been shown to restore dopaminergic neurotransmission loss in PD models, with enhanced effects when combined with UMP. <cite class="reflink"><a href="#m-cansev">M. Cansev</a></cite> 
					</p>
					<p>
						In a 2006 study conducted by researchers from two universities, Brain <abbr title="Phosphatidylcholine">PC</abbr> rose by 13&ndash;22% with uridine and choline alone, or DHA alone, or by 45% with the combination. Oral administration of uridine or DHA alone was shown to increase synaptic proteins and phospholipids, and in combination, a synergistic effect was noticed. Later research confirmed the cognitive benefits of these effects. <cite class="reflink"><a href="#s-holguin">S. Holguin</a></cite>
					</p>
					
					<h4>Uridine and the BBB</h4>
					<p>
						UMP is transported across the blood-brain barrier by nucleoside transporters. In the brain, UMP enhances neurite outgrowth and improves synaptic transmission. <cite class="reflink"><a href="#l-wang">L. Wang</a></cite> 
					</p>
					
					<h4>
						Uridine Monophosphate Product
					</h4>
					<ul class="product-list">
						<li>
							<a href="https://www.amazon.com/Monophosphate-Disodium-Supports-Cognitive-Mitochondrial/dp/B01BYY0QY0/ref=sr_1_4_pp?s=hpc&sr=1-4&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B086KMB9YN&amp;linkId=e758783750e802b48ff75aa147f0afa9"
							target="_blank"
							>Uridine Monophosphate Powder</a>
						</li>
					</ul>
					
					<h4>Uridine References</h4>
					<ol class="reference-list">
						<li id="m-cansev2">
							<a href="https://pubmed.ncbi.nlm.nih.gov/16769123/"
							title="Uridine and cytidine in the brain: Their transport and utilization"
							target="_blank"
							>Uridine and cytidine in the brain: Their transport and utilization</a>, Mehmet Cansev.
							<p>
								Uridine and cytidine are transported across the blood-brain barrier by nucleoside transporters. 
							</p>
						</li>
						<li id="l-wang">
							<a href="https://pubmed.ncbi.nlm.nih.gov/16055952/"
							target="_blank"
							title="Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats">Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats</a>, Lei Wang
						</li>
						<li id="n-agarwal">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020593/"
							title="Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T"
							target="_blank"
							>Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T</a>, Nivedita Agarwal, et al.
							<p>
								 This small study on 17 healthy males found that daily supplementation with 2g of uridine significantly increased levels of total phosphomonoesters (PME) and phosphatidylethanolamine (PEtn) over one week.
							</p>
						</li>
	
		<!-- Uridine with DHA references -->
						<li id="r-j-wurtman">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011061//"
								title="A Nutrient Combination that Can Affect Synapse Formation"
								target="_blank"
								>A Nutrient Combination that Can Affect Synapse Formation</a>, Richard J. Wurtman.
						</li>                    
						<li id="m-cansev">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592845/"
							title="Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease"
							target="_blank"
							>Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease</a>, Mehmet Cansev, et al.
						</li>
						
						<li id="s-holguin">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2478743/"
							title="Chronic Administration of DHA and UMP Improves the Impaired Memory of Environmentally Impoverished Rats"
							target="_blank"
							>Chronic Administration of DHA and UMP Improves the Impaired Memory of Environmentally Impoverished Rats</a>, Sarah Holguin, et al.
						</li>
					</ol>
				</section>
				<section id="citicoline">
					<h3>
						CDP-Choline (Cytidine 5'-diphosphocholine)
					</h3>
					<ul>
						<li>Mechanisms: Neuroprotective, Mitochondrial, Dopaminergic side-effects, Senolytic
						<li>Dose: 500mg ED 
						<li>Fat-soluble: ‚ùå
						<li>BBB: ‚úÖ CDP-Choline‚Äôs metabolites cross the BBB 
						<li>Safety: 8/10 (80% œÉ)
						<li>Efficacy: 7/10 (85% œÉ)
					</ul>
					<p>
						CDP-Choline (cytidine diphosphate-choline, also "Citicoline") is an essential intermediate in the biosynthetic pathway of structural phospholipids, particularly <abbr title="Phosphatidylcholine">PC</abbr>, found in cell membranes through the body, especially the liver and brain. <cite class="reflink"><a href="#jj-secades">J.J. Secades</a></cite>
					</p>
					
					<p>
						CDP-Choline supports cognitive function, including memory, and offers neuroprotection, potentially slowing age-related cognitive decline and supporting brain health in neurodegenerative diseases.
					</p>
					<p>
						It increases brain choline uptake for PC and acetylcholine production, for neuronal membranes and myelin sheaths. Clinical studies show its benefits for brain health in patients with mild cognitive impairment and other neurological conditions.
					</p>
					
					<p>                                     
						CDP-Choline has several benefits over direct <abbr title="Phosphatidylcholine">PC</abbr> supplementation through its efficient metabolic conversion and broader physiological effects. CDP-Choline is digested into cytidine and choline, which are absorbed into the bloodstream and can then be reassembled into CDP-Choline within cells. Directly supplementing does not achieve the same level of metabolic conversion and physiological effects.  <cite class="reflink"><a href="#u-kansakar">U. Kansakar</a></cite>
					</p>
					
					<p>
						CDP-Choline's many beneficial effects and supporting evidence are explained by the large role it plays in the body.
					</p>
					<p>
						In rat brains, citicoline induced sirtuin expression, which was also observed in cultured neurons and lymphocytes, suggesting that a significant neurovascular protections is conferred by citicoline (either directly or indirectly) via SIRT-1. <cite class="reflink"><a href="#f-oddone">F. Oddone</a></cite>
					</p>
					
					<h4>CDP-Choline and the BBB</h4>
					<p>
						The breakdown products cytidine and choline cross the BBB and are reassembled to provide a synergistic impact on brain function and cellular health.
					</p>
					
					<h4>CDP-Choline in PD</h4>
					<p>
						CDP-Choline supplementation can effectively reduce the dosage and consequential side effects of <abbr title="Dopamine Replacement Therapy">DRT</abbr>. <cite class="reflink"><a href="#r-eberhardt">R. Eberhardt</a></cite>
					</p>
					
					<p>
						Glutamate excitotoxicity is a problem of cellular damage in PD and various other neurodegenerative diseases. This happens when neurons are damaged and killed by the excessive glutamate.  <cite class="reflink"><a href="#f-a-arnold">Arnold</a></cite>
					</p>
					
					<p>     
						CDP-Choline reduces glutamate excitotoxicity and oxidative stress, increases neurotrophin levels, enhances neurotransmitter release (such as norepinephrine and dopamine), promotes mitochondrial function, and modulates insulin signaling. <cite class="reflink"><a href="#c-mir">C. Mir</a></cite>
					</p>
					
					<p>
						Neurotrophins BDNF and NT-3, a protein growth factor that belongs to the NGF (Nerve Growth Factor) family of neurotrophins, are reduced in PD. This is problematic, as neurotrophins increase neuronal survival and growth. Their depletion in PD likely contributes to progressive neurodegeneration (PN). CDP-choline increases neurotrophin activity and expression, which is neuroprotective, and are reported to have noticeable positive effects. <cite class="reflink"><a href="#k-a-jellinger">Jellinger</a>, <a href="#p-arenth">P. Arenth</a></cite>
					</p>
					
					<p>
					 A 2022 review found profound neurological and cognitive benefits from some choline-containing phospholipids (CCPLs), in particular alpha-GPC, and also CDP-choline. They attribute these results by the improvement on ischemic conditions, increased synthesis of phospholipids and neurotransmitters, incorporation into the membrane phospholipid structure, and improved mitochondrial metabolism. <cite class="reflink"><a href="#p-roy">P. Roy</a></cite>
					</p>
					
					<h4>Ischemic Mitigation</h4>
					<p>
						 In patients with chronic cerebral ischemia, citicoline improves scores on cognitive rating scales. CDP-choline prevents ischemia-induced tissue accumulation of free fatty acids and reduces infarct volume (direct measurement of the extent of tissue death or necrosis caused by an ischemic stroke), and brain edema, thus resulting in an antiapoptotic effect that is related to the mitochondrial-dependent cell death mechanism. <cite class="reflink"><a href="#jj-secades">J.J. Secades</a></cite>
					</p>
					
					<p>
						CDP-coline improves axonal transport deficits and supports axon regeneration. Axon regeneration is limited in adults, partly due to the reduced growth potential of mature neurons. <cite class="reflink"><a href="#f-oddone">F. Oddone</a>, <a href="#c-iulia">Iulia</a></cite>
					</p>
	
					<h5>Uridine and CDP-Choline</h5>
					<p>
						CDP-Choline aids in the synthesis of <abbr title="Phosphatidylcholine">PC</abbr> and serves as a precursor to choline and uridine in the brain. Uridine, a nucleotide base, can convert to back CDP-choline and vice versa through natural metabolic pathways.
					</p>
					
					<p>
						Supplementing with both uridine and CDP-Choline together can significantly benefit brain health and cognitive function, often allowing for lower doses of each. This combination enhances neuroprotection, memory, and learning by boosting acetylcholine production. These synergistic effects are increased with the addition of <abbr title="Docosahexanoic Acid">DHA</abbr>. <cite class="reflink"><a href="#b-s-baumel">B.S. Baumel</a></cite>
					</p>
	
					<p>
						Both uridine and CDP-Choline are neuroprotective and independently contribute to the production of PC, which supports acetylcholine synthesis and enhances cell membrane integrity.
					</p>
					<p>
						Because Uridine increases CDP-choline levels, it is necessary to balance their co-supplemention. Uridine is a precursor to CDP-choline, increasing uridine levels can potentially affect the balance of these two compounds in the body.
					</p>
					
					<p>
						Uridine and CDP-choline work synergistically to enhance brain health and cognitive function. CDP-choline aids in the synthesis of <abbr title="Phosphatidylcholine">PC</abbr> and serves as a precursor to both choline and uridine in the brain. Uridine can convert to CDP-choline and also supports RNA synthesis during cell growth and repair. Combined, these compounds enhance memory and learning by boosting acetylcholine production, improve cell membrane integrity, and provide neuroprotection. UMP, a precursor to uridine, supports dopamine levels and contributes to the synthesis of CDP-choline, making it essential to balance their supplementation for optimal effects.
					</p>
					
					<p>
					   Citicoline is generally well-tolerated with no serious side effects reported. However, excessive supplementation may cause imbalances, especially in advanced stages of disease.
					</p>
					
					<h5>CDP-Choline Supplementation</h5>
					<p>
						A typical dosage of 500 mg CDP-choline ED is considered safe for most people, but individual tolerance may vary.
					</P>
					<p>
						The effects of CDP-choline vary on individual bases and are affected by other supplements and medications being used, so the dose will need to be custom-tailored.
					</p>
					
					<h5>Anticholinergics ‚ùå CAUTION</h5>
					<p>
						Contrary to the dying myth, acetylcholine does not cause the tremors of PD. The drugs <em>given</em> to reduce CDP-choline in PD, such as Trihexyphenidyl and Benztropine, impact neurological function, resulting in confusion, memory issues, hallucinations, dry mouth, blurry vision, and urinary retention problems &mdash; serious side effects.
					</p>
					
					<p>
					<em>Increasing</em> choline by 1,200 mg of supplemental citicoline improved tremors in PD and allowed patients to halve their L-dopa + decarboxylase inhibitor dose. Uridine increases CDP. It's important to have a healthcare provider that understands and accounts for this as part of a holistic plan.
					</p>
					
					<p>
						CDP-choline, uridine monophosphate (UMP), and alpha-GPC can augment the effects of DRT due to their neurotransmitter synthesis, particularly acetylcholine, which can interact with dopamine pathways. It is important to balance their supplementation DRT under medical supervision. 
					</p>
					
					<h4>Product</h4>
					<p>
						<a href="https://www.amazon.com/gp/product/B001ESE21K/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B001ESE21K&amp;linkId=1a2fefa4dbb6e04cc9613e95c02b9867">
							Healthy Origins Cognizin Citicoline 250 MG, 150 Count
						</a>
					</p>
					
					<h4><img src="img/cdp-choline.jpeg" alt="Healthy Origins Cognizin Citicoline 250 MG, 150 Count"></h4>
					
					<h4>Citicoline References</h4>
	
					<ol class="reference-list">
					
						<li id="jj-secades">
							<a href="https://pubmed.ncbi.nlm.nih.gov/8709678/"
							title="CDP-choline: pharmacological and clinical review"
							target="_blank"
							>CDP-choline: pharmacological and clinical review</a>, J J Secades, G Frontera.
						</li>
						
						<li id="u-kansakar">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025538/"
							title="Choline supplements: An update"
							target="_blank"
							>Choline supplements: An update</a>, Urna Kansakar, et al.
						</li>
						
						<li id="f-oddone">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003774/"
							title="Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review"
							target="_blank"
							>Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review</a>, Francesco Oddone, et al.
						</li>
					
						<li id="r-eberhardt">
							<a href="https://pubmed.ncbi.nlm.nih.gov/2289218/"
							title="Citicoline in the treatment of Parkinson's disease"
							target="_blank">Citicoline in the treatment of Parkinson's disease</a>, R Eberhardt, et al.
						</li>
						<li id="f-a-arnold">
							<a href="https://www.mdpi.com/1422-0067/25/11/5587"
							title="Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration"
							target="_blank"
							>Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration</a>, Frederick J. Arnold.
						</li>
	
						<li id="c-mir">
							<a href="https://pubmed.ncbi.nlm.nih.gov/12663935/"
							title="CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons"
							target="_blank"
							>CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons</a>, Cecilia Mir, et al.
						</li>
	
						<li id="p-arenth">
							<a href="https://www.sciencedirect.com/science/article/abs/pii/S1934148211001766"
							title="CDP-Choline as a Biological Supplement During Neurorecovery: A Focused Review"
							target="_blank"
							>CDP-Choline as a Biological Supplement During Neurorecovery: A Focused Review</a>, Patricia M. Arenth, et al.
						</li>
						
						<li id="k-a-jellinger">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823450/#sec-a.i.g"
							title="Basic mechanisms of neurodegeneration: Dysfunction of neurotrophins"
							target="_blank"
							>Basic mechanisms of neurodegeneration: Dysfunction of neurotrophins</a>, Kurt A Jellinger.
						</li>
											
						<li id="p-roy">
							<a 
							target="_blank"                        href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541750/">Effects of choline containing phospholipids on the neurovascular unit: A review</a>, Proshanta Roy, et al.
						</li>
	
						<li id="c-iulia">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29450391/"
							>Citicoline - a neuroprotector with proven effects on glaucomatous disease</a>, Chitu Iulia, et al.
						</li>
					</ol>
				</section>
				<section id="alpha-gpc">
					<h3>Alpha-GPC</h3>
					
					<ul>
						<li>Mechanisms: Dopaminergic, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative
						<li>Dose: 300 ‚Äì 600 mg Pre-WO üèãÔ∏èÔ∏è
						<li>Fat-soluble: ‚ùå 
						<li>BBB: ‚úÖ (via transporters, <abbr title="Choline Transporter">CT</abbr>, <abbr title="High Affinity Choline Transporter">HACT</abbr>, and passive diffusion)
						<li>Safety: 6/10 (50% œÉ)
						<li>Efficacy: 8/10 (60% œÉ)
					</ul>
					
					<p>
						Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a highly bioavailable, naturally occurring form of choline that is synthesized for dietary supplements.
					</p>
					
					<h4>Benefits</h4>
					<p>
						Alpha-GPC increases the release of acetylcholine, promotes learning and memory, and counters cognitive impairment. It has been shown to decrease age-dependent structural alterations in the frontal cortex and hippocampus of rats' brains. <cite class="reflink"><a href="#f-amenta">F. Amenta</a></cite> 
					</p>
					
					<p>
						A review study published in Fronteirs in Cell Neuroscience highlighted some of the amazing benefits of alpha-GPC, considering the most promising molecule for brain disorders characterized by vascular impairment and called for larger attentively controlled studies. 
					</p>
					
					<p>
						Citing a rodent model study, they highlighted how administration of Œ±-GPC (400 mg/kg) for 7 days countered the increase of stress hormones, reduced hearing loss, and prevented neuronal injury in rats. These neuroprotective effects were due to the increase of choline acetyltransferase (ChAT), reduction of brain neuroinflammation, and enhanced BDNF expression in the hippocampus. 
					</P>
					
					<p>
						The researchers cited other research showing that Alpha-GPC contributes to anabolic processes responsible for membrane phospholipid and glycerol-lipid synthesis, positively influencing membrane fluidity. <cite class="reflink"><a href="#p-roy-gpc">P. Roy</a></cite> 
					</p>
					
					<h4>Alpha-GPC and Exercise</h4>
					
					<p>
						A double blind, placebo controlled, cross-over design study in 2015 found that 600 mg per day of alpha-GPC increased lower body force production after just 6 days, making a recommendation for speed and power athletes to enhance muscle performance. <cite class="reflink"><a href="#d-bellar">Bellar</a></cite> 
					</p>
					
					<p>
						Another small, randomized, double-blind, placebo-controlled, crossover study found that alpha-GPC supplementation prevents exercise-induced reductions in choline levels, increases endurance performance, and increases growth hormone secretion. <cite class="reflink"><a href="#a-parker">Parker</a></cite> 
					</p>
					
					<h4>Side effects</h4>
					<p>
						Alpha-GPC may increase the production of Trimethylamine-N-oxide (TMAO) in the gut, which may increase the risk of stroke. A review study published in 2021 found that alpha-GPC usage was associated with a 46% higher risk of stroke. <cite class="reflink"><a href="#g-lee">G. Lee</a></cite> 
					</p>
									
					<h4>Supplementation</h4>
					<p>
						Alpha-GPC's rapid uptake leads to sharp increases in acetylcholine make it an excellent choice 60 min prior to training sessions of maximal power output, as part of a total cholinergic stack. Typical pre-workout dosage is 300 - 600 mg pre-workout.
					</p>
					
					<h4>References</h4>
					<ol class="reference-list">
					
						<li id="f-amenta">
							<a href="https://www.sciencedirect.com/science/article/abs/pii/B9780128158548000306/"
							title="Chapter 30 - Choline-containing phospholipids and treatment of adult-onset dementia disorders"
							target="_blank"
							>Chapter 30 - Choline-containing phospholipids and treatment of adult-onset dementia disorders</a>, Francesco Amenta, et al.
						</li>
						
						<li id="p-roy-gpc">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541750/"
							title="Effects of choline containing phospholipids on the neurovascular unit: A review"
							target="_blank"
							>Effects of choline containing phospholipids on the neurovascular unit: A review</a>, Proshanta Roy, et al.
						</li>
						
						<li id="d-bellar">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650143/"
							title="The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength"
							target="_blank"
							>The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength</a>, David Bellar, et al.
						</li>
						<li id="a-parker">
							<a href="https://jissn.biomedcentral.com/articles/10.1186/1550-2783-12-S1-P41"
							title="The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility"
							target="_blank"
							>The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility</a>, Adam G Parker, et al.
						</li>
						
						<li id="g-lee">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613599/"
							title="Association of L-Œ± Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years"
							target="_blank"
							>Association of L-Œ± Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years</a>, Gyeongsil Lee, et al.
						</li>
					</ol>
				</section>
				<section id="phosphatidylserine">
					<h3>Phosphatidylserine (PS)</h3>
					<ul>
						<li>Mechanisms: Dopaminergic, Anti-inflammatory, Mitochondrial, Neuroprotective
						<li>Dose: 150mg Post-workout, 150mg üí§
						<li>Fat-soluble: ‚úÖ
						<li>BBB: ‚úÖ 
						<li>Safety: 6/10 (50% œÉ)
						<li>Efficacy: 6/10 (60% œÉ)
					</ul>
					
					<h4>Benefits</h4>
					<p>
						Phosphatidylserine (PS) is an essential component of cellular membranes. It helps regulate membrane support, signal transduction, inhibits neuroinflammation, provides neuroprotection, and improves cognitive function.
					</p>
					
					<h4>Details and Mechanisms</h4>
					<p>
						PS binds to various proteins and is involved in many biological processes, including enzyme activation, apoptosis, neurotransmission, and synaptic refinement. Dysregulation of these processes is common in various CNS diseases. <cite class="reflink"><a href="#x-ma">X. Ma</a></cite>
					</p>
					
					<p>
						In a double-blind study, elderly patients with severe cognitive decline were treated with brain cortex-derived PS (BC-PS) 300 mg/day for 6 months, compared with placebos, BC-PS administration significantly improved the storage, learning, and retrieval abilities of memory in patients. <cite class="reflink"><a href="#x-ma">X. Ma</a></cite>
					</p>
					
					<h4>PS as a Self-emulsifying Drug Delivery System (SEDDS)</h4> 
					<p>
						SEDDS (Self-Emulsifying Drug Delivery Systems) are formulations designed to improve the oral bioavailability of poorly water-soluble substances. While PS itself is not a SEDDS, taking it with such substances may enhance their absorption and bioavailability. This is because it is both. PS liposomes loaded with astragaloside IV and nestifin-1 were shown to facilitate their penetration of the blood-brain barrier and reduce the expression of Œ±-synuclein, making PS liposome an effective delivery tool for other substances. <cite class="reflink"><a href="#y-kuo">Y. Kuo</a></cite>
					</p>
	
					<h4>Supplementation ‚Äî Brain-Derived PS (Choric PS)</h4>
					<p>
						 PS promotes relaxation and reduces cortisol, making it a good choice for an post-workout recovery and evening supplementation at about 100 mg - 400 mg once or twice daily. <cite class="reflink"><a href="#m-kingsley">M. Kingsley</a></cite>
					</p>
					
					<h4>References</h4>
					<ol class="reference-list">
											 
						<li id="x-ma">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382310/"
							title="Phosphatidylserine, inflammation, and central nervous system diseases"
							target="_blank"
							>Phosphatidylserine, inflammation, and central nervous system diseases</a>, Xiaohua Ma, et al.
						</li>
						
						<li id="m-kingsley">
							<a href="https://pubmed.ncbi.nlm.nih.gov/16869708/"
							title="Effects of phosphatidylserine supplementation on exercising humans"
							target="_blank"
							>Effects of phosphatidylserine supplementation on exercising humans</a>, Michael Kingsley.
						</li>
						<li id="y-kuo">
							<a href="https://pubmed.ncbi.nlm.nih.gov/34579880/"
							title="Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment"
							target="_blank"
							>Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment</a>, Yung-Chih Kuo, et al.
						</li>
	
					</ol>
				</section>
				
				
				<h4>Choline References</h4>
				<ol class="reference-list">
				
					<li id="m-zhou">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997672/"
						title="Effects of different fatty acids composition of phosphatidylcholine on brain function of dementia mice induced by scopolamine"
						target="_blank"
						>Effects of different fatty acids composition of phosphatidylcholine on brain function of dementia mice induced by scopolamine</a>, Miao-miao Zhou, et al.
					</li>
					<li id="m-amalric">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340002/"
						title="Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders"
						target="_blank"
						>Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders</a>, Marianne Amalric, et al,
					</li>
					<li id="b-s-baumel">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139993/"
						title="Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review"
						target="_blank"
						>Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review</a>, Barry S. Baumel, et al.
					</li>
					<li id="t-dou">
						<a href="https://pubmed.ncbi.nlm.nih.gov/35904551/"
						title="Phosphatidylcholine and Phosphatidylserine Uniquely Modify the Secondary Structure of Œ±-Synuclein Oligomers Formed in Their Presence at the Early Stages of Protein Aggregation"
						target="_blank"
						>Phosphatidylcholine and Phosphatidylserine Uniquely Modify the Secondary Structure of Œ±-Synuclein Oligomers Formed in Their Presence at the Early Stages of Protein Aggregation</a>
					</li>
					<li id="g-zhai">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537766/"
						title="Serum-Based Lipid Panels for Diagnosis of Idiopathic Parkinson‚Äôs Disease"
						target="_blank"
						>Serum-Based Lipid Panels for Diagnosis of Idiopathic Parkinson‚Äôs Disease</a>, Guangju Zhai.
	
					</li>
				</ol>
			</section>
			
			<section id="magnesium-threonate">
				<h3>
					Magnesium L-Threonate
				</h3>
				<ul>
					<li>Mechanisms: Dopaminergic, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant (GSK3Œ≤ dysregulation)
					<li>Dose: 300mg ED/EOD üí§
					<li>Fat-soluble: ‚ùå 
					<li>BBB: ‚úÖ
					<li>Safety: 8/10 (80% œÉ)
					<li>Efficacy: 9/10 (95% œÉ)
				</ul>
				
				<p>
				Magnesium L-Threonate is a highly bioavailable form of magnesium that, unlike most magnesium supplements, crosses the blood-brain barrier to strongly support brain health and cognitive function. 
				</p>
				
				<p>
					In a 2019 rodent study where magnesium L-Threonate was compared to magnesium sulfate, was shown that only the L-Threonate form crossed the blood-brain barrier, where it then inhibited oxidative stress, attenuated motor deficits, and slowed the progression of neurodegeneration. <cite class="reflink"><a href="#y-shen">Y. Shen</a></cite> 
				</p>
				
				<p>
					 A 2022 study from Nanjing Medical University found that Magtein¬Æ significantly improved memory and cognition in healthy Chinese adults, with greater benefits in older participants. <cite class="reflink"><a href="#c-zhang">C. Zhang</a></cite> 
				</p>
	
				<h4>Supplementation</h4>
				<p>
					Magnesium can promote relaxation and improve sleep quality. Therefore, it is recommended to take this supplement in the evening.
				</p>
				
				<h4>Product</h4>
				<figure>
					<img src="img/neuromag.jpeg" alt="neuromag">
					<figcaption>
					<p>
					<a 
					target="_blank"
					title="Life Extension Neuro-Mag Magnesium L-Threonate"
															href="https://www.amazon.com/gp/product/B07KWM4C5L/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07KWM4C5L&amp;linkId=8f6f3f54762aeaec83a6e9014c89c8fe"
					>Life Extension Neuro-Mag Magnesium L-Threonate</a>
					</p>
					</figcaption>
				</figure>
				
				<h4>
					References
				</h4>
				
				<ol class="reference-list">
					<li id="y-shen">
						<a 
						href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857673/"
						title="The treatment with MgT is associated with an increase of Mg in the CSF. MgT, rather than MgSO4, can significantly attenuate MPTP-induced motor deficits and dopamine (DA) neuron loss."
						target="_blank"
						>The treatment with MgT is associated with an increase of Mg in the CSF. MgT, rather than MgSO4, can significantly attenuate MPTP-induced motor deficits and dopamine (DA) neuron loss</a>, Yanling Shen, et al.
					</li>
	
					<li id="c-zhang">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786204/"
							title="A Magtein¬Æ, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults"
							target="_blank"
							>A Magtein¬Æ, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults</a>, Chengxiang Zhang, et al.
					</li>
				</ol>
			</section>
			
			<section id="vitamin-d">
				<h3 class="neuroprotective">
					Vitamin D3
				</h3>
				<!--
				Vitamin D3, or cholecalciferol, is a fat-soluble vitamin essential for various bodily functions. It aids in calcium absorption, supporting bone health and helping prevent conditions like osteoporosis. Beyond its role in bone maintenance, Vitamin D3 influences immune function and mood. It is synthesized through sunlight exposure and can also be obtained from diet and supplements. Its potential benefits in neurological health, particularly in conditions like Parkinson's disease, are an area of ongoing research.
				-->
				<p>
					Vitamin D3 stimulates the osteoblasts to produce osteocalcin (OCN). Vitamin K2 converts some of this osteocalcin into its active form, carboxylated OCN. The remaining undercarboxylated OCN (ucOCN) enters the bloodstream and acts as a hormone in various tissues, including the brain. <cite class="reflink"><a href="#c-shan">C. Shan</a></cite>
				</p>
				
				<h4>D3 and Parkinson's Disease</h4>
				<p>
					The Parkinson‚Äôs Disease Research, Education, and Clinical Center at the Portland and Puget Sound Veteran Affairs (VA) Clinics conducted an add-on study to a longitudinal study on neuropsychiatric function in individuals with PD. Researchers found that higher plasma vitamin D levels were associated with improved cognition and mood in PD patients without dementia. <cite class="reflink"><a href="#a-peterson">A. Peterson</a></cite>
				</p>
				
				<h4>Supplementation</h4>
				<p>
					More is not always better! Too much vitamin D3 can disturb calcium levels. Vitamin D3 levels can be optimized with regular bloodwork and refined supplementation accordingly. 4,000 IU per day is safe. D3 is stored in the body, so a missed dose can be compensated by doubling the intake the next day.
				</p>
				<h4>
					Vitamin D References
				</h4>
				<ol class="reference-list">
					<li id="a-peterson">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966187/">Memory, Mood, and Vitamin D in Persons with Parkinson‚Äôs Disease</a>, Amie L. Peterson, et al.
					</li>
					<li id="c-shan">
						<a href="https://molecularbrain.biomedcentral.com/articles/10.1186/s13041-019-0444-5"
						title="Roles for osteocalcin in brain signalling: implications in cognition- and motor-related disorders"
						target="_blank"
						>Roles for osteocalcin in brain signalling: implications in cognition- and motor-related disorders</a>, Chang Shan, et al.
					</li>
				</ol>
			</section>
			
			<section id="vitamin-b1">
				<h4 class="neuroprotective dopaminergic">
					 Vitamin B-1 (Thiamine)
				</h4>
				<ul>
					<li>Mechanisms: Dopaminergic, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant (GSK3Œ≤ dysregulation)
					<li>Dose: 300mg ED/EOD üçΩÔ∏è
					<li>Fat-soluble: ‚ùå 
					<li>BBB: ‚úÖ (50%)
					<li>Safety: 8/10 (80% œÉ)
					<li>Efficacy: 9/10 (95% œÉ)
				</ul>
				
				<p>
					High-dose thiamine has repeatedly been shown to reverse motor and non-motor symptoms in PD. <cite class="reflink"><a href="#a-constantini">a-constantini</a>, <a href="#p-bager">p-bager</a></cite>
				</p>
				<p>
					<abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr> gene is responsible for such as thiamin biosynthesis. Mutations in the DJ-1 gene can result in a loss of function of the protein. Genetic testing for DJ-1 mutations may help predict thiamine's usefulness. <cite class="reflink"><a href="#k-luong">k-luong</a></cite>
				</p>
				
				<p>
					Thiamine has poor bioavailability but can cross the BBB through passive diffusion when its levels in the blood are high.
				</p>
				<ol class="reference-list">
					<li id="a-constantini">
						<a href="https://pubmed.ncbi.nlm.nih.gov/26505466/"
						title="Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study"
						target="_blank"
						>Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study</a>, A. Costantini, et al.
						<p>
							Patients received 100 mg of thiamine, injected intramuscularly twice a week, without any change to personal therapy. All the patients were re-evaluated after 1 month and then every 3 months during treatment. Administration of parenteral high-dose thiamine was effective in reversing PD motor and nonmotor symptoms. 
						</p>
					</li>
					
					<li id="p-bager">
						<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0301354"
						title="High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial"
						target="_blank"
						>High-dose oral thiamine versus placebo for chronic fatigue in patients with primary biliary cholangitis: A crossover randomized clinical trial</a>, Palle Bager, et al.
						<p>
							Four weeks of high-dose (600‚Äì1800 mg daily) oral thiamine treatment in patients with PBC was well tolerated and safe. However, high-dose thiamine was not superior to placebo in reducing PBC-related fatigue.
						</p>
					</li>
					
					<li id="k-luong">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493530/"
						title="The Beneficial Role of Thiamine in Parkinson Disease"
						target="_blank"
						>The Beneficial Role of Thiamine in Parkinson Disease</a>, Khanh v. q. L∆∞∆°ng and Lan T. H. Nguy·ªÖn.
						<p>
							 <abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr> gene is responsible for such as thiamin biosynthesis. Mutations in the DJ-1 gene can result in a loss of function of the protein. 
						</p>
					</li>
				</ol>
			</section>
			
			<section id="vitamin-b6">
				<h4 class="neuroprotective dopaminergic">
					Vitamin B-6 (Pyridoxine)
				</h4>
				
				<p>
					Vitamin B6, also known as pyridoxine, is neuroprotective, and is used in neurotransmitters synthesis, glutamatergic system regulation, and nervous system balance and maintenance.
				</p>
				<p>
					Vitamin B6 is necessary for dopamine biosynthesis and antioxidant properties. However, high doses of vitamin B6 can cause peripheral neuropathy, and it is essential to consume it as part of a balanced diet and consult with a healthcare professional before taking supplements.
				</p>
	
				<p>
					Vitamin B6 helps in reducing the side effects of dopaminergic treatments,
				</p>
			</section>
			<section id="vitamin-b12">
				<h4>
					Vitamin B-12 (Cobalamin)
				</h4>
				<h5>How B-12 helps Parkinson's Disease</h5>
				<p>
					Vitamin B-12 reduces <abbr title="Reactive Oxygen Species">ROS</abbr> and improves mitochondrial biogenesis regulator <abbr title="Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha">PGC-1Œ±</abbr>.
				</p>
				<p>
					Vitamin B-12 has multiple mechanisms related to <abbr title="Leucine Rich Repeat Kinase 2">LRRK2</abbr> expressions that protect dopaminergic neurons. B-12 inhibits LRRK2 kinase activity. This protects dopaminergic neurons from toxicity induced by LRRK2 and its mutant form, LRRK2-G2019S.
				</p>
				<p>
					Vitamin B-12 prevents LRRK2-G2019S-potentiated &alpha;-synuclein accumulation in dopaminergic neurons.
				</p>
				<ol>
					<li>
						<a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
						title="Vitamin B12 modulates Parkinson‚Äôs disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection"
						target="_blank">Vitamin B12 modulates Parkinson‚Äôs disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection</a>
						<p>
							Vitamin B-12 protected dopaminergic neurons from toxicity induced by LRRK2 and its mutant form, LRRK2-G2019S. The effect was shown to improve deficits in dopamine transmission in LRRK2-PD mouse models.
						</p>
					</li>
					 <li>
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854476/"
						title="Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson‚Äôs Disease Models by Alleviating Oxidative Stress"
						target="_blank"
						>Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson‚Äôs Disease Models by Alleviating Oxidative Stress</a>
						<p>
							This multiple-model study demonstrated that vitamin B-12 significantly ameliorated oxidative stress by reducing ROS and alleviating reductants in a cellular PD model. In vivo, B-12 rescued the movement deficit of C. Elegans in the mouse PD model. Mechanistically, B-12 reduced JNK phosphorylation and improved the mitochondrial biogenesis regulator <abbr title="Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alph">PGC-1Œ±</abbr>. 
						</p>
					</li>
				</ol>
			</section>
			<section id="tocotrienols">
				<h4>
					Tocotrienols and Tocopherols
				</h4>
				<ul>
					<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-cancer
					<li>Dose: 150 ‚Äì 300 IU ED/EOD üçΩÔ∏è
					<li>Fat-soluble: ‚úÖ
					<li>BBB: ‚úÖ
					<li>Safety: 8/10 (80% œÉ)
					<li>Efficacy: 5/10 (60% œÉ)
				</ul>
				
				<p>
				Vitamin E is a group of eight fat-soluble compounds, comprising four tocopherols and four tocotrienols that offer a spectrum of benefits.
				</p>
				<dl>
					<dt>Tocopherols</dt>
					<dd><strong>Œ±-</strong> ‚Äî most common and studied form, antioxidant, immune-enhancing, vascular and skin effects</dd>
					<dd><strong>Œ≤-</strong> ‚Äî antioxidant, anti-inflammatory</dd>
					<dd><strong>Œ≥-</strong> ‚Äî antioxidant, anti-inflammatory, neutralizes <abbr title="reactive nitrogen species">RNS</abbr></dd>
					<dd><strong>Œ¥-</strong> ‚Äî antioxidant, anti-inflammatory, neutralizes <abbr title="reactive nitrogen species">RNS</abbr></dd>
					<dt>Tocotrienols</dt>
					<dd><strong>Œ±-</strong> ‚Äî strongly neuroprotective, stabilizes cellular membranes</dd>
					<dd><strong>Œ≤-</strong> ‚Äî antioxidant, anti-inflammatory</dd>
					<dd><strong>Œ≥-</strong> ‚Äî anti-tumorogenic, antihyperlipidemic</dd>
					<dd><strong>Œ¥-</strong> ‚Äî anti-cancer, strong antioxidant</dd>
				</dl>
				
				<p>
					Tocotrienols are neuroprotective, anti-cancer, anti-oxidative, and cholesterol-lowering in ways tocopherols aren't. Most vitamin E supplements are only alpha-tocopherol, which has the effect of reducing the body's levels of gamma tocopherol. This is bad, because unlike alpha-tocopherol, gamma-tocopherol and delta-tocopherol can scavenge reactive nitrogen species in addition to reactive oxygen species. <cite class="reflink"><a href="#a-abraham">A. Abraham</a>, <a href="#m-clarke">M. Clarke</a>, <a href="#d-wolf">D. Wolf</a></cite>
				</p>
				<p> 
					Consuming the full spectrum of all eight natural forms of vitamin E avoids problems with unilateral Œ±-tocopherol supplementation and provides maximum synergy and health benefit. <cite class="reflink"><a href="#c-sen">C. Sen</a></cite>
				</p>
	
				<h5>Neuroprotective Effects</h5>
				
				<p>
					Tocotrienols have been shown to improve learning impairment in elderly subjects. A 2018 double-blind study out of Japan showed that the combination of tocotrienols with astaxanthin improves the composite memory and verbal memory of Japanese adults who feel a memory decline. Astaxanthin and vitamin E are anti-oxidative, but tocotrienols are more than that. <cite class="reflink"><a href="#t-sekikawa">T. Sekikawa</a></cite>
				</p>
				
				<p>
					Tocotrienols cross the BBB, exerting neuroprotective effects independent of their antioxidant activity by binding to the estrogen receptor, as shown in multiple studies. <cite class="reflink"><a href="#t-matsura">T. Matsura</a>, <a href="#r-naomi">R. Naomi</a></cite>
			   </p>
			   
			   <p>
				   Tocotrienols also reduce BBB permeability by modulating tight junction proteins and reducing oxidative and inflammatory damage to the BBB. This helps maintain its integrity, which is essential for protecting the brain. <cite class="reflink"><a href="n-kaneai">N. Kaneai</a></cite>
			   </p>
			   
			   <p>
					Tocotrienols more effectively inhibit lipid peroxidation compared to tocopherols, due to better incorporation into cell membranes. This action protects mitochondria and reduces oxidative stress. Tocotrienols have been shown to induce apoptosis of cancer cells while protecting neuronal cells from glutamate- and peroxidative-induced death. <cite class="reflink"><a href="#b-aggarwal">B. Aggarwal</a> <a href="#r-c-chiste">R.C. Chiste</a></cite>
				</p>
	
				<p>
					A 2021 controlled rodent model study showed that Œ±- and Œ≥- tocotrienols improved motor function and neuronal uptake in hippocampal cells, with Œ±-tocotrienol demonstrating superior neuroprotective effects and preventing further reduction of dopaminergic neurons. <cite class="reflink"><a href="#m-kumari">M. Kumari</a></cite>
				</p>
				
				<h4>Human Trial Underway</h4>
				<p>
					A large scale human trial, <a title="Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial" href="https://clinicaltrials.gov/study/NCT04491383" target="_blank"><q>Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial</q></a>, was opened on April 2021. This two-year study is designed to compare the effects of 400mg/day tocotrienols vs placebo on neuropsychological conditions using cognitive tests and bloodwork, to evaluate PD biomarkers and for safety monitoring. Tocotrienols are available over the counter, so participation in the trial is not required to use them.
				</p>
				
				<h4>Supplementation and Safety</h4>
	
				<p>
					Vitamin E is best taken with dietary fat and other fat-soluble supplements.
				</p>
				<p>
					Vitamin E can thin the blood. Individuals taking blood thinners, those with a history of stroke or brain bleeding should be cautious when taking vitamin E supplements.
				</p>
				<p>
					Light to moderate supplementation consisting of a naturally-sourced, balanced blend of the four tocotrienols and four tocopherols provides benefits while avoiding these risks. Do not exceed the recommended dose. High doses of vitamin E, particularly the synthetic form dl-alpha-tocopherol, are unhelpful to neurodegenerative conditions and are toxic.
				</p>
				
				<h4>
					References
				</h4>
				<ol class="reference-list">
				
					<li id="a-abraham">
						<a href="https://pubmed.ncbi.nlm.nih.gov/29746786/"
						title="Vitamin E and its anticancer effects"
						target="_blank"
						>Vitamin E and its anticancer effects</a>, Annette Abraham, et al.
					</li>
					
					<li id="c-sen">
						<a href="https://www.sciencedirect.com/science/article/abs/pii/S0024320505012361"
						title="Tocotrienols: Vitamin E beyond tocopherols"
						target="_blank"
						>Tocotrienols: Vitamin E beyond tocopherols</a>, Chandan K. Sen, et al.
					</li>
					<li id="d-wolf">
						<a href="https://academic.oup.com/nutritionreviews/article/64/6/295/1830820"
						title="How an Increased Intake of Alpha-Tocopherol Can Suppress the Bioavailability of Gamma-Tocopherol"
						target="_blank"
						>How an Increased Intake of Alpha-Tocopherol Can Suppress the Bioavailability of Gamma-Tocopherol</a>, George Wolf, DPhil.
					</li>
						
					<li id="m-clarke">
						<a href="https://www.sciencedirect.com/science/article/pii/S0002916523292473"
						title="Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes."
						target="_blank"
						>Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes.</a>, M. Clarke, et al.
						<p> 
							This <abbr title="Randomized Controlled Trial">RCT</abbr> found that supplementation with alpha-tocopherol (the common form) decreased red blood cell gamma-tocopherol, whereas mixed tocopherols increased both serum alpha-tocopherol and serum and cellular gamma-tocopherol. 
						</p>
					</li>
					<li id="t-sekikawa">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705074/"
						title="Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind, placebo-controlled study"
						target="_blank"
						>Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind, placebo-controlled study</a>, Takahiro Sekikawa, et al.
					</li>
					
					<li id="t-matsura">
						<a href="https://pubmed.ncbi.nlm.nih.gov/31619646/"
						>Protective Effect of Tocotrienol on In Vitro and In Vivo Models of Parkinson's Disease</a>, Tatsuya Matsura.
						<p>
							This rodent model study demonstrated that tocotrienols bind to the estrogen receptor in vitro, resulting in relieved PD-related symptoms. The result was explained by the observed cellular signalling that led to cytoprotective effects.
						</p>
					</li>
					
					<li id="r-naomi">
						<a href="https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.754086/full"
						title="An Interactive Review on the Role of Tocotrienols in the Neurodegenerative Disorders"
						target="_blank"
						>An Interactive Review on the Role of Tocotrienols in the Neurodegenerative Disorders</a>, Ruth Naomi, et al.
					</li>
					<li id="n-kaneai">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788404/"
						title="Tocotrienol improves learning and memory deficit of aged rats"
						target="_blank"
						>Tocotrienol improves learning and memory deficit of aged rats</a>, Nozomi Kaneai, et al.
					</li>
					<li id="b-aggarwal">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956867/"
						title="Tocotrienols, the Vitamin E of the 21st Century: It‚Äôs Potential Against Cancer and Other Chronic Diseases"
						target="_blank"
						>Tocotrienols, the Vitamin E of the 21st Century: It‚Äôs Potential Against Cancer and Other Chronic Diseases</a>, Bharat B. Aggarwal, et al.
					</li>
					<li id="r-c-chiste">
						<a href="https://pubmed.ncbi.nlm.nih.gov/23140681/"
						title="In vitro scavenging capacity of annatto seed extracts against reactive oxygen and nitrogen species"
						target="_blank"
						>In vitro scavenging capacity of annatto seed extracts against reactive oxygen and nitrogen species</a>, Renan Campos Chist√©, et al.
						<p>
							Annatto seeds contain several carotenoids, terpenoids, tocotrienols and flavonoids, which reduce <abbr title="Reative Oxygen and Nitrogen Species">RONS</abbr>.
						</p>
					</li>
					<li id="m-kumari">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150907/"
						title="Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis"
						target="_blank"
						>Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis</a>, Mangala Kumari.
						<p>
							&ldquo;&hellip;this study revealed that supplementation of Œ±- and Œ≥-T3 was able to ameliorate the motor deficits induced by 6-OHDA and improve the neuronal functions by reducing inflammation, reversing the neuronal degradation, and preventing further reduction of dopaminergic neurons in the SN and striatum (STR) fibre density.&rdquo;
						</p>
					</li>
				</ol>
				
				<!--
				<h5>
					Product
				</h5>
				<ul class="product-list">
					<li>
						<figure>
							<img src="img/tocotrienols.jpeg" alt="mixed tocotrienols">
							<figcaption>
								<p>
									<a href="https://www.amazon.com/Kala-Health-Vitamin-softgels-tocotrienols/dp/B07S52CF4L/ref=pd_ci_mcx_mh_mcx_views_0?pd_rd_i=B07S52CF4L"
									title="Doctor's Best Tocotrienols contains EVNol SupraBio Full Spectrum Vitamin E Complex"
					target="_blank"
				>Doctor's Best Tocotrienols contains EVNol SupraBio Full Spectrum Vitamin E Complex</a>
								</p>
							</figcaption>
						</figure>
					</li>
					<li>
						<a href="https://www.amazon.com/gp/product/B00AZQXO3E/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00AZQXO3E&amp;linkId=3ba360ffd9243d4be9db93ad7adaf534"
						title="Kala Health Unique Formula with All 8 Tocopherols and Tocotrienols Vitamin E‚Äì Contains no PAH‚Äôs, Heavy Metals, Contaminants or Preservatives - Certified Sustainable - Hair, Scars and Skin"
						target="_blank"
					>Kala Health Unique Formula with All 8 Tocopherols and Tocotrienols</a>
					</li>
				</ul>
			-->
			</section>
			<section id="nicotinamides">
				<h3>NAD+ and its precursors NMN, NR, and Niacin</h3>
	
				<h3>Nicotinamide Adenine Dinucleotide (NAD+)</h3>
				<p>
					NAD+ is a coenzyme involved in energy metabolism, DNA repair, and cell signaling.
				</p>
	
				<p>
					 NAD+ reduces oxidative stress (including in the brain). This promotes recovery on a cellular level and leads to better energy metabolism, neuroprotection, mitochondrial function, and DNA repair. 
				</p>
				
				<p>
					NAD+ affects macrophages to reduce the production of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines.
				</p>
	
				<p>
					NAD+ promotes mitophagy, leading to mitogenesis. This promotes neuronal survival and function and decreases ROS. Lower ROS levels reduce oxidative stress, which can prevent the misfolding and aggregation of Œ±-synuclein.
				</p>
				
				<h4>Declining NAD+ Levels</h4>
				<p>
					Declining NAD+ levels contribute to reduced mitochondrial function and impaired cellular energy metabolism in neurons, making them more susceptible to oxidative damage and degeneration, particularly in PD, necessitating intervention.
				</p>
	
				<p>
					Raising NAD levels (through injection, precursor supplementation, and upregulation via exercise) improves mitochondrial function and count in neuronal cells. This explains how it improves neurotransmission, synaptic plasticity, and improved motor symptoms.
				</p>
				<p>
					NAD+ is essential for mitochondrial function which is significant in the pathogenesis of Parkinson's disease.
				</p>
				<h4>NAD Precursors</h4>
				<p>
					Supplementation with NAD precursors NMN, NR, and niacin, increases cellular levels of NAD+ (nicotinamide adenine dinucleotide). Among these, NMN appears to be the safest, best-tolerated, and most effective in increasing NAD+ production. This is because NMN converts to NAD+ more directly than the other precursors.
				</p>
	
				<p>
					Niacin increases NAD+ levels but through a different metabolic pathway than NMN and NR.
				</p>
				<section id="nmn">
					<h3>Nicotinamide Mononucleotide (NMN)</h3>
					<ul>
						<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant
						<li>Dose: 1000mg ED
						<li>Fat-soluble: ‚ùå
						<li>BBB: ‚úÖ
						<li>Safety: 8/10 (80% œÉ)
						<li>Efficacy: 7/10 (65% œÉ)
					</ul>
					
					<p>
						Supplemental Nicotinamide Mononucleotide (NMN) is directly converted to NAD+, increasing NAD+ levels. <cite class="reflink"><a href="#c-shade">C Shade</a></cite>
					</p>
					
					<h4>NMN and Mental Performance</h4>
					<p>
						Oral administration of NMN was been shown to increase NAD+ levels in an rodent brains <cite class="reflink"><a href="#d-i-ingram">D. Ingram</a></cite> and extremely large doses (500 mg/kg) injected over 10 days were shown caused sustained improvement in cognitive function in rodents, as assessed by the Morris water maze. <cite class="reflink"><a href="#xionan-wang">X. Wang</a></cite>
					</p>
					
					<p>
						Preclinical studies and some clinical trials have shown promising results regarding the potential benefits of NMN supplementation in Parkinson's disease. <cite class="reflink"><a href="#d-i-ingram">D.I. Ingram</a>, <a href="#x-chen">X. Chen</a></cite> 
					</p>
					
					<h4>NMN and Exercise Performance</h4>
					<p>
						NMN dose-dependently improves exercise performance. <cite class="reflink"><a href="#b-lao">B. Lao</a></cite>
					</p>
					<p>
						Long-term NMN supplementation at lower doses has shown increased NAD+ levels, improved insulin sensitivity, enhanced mitochondrial function, anti-aging effects, and cardiovascular health. <cite class="reflink"><a href="#k-f-mills">K.F. Mills</a></cite>
					</p>
										
					<h4>Supplementation</h4>
					<p>
						A typical dose of NMN is about 1g per day. It's safe and effective at much higher levels, as shown in human studies and rodent models. <cite class="reflink"><a href="#l-yi">L. Yi</a></cite>
					</p>                    
					
					<h4>NMN Bulk Powder</h4>
					<p>
						<a href="https://www.prohealth.com/products/prohealth-nmn-pro-powder-1-kilo-ph537?selling_plan=3992027236">NMN Bulk &mdash; Prohealth Longevity</a>
					</p>
					<p>
						ProHealth Longevity is a well-established company that provides GMP compliance and third-party testing for purity and potency.
					</p>
					
					<h4>NMN References</h4>
					<ol class="reference-list">
					
						<li id="c-shade">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238909/"
							target="_blank"
							title="The Science Behind NMN‚ÄìA Stable, Reliable NAD+Activator and Anti-Aging Molecule">The Science Behind NMN‚ÄìA Stable, Reliable NAD+Activator and Anti-Aging Molecule</a>, Christopher Shade.
							
						</li>
						
						<li id="d-i-ingram">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778478/"
							title="Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain"
							target="_blank"
							>Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain</a>, Donald K. Ingram.

						</li>
						<li id="xionan-wang">
							<a href="https://pubmed.ncbi.nlm.nih.gov/27130898/"
							target="_blank"
							title="Nicotinamide mononucleotide protects against Œ≤-amyloid oligomer-induced cognitive impairment and neuronal death"
							>Nicotinamide mononucleotide protects against Œ≤-amyloid oligomer-induced cognitive impairment and neuronal death</a> by Xiaonan Wang, et al.
							<p>
								This rodent study found that large doses (500mg/kg) of NMN injected over 10 days caused sustained improvement in cognitive function as assessed by the Morris water maze.
							</p>
						</li>
						
						<li id="k-f-mills">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668137/"
							title="Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice"
							target="_blank"
							>Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice</a>, Kathryn F. Mills, et al.
							<p>
							
							</p>
						</li>
						<li id="l-yi">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735188/"
							title="The efficacy and safety of Œ≤-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial"
							target="_blank"
							>The efficacy and safety of Œ≤-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial</a>, Lin Yi, et al.
							<p>
							
							</p>
						</li>
					
						<li id="x-chen">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803565/"
							>Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment</a>, Xiaohong Chen, et al.              
							<p>
								This rodent model study found 250mg/kg and 500mg/kg NMN inhibited cell death at the acute phase of photoreceptor injury, with greater protection at 500 mg/kg.
							</p>
						</li>
						<li id="b-lao">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265078/"
							target="_blank"
							title="Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study"
							>Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study</a>, Bagen Liao, et al.
							<p>
								This double-blind RCT showed that 6 weeks NMN increased the aerobic capacity of humans during exercise training in groups taking 300mg, 600mg, and 1200mg twice per day.
							</p>
						</li>
					</ol>
				</section>
				
				<section id="nr">
					<h3>Nicotinamide Riboside (NR)</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
						<li>Dose: 300-500mg ED
						<li>ü©∏üß†BBB: ‚úÖ
						<li>Safety: 8/10 (85% œÉ)
						<li>Efficacy: 6/10 (70% œÉ)
					</ul>
					<p>
					NR is phosphorylated to NMN by the enzyme nicotinamide riboside kinase.
					</p>
					
					<h4>Supplementation</h4>
				
					<p>
						The recommended dose is 300-500mg ED, taken along with NMN and niacin and occasional NAD+ injections. Oral supplementation of NR at 3000mg daily for 30 days was safe and well-tolerated.
					</p>
					
					<h4>NR References</h4>
					<ol>
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/29599478/7"
							title="Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults"
							target="_blank"
							>Chronic NR supplementation in older adults</a>
							<p>
								This small-scale RCT (Randomized Controlled Clinical Trial) found that chronic oral supplementation with 1000mg of NR daily increased NAD+ levels in healthy middle-aged and older adults. 
							</p>
						</li>                   
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/38016950/"
							target="_blank"
							title="NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease"
						>NR-SAFE trial</a>, a Phase I clinical trial published in 2023 found that high-dose NR supplementation (3,000 mg/day) was well-tolerated and associated with improved motor symptoms in patients with PD.
						</li>
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/35235774/"
							title="The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson‚Äôs disease"
							target="_blank"
							>NADPARK</a>
							<p>
								A phase I clinical trial published in 2022 found that NR supplementation increased whole blood NAD+ levels and expanded the NAD+ metabolome in patients with PD.
							</p>
						</li>
					</ol>
				</section>
				
				<section id="niacin">
					<h3>Niacin</h3>
					<ul class="treatment-rating">
						<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
						<li>Dose: 100-300mg BID
						<li>ü©∏üß†BBB: ‚úÖ
						<li>Safety: 7/10 (75% œÉ)
						<li>Efficacy: 5/10 (60% œÉ)
					</ul>
					<p>
						Niacin increases NAD+ levels through a longer metabolic pathway than that of NMN however, NMN and NR are considered superior due to their more direct conversion pathways and higher efficiency, supported by various studies and research.
					</p>
					
					<h4>Safety</h4>
					<p>
					Niacin causes a flushing at higher doses. This is harmless but may be uncomfortable. 
					</p>
	
					<h4>Niacin References</h4>
					<ol>
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245760/"
						>Niacin Enhancement for Parkinson‚Äôs Disease: An Effectiveness Trial</a>
						</li>
					</ol>
				</section>
				
				<section id="nad-injection">
					<h4>NAD+ Injection &amp; IV Drip</h4>
					<ul class="treatment-rating">
						<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
						<li>Dose: Varies (injections or infusions)
						<li>ü©∏üß†BBB: ‚úÖ
						<li>Safety: 8/10 (85% œÉ)
						<li>Efficacy: 7/10 (75% œÉ)
					</ul>
					<p>
						NAD can be injected intramuscularly, subcutaneously, or intravenously via a drip. It is popular, safe, generally enjoyed, and very well-tolerated. 
					</p>
	
					<h4>NAD Product</h4>
					<figure>
						<img src="./img/nad__750mg_30.png" alt="peptide sciences NAD+">
						<figcaption>
							<p>
							<a href="https://www.peptidesciences.com/nadplus-750mg"
							target="_blank">NAD+ 750mg &mdash; Peptide Sciences</a> (wait for 15% off sale) Peptide Sciences is the place for peptides. Compared to others, only PS sells lyophilized peptides.
							</p>
						</figcaption>
					</figure>
					
					<h4>NAD+ Injection References</h4>
					<ol>
						<li>
							<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2019.00257/full"
							title="A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+"
							target="_blank">A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+</a>
						
							<p>
								Eleven (Test n = 8, Control n = 3) male participants aged 30&ndash;55 years received 750 mg NAD+ in normal saline over a 6 h period. This resulted in a significant and quick elevation of intracellular NAD+.
							</p>
						</li>
					</ol>
				</section>
				
				<h4>NAD+ References</h4>
				<ol>
					<li>
						<a href="https://pubmed.ncbi.nlm.nih.gov/8101414/">Nicotinamide adenine dinucleotide (NADH)&mdash;a new therapeutic approach to Parkinson's disease.</a>
					</li>
					<li>
						<a href="https://pubmed.ncbi.nlm.nih.gov/27798264/">NAD+ repletion reverses age-related behavioral and synaptic deficits in mice</a>
						<p>
							This study demonstrates supplementation with NAD+ precursors, including NMN, improves mitochondrial function, synaptic plasticity, and cognitive function in aged mice. The findings suggest that NAD+ repletion may have potential therapeutic benefits for age-related neurological disorders.
						</p>
					</li>
					<li>
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963035/">NAD+ metabolism and its roles in cellular processes during ageing</a>
						<p>
							NAD+ metabolism in cellular processes associated with aging and age-related diseases, including neurodegenerative disorders like PD. It highlights the potential therapeutic implications of NAD+ precursors in
							mitigating age-related declines in cellular function and promoting healthy aging.
						</p>
					</li>
					<li>
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518566/">Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model</a>
						<p>
							Although this study focuses on a cardiomyopathy model in Friedrich's ataxia, it provides insights into the potential benefits of NMN supplementation in a disease characterized by mitochondrial dysfunction.
							The findings suggest that NMN administration improves cardiac function and bioenergetics through SIRT3-mediated mechanisms, highlighting the importance of NAD+ metabolism in mitochondrial health.
						</p>
					</li>
					<li>
						<a href="https://www.heraldopenaccess.us/openaccess/intravenous-administration-of-nicotinamide-adenine-dinucleotide-alleviates-tremors-associated-with-parkinson-s-disease-a-case-report"
						>A Case Report</a>
						<p>
							This single case study used BR+NAD ("Brain Restoration Plus" NAD) comprised of multiple IV infusions of NAD+ over six days, as well as added oral supplementation of Vitamin C, B6, Folate, Selenium, N-acetyl-L-cysteine, N-acetyl-L-tyrosine, and electrolytes. Following Day 6, he received sublingual NAD+ tablets (300mg, twice per day) for 14 days.
						</p>
						<p>
							The patient initially presented with bilateral hand tremors (significantly more pronounced in the right hand), shuffling gate/gait rigidity, and impairments in movements of the hands and fingers
						<p>
							Over the six NAD+ the six NAD+ treatment days, the patient showed a significant decline in hand tremors, development of a steady gate, increased sociability, increased cognitive functioning, and improved sleep.
						</p>
					</li>
				</ol>
			</section>
			<section id="senolytics">
				<h3>Senolytics</h3>
				<p>
					Senolytics are used to selectively induce the death of senescent cells. Senolytic means "senescent cell destruction".
				</p>
	
				<h4>Senolytics in Parkinson's Disease</h4>
				<p>
					Senolytics inhibit and help degrade &alpha;-synuclein aggregation.
				</p>
				<p>
					In PD, &alpha;-synuclein and especially its mutant forms damage mitochondria, causing a leak of sirtuins from the inner membrane of the mitochondria leading to mitochondrial failure and eventual cell failure.
				</p>
				<p>
					Aggregates of &alpha;-synuclein form Lewy bodies inside the cell and block T-cells from activating the lysosome of non-functioning "zombie" cells.
				</p>
				<p>
					Senolytics help prevent the formation of &alpha;-synuclein aggregates. This has numerous benefits, including neuroprotection, decreased neuroinflammation, improved mitochondrial function, neurogenesis, and autophagy.
				</p>
				<p>
					Senolytics reduce the formation of Lewy bodies and facilitate T-cell activation of the lysosome in senescent cells by preventing obstruction by  &alpha;-synuclein aggregates
				</p>
	
	
				<section id="urolithin-a" class="mitochondrial senolytic neuroprotective">
					<h3>Urolithin-A</h3>
					<ul>
						<li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant
						<li>Dose: 1000mg ED
						<li>Fat-soluble: ‚úÖ
						<li>ü©∏üß† BBB: ‚úÖ
						<li>Safety: 8/10 (80% œÉ)
						<li>Efficacy: 6/10 (70% œÉ)
					</ul>
					
					<h4>Overview</h4>
					<p>
						Urolithin-A is a naturally occurring compound produced by gut bacteria through the transformation of polyphenols, such as ellagitannins and ellagic acid, found in small amounts of some foods like wild berries (pomegranates, etc), walnuts, and tea. Urolithin-A supplementation stimulates mitophagy and mitochondrial function in several tissues.
					</p>
					
					<h4>Benefits</h4>
					<p>
						Urolithin-A-induced mitophagy promotes mitogenesis. This promotes neuronal survival and function, making Urolithin-A strongly neuroprotective. <cite class="reflink"><a href="#p-andreux">P. Andreux</a></cite>
					</p>
					
					<h4>Mitophagy</h4>
					<p>
						Mitophagy is a cellular process that recycles and removes damaged or unhealthy mitochondria, leading to their replacement with new, healthy mitochondria. 
					</p>
					
					<h5>Urolithin-A and the PINK1-Parkin Pathway</h5>
					
					<p>
						The PINK1-Parkin pathway is necessary for the removal of damaged mitochondria. In some conditions, including PD, it is impacted. When PINK1 enters healthy mitochondria, the mitochondria remove it. However, when the mitochondria are damaged, PINK1 accumulates on the outer membrane. This signals the recruitment of Parkin to the outer membrane, which marks the damaged mitochondria for recognition by autophagosomes. The autophagosomes engulf the damaged mitochondria and transport them to the cell's lysosome for degradation. This process, known as <dfn>mitophagy</dfn>, signals the cell to initiate  <dfn>mitochondrial biogenesis</dfn>, restoring cellular energy and function.
					</p>
					
					<h4>Mitophagy in Parkinson's Disease</h4>
					<p>
						In PD, there is an abnormally higher number of damaged mitochondria. These damaged mitochondria accumulate alpha-synuclein and contribute to the formation of Lewy bodies. Inducing mitophagy helps clear these harmful mitochondria and restore cellular energy production. This process protects against dopaminergic neurodegeneration.
					</p>
					
					<p>
						A 2021 study using a PD-induced rodent model found urolithin-A exerted neuroprotective effects by promoting mitochondrial biogenesis via SIRT1-PGC-1Œ± signaling pathway and ameliorated both motor deficits and nigral-striatal dopaminergic neurotoxicity. <cite class="reflink"><a href="#jia-liu">J. Liu</a></cite>
					</p>
	
					<p>
						A 2019 rodent study out of Guangzhou, China found Urolithin-A, in a mouse model of AD, significantly improved spatial learning and memory, protected neurons from death, reduced neuroinflammation, and triggered neurogenesis. <cite class="reflink"><a href="#z-gong">Z. Gong</a></cite>
					</p>
					<p>
						A 2023 review study found Urolithin-A was neuroprotective, protected against brain injuries, improved mitophagy and overall mitochondrial functions of the nerve cells, inhibited monoamine oxidase, and reduced cognitive decline. <cite class="reflink"><a href="#o-wojciechowska">O. Wojciechowska</a></cite>
					</p>
					
					<h4>Product</h4>
					<figure>
						<img src="img/urolithin-a-activity.png"
						class="block-image">
					
						<figcaption>
							<p>
								Urolithin-A benefits include reduced neuroinflammation, reduced &alpha;-synuclein aggregation, decreased apoptosis, protection of dopaminergic neurons, improved mitochondrial function, and improved motor and cognitive function.
							</p>
							<p>
								<cite>Urolithin A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management</cite>, O. Wojciechowska, et al.
							</p>
						</figcaption>
					</figure>
					
					<h4>Exercise Performance</h4>
					<p>
						A 2022 <abbr title="randomized controlled trial">RCT</abbr> found Urolithin-A improved muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. <cite class="reflink"><a href="#a-singh">A. Singh</a></cite>
					</p>
					
					<p>
						Another <abbr title="randomized controlled trial">RCT</abbr> in 2022 found Urolithin-A conferred a significant improvement in muscle endurance and reduced <abbr title="C-Reactive Protein">CRP</abbr>. <cite class="reflink"><a href="#s-liu">S. Liu</a></cite>
					</p>
					
					<h4>Supplementation</h4>
					
					<p>
						1000mg per day of Urolithin-A is safe and well-tolerated in humans.
					</p>
					
					<p>
						Urolithin-A is fat-soluble and can cross the BBB. Taking with food or other fat-soluble vitamins may improve absorption. 
					</p>
					
					<h4>Food Sources</h4>
						Pomegranates contain ellagitannins, convertible to urolithin A by gut bacteria in 30% to 50% of people. Optimistically, eating 1 pomegranate might yield a negligible 2 milligrams of Urolithin-A &mdash; <em>not enough</em>!             
					
					<h4>Side Effects</h4>
					<p>
						Potential unknown side effects might include gastric upset or potential interactions with certain medications that also undergo hepatic metabolism.  Taking with food may help.
					</p>
	
					<h4>References</h4>
					<ol class="reference-list">
						<li id="p-andreux">
							<a href="https://pubmed.ncbi.nlm.nih.gov/32694802/"
							title="The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
	"
							target="_blank"
							>The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans</a>, P√©n√©lope A Andreux, et al.
							<p>
								This clinical trial found Urolithin-A induces a molecular signature of improved mitochondrial and cellular health following regular oral consumption in humans.
							</p>
						</li>
	
						<li id="jia-liu">
							<a href="https://pubmed.ncbi.nlm.nih.gov/34905594/"
							title="Urolithin-A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1Œ± signaling pathway"
							target="_blank"
							>Urolithin-A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1Œ± signaling pathway</a>, Jia Liu, et al.
							<p>
								This rodent study demonstrated Urolithin-A's neuroprotective effects, promoting mitochondrial biogenesis via SIRT1-PGC-1Œ± signaling.
							</p>
						</li>
						
						<li id="z-gong">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417212/"
							title="Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice"
							target="_blank"
							>Urolithin-A attenuates memory impairment and neuroinflammation</a>, Zhuo Gong, et al.
							<p>
								 Urolithin-A significantly improved spatial learning and memory, protected neurons from death, reduced neuroinflammation, and triggered neurogenesis.
							</p>
						</li>
						
						<li id="o-wojciechowska">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376282/"
							title="Urolithin-A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management"
							target="_blank"
							>Urolithin-A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management</a>, Olga Wojciechowska and Ma≈Çgorzata Kujawska.
							<p>
								This review study found Urolithin-A reduced cognitive decline, increased mitochondrial quality and content, and protected against neurodegeneration.
							</p>
						</li>
						
						<li id="a-singh">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133463/" title="Urolithin-A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults"
							target="_blank"
							>Urolithin-A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults</a>, Anurag Singh, et al.
							<p>
								This randomized, placebo-controlled trial in middle-aged adults found Urolithin-A improved muscle strength, exercise performance, inflammation, and biomarkers of mitochondrial health.
							</p>
						</li>
						<li id="s-liu">
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777576/"
								title="Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults"
								target="_blank"
								>Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults</a>, Sophia Liu, et al.
							<p>
								Ceramides and plasma CRP were significantly lower in the Urolithin A group compared to the placebo group. (Ceramides are sphingolipids used in cellular signaling, membrane integrity, and cellular stress response. Elevated ceramides indicate inflammation and metabolic disorder.)
							</p>
						</li>
					</ol>
				</section>
	
				<section id="resveratrol">
					<h4>
						Resveratrol
					</h4>            
	
					<p>
						Resveratrol has displayed potent neuroprotective efficacy in several PD animal models.
					</p>
					<h5>
						How it works:
					</h5>
					<p>
						Resveratrol inhibits &alpha;-synuclein aggregation and cytotoxicity, lowering the levels of total &alpha;-synuclein and oligomers, and reducing neuroinflammation and oxidative stress in a dose-dependent manner.
					</p>
					<h5>
						Product:
					</h5>
					<p>
						<a
							href="https://www.amazon.com/gp/product/B00IM21FBG/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00IM21FBG&amp;linkId=ec9df367e733c718d4c8ac89e53e5bdf"
							target="_blank"
						>Purity Labs Organic Trans-Resveratrol 1,500MG Enhanced with Quercetin</a>
					</p>
					<img src="img/trans-resveratrol.jpeg" alt="trans-resveratrol">
					<p>
						Purity Labs Trans-Resveratrol is a high dose, 2 pills per day formula. It might be better to take just one
					</p>
					
					<h4>Resveratrol References</h4>
					<ol>
						<li>
							<a href="https://scienceofparkinsons.com/tag/resveratrol/"
							target="_blank"
							>Brain. On. Fire | The Science of Parkinson&rsquo;s.
							</a>
							(this article covers other published research on compounds with inhibitory activities on components of the NLRP3 inflammasome pathway, including EGCG, Curcumin, Sulforaphane, and Quercetin)
						</li>
	
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/33967780/"
							target="_blank"
							>Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies
							</a>
						</li>
					</ol>
				</section>
				<section id="fisetin">
					<h3>Fisetin</h3>
					<p>
						Fisetin is a fat-soluble polyphenol capable of crossing the BBB. Fisetin is found in many fruits and vegetables, such as strawberries, apples, persimmons, onions, and cucumbers.
					</p>
					<h4>Fisetin References</h4>
					<ol>
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/34199487/">Small Molecule Fisetin Modulates Alpha-Synuclein Aggregation</a>
						</li>
						<li>
							Fisetin <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527824/">helps to maintain glutathione (GSH) levels</a>.</li>
						<li>
							<a href="https://link.springer.com/article/10.1007/s11626-013-9681-6">Fisetin reduces ROS production</a>
						</li>
					</ol>
				</section>
				<section id="quercetin">
					<h3>Quercetin</h3>
					<p>
						Quercetin is a fat-soluble flavonoid capable of crossing the BBB. Quercetin is naturally found in many plant foods like fruits and vegetables, especially apples, onions, and capers.
					</p>
					
					<p>
						Quercetin inhibits Œ±-synuclein aggregation, protects mitochondria, and modulates various cell-signaling pathways to promote neuronal survival and function.
					</p>
					
					<h4>Quercetin References</h4>
					<ol>
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014205/">Animal Study by Zhang et al. (2017)</a> 
							<p>
								Investigated the effects of quercetin on mice models of Parkinson's disease, showing reduced Œ±-synuclein aggregation and improved motor function.
							</p>
						</li>
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472805/">Neuroprotective Role of Quercetin against Alpha-Synuclein-Associated Hallmarks in Parkinson‚Äôs Disease</a>
							<p>
								This cell culture study demonstrated quercetin's ability to reduce alpha-synuclein aggregation and protect dopaminergic neurons from oxidative stress in vitro.
							</p>
						</li>
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094159/">The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms</a>
							<p>
								This review article synthesizes existing research on the mechanisms by which quercetin may benefit brain health, including anti-inflammatory and neuroprotective effects. It provides a comprehensive overview of both preclinical and some clinical studies, making it a valuable resource for understanding the potential applications of quercetin.
							</p>
						</li>
						<li>
							<a href="https://pubmed.ncbi.nlm.nih.gov/31654381/"
							>Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats</a>
							<p>
								This preclinical study conducted on rats found the combination of quercetin and piperine provided substantial neuroprotection in the rat model of Parkinson's disease, suggesting potential for therapeutic use.
							</p>
						</li>
					</ol>
				</section>
				<section id="sulforaphane">
					<h3>Sulforaphane ‚Äî TODO</h3>
				</section>
				<section id="apigenin">
					<h3>Apigenin ‚Äî TODO</h3>
				</section>
				
				
				<section id="piperlongum">
					<h3>Piperlongumin ‚Äî TODO</h3>
					<!-- 
					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087492/
					>
				</section>
				
				<section id="theaflavin">
					<h4>Theaflavin</h4>
					<p>
						Theaflavin, from black tea, is senolytic.
					</p>
				</section>
				<section id="blueberry">
					<h4>Blueberry</h4>
				
				Blueberry juice augments exercise-induced neuroprotection in a Parkinson‚Äôs disease model through modulation of GDNF levels
				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935512/
				</section -->
			</section>
			</section>
		</section>
	</section>
    <section id="summary">
        <h2>Summary</h2>

        <p>
            Ultimately, health is a personal matter, and addressing it is an individual responsibility. This guide serves as an outline intended to aid in addressing this issue and maximizing one's health span based on the latest scientific research, rather than healthcare dogma, falsehoods, or empty promises meant to boost self-esteem.
        </p>
        
        <p>
            Narratives designed to foster good self-estimation provide a false sense of reality, create dependence on external validation, impact relationships, and lead to missed opportunities for improvement. This guide lays a solid foundation for digging beneath the surface, separating fact from fiction, and looking at things from all angles. The responsibility now rests with you to take proactive steps forward.
        </p>
    </section>
    
</body>
</html>
